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Abstract
P2X7 is an adenosine 5’-triphosphate (ATP)-gated ion channel that plays many roles in
health and disease. P2X7 is present on various cell types, including most immune cells,
and its activation on these cells promotes inflammatory and immune responses. As such,
P2X7 presents a potential therapeutic target for multiple inflammatory disorders
including graft-versus-host disease (GVHD) and amyotrophic lateral sclerosis (ALS).
Therefore, the general aim of this thesis was to investigate P2X7 as a therapeutic target
in mouse models of these disorders.
Chapter 3 characterised murine (m)P2rx7 and human (h)P2RX7 gene expression and
disease

impact

in

the

gut,

skin,

liver

and

lung

of

a

humanised

NOD.Cg-PrkdcscidIl2rg tm1Wjl/SzJ (NSG) mouse model of GVHD. Humanised mice were
established by intraperitoneal (i.p.) injection of human immune cells. mP2rx7 expression
was increased in the gut and skin, while hP2RX7 was present in all tissues of humanised
mice. The skin, liver and lung but not the gut from these mice displayed histological
GVHD. This chapter also identified ear swelling and mReg3g (encoding regenerating
islet-derived 3γ) expression as potential biomarkers of skin and early gut GVHD,
respectively.
Chapters 4 and 5 examined if the P2X7 antagonists Brilliant Blue G (BBG) (Chapter 4)
or pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) (Chapter 5) could
reduce GVHD in humanised mice. P2X7 blockade impaired clinical and histological
GVHD development but did not prolong survival. Although similar benefits were
observed between treatments, BBG impaired GVHD more effectively than PPADS.
Reduced GVHD corresponded with increased human regulatory T cells (Tregs), and
reduced serum human interferon (IFN)γ. Additionally, BBG preserved human Tregs
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in vitro, suggesting this compound may act via a similar mechanism in vivo to reduce
GVHD.
Chapter 6 investigated if combinational therapy with post-transplant cyclophosphamide
(PTCy) and BBG (PTCy+BBG) could further reduce GVHD and increase human Tregs
compared to PTCy alone in humanised mice. PTCy+BBG enhanced protection against
disease with reduced clinical and histological liver GVHD. These reductions in GVHD
were accompanied by increased hCD39+ Tregs and reduced serum hIFNγ. BBG did not
diminish any of the beneficial effects provided by PTCy, suggesting that P2X7 blockade
with PTCy may be clinically viable if refined further.
Chapter 7 elucidated the mechanism of action of the P2X7 antagonist JNJ-47965567
against mouse P2X7 and analysed data and tissues from a preclinical trial using this
compound in a superoxide dismutase 1 (SOD1) G93A mouse model of ALS. JNJ-47965567
inhibited mouse P2X7 in a non-competitive manner. This compound altered spinal cord
gene expression, with increased Nqo1 (encoding NAD(P)H dehydrogenase (quinone 1)),
but did not impact peripheral immune cells or serum cytokines in SOD1 G93A mice.
Finally, Chapter 8 identified and characterised a novel P2X7 antagonist from a library of
amiloride and 5-(N, N-hexamethylene) amiloride (HMA) analogues. 6-furopyridine
substituted HMA (6-FPHMA) was identified and characterised as a non-competitive
human P2X7 antagonist and it was able to reduce P2X7-mediated interleukin (IL)-1β
release. Moreover, 6-FPHMA inhibited canine and murine P2X7, but also inhibited P2X4
and P2Y receptors, limiting its use as a lead compound for future drug development.
In summary, this study established a role for P2X7 on donor immune cells in GVHD, but
not systemic immune cells in ALS, and identified a novel, non-specific P2X7 antagonist.
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Collectively, this thesis supports the notion that P2X7 blockade is a potential therapeutic
in GVHD, due to the preservation of donor Tregs to suppress inflammation.
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Chapter 1: Introduction
Purinergic signalling comprises a number of extracellular nucleotides and nucleosides,
cell surface receptors, ecto-enzymes and nucleotide release pathways that allow for
cell-to-cell communication (Giuliani et al., 2019). This signalling involves P1 receptors
activated by extracellular adenosine and P2 receptors activated by extracellular adenosine
5’-triphosphate (ATP), and in some instances other extracellular nucleotides (Giuliani et
al., 2019). P2 receptors are further divided into P2X or P2Y receptors which are trimeric
ligand-gated ion channels or G-protein coupled receptors, respectively (Burnstock, 2018).
P2X receptors compose seven subtypes (P2X1, P2X2, P2X3, P2X4, P2X5, P2X6 and
P2X7) and can assemble into homomeric or heteromeric channels (Burnstock, 2016).
P2X receptors have been implicated in a wide range of diseases including neurological
and inflammatory disorders (Burnstock et al., 2011). This chapter will focus on P2X7,
particularly in humans and mice, and its pro-inflammatory role and potential as a
therapeutic target in inflammatory diseases.

1.1. P2X7
1.1.1. P2X7 structure
The gene encoding the human (h) P2X7 subunit, P2RX7, is comprised of 13 exons found
in chromosome 12q24 (Buell et al., 1998b). P2RX7 has been observed in at least 55
species, but recombinant receptors have been characterised in only a handful of species
(Sluyter, 2017), including human (Rassendren et al., 1997), mouse (m) (Chessell et al.,
1998b), rat (r) (Surprenant et al., 1996), canine (c) (Roman et al., 2009), panda (pd)
(Karasawa et al., 2016) and chicken (Kasuya et al., 2017). Mammalian, including human,
P2X7 subunits are comprised of 595 amino acids, except guinea pig P2X7 which is
comprised of 594 amino acids, and P2X7 from these mammalian species share 77-97 %
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sequence identity with hP2X7 (Sluyter, 2017). The P2X7 subunit is comprised of
cytosolic N- and C-terminuses, two transmembrane domains and a large extracellular
loop containing the ATP binding sites (Jiang et al., 2021b).
Early structural modelling of P2X7 (Jiang et al., 2013), based on the crystal structure of
zebrafish P2X4 (Hattori et al., 2012; Kawate et al., 2009), indicated that P2X7 subunits
have a dolphin-like shape, similar to P2X4. The solved crystal structure of
ATP-unbound (closed) truncated pdP2X7 indicated that P2X7 subunits did form this
dolphin-like architecture, and combined to form a trimeric structure with a chalice-like
shape (Karasawa et al., 2016). More recently, the structures of truncated chicken (Kasuya
et al., 2017) and full-length rat (McCarthy et al., 2019) P2X7, which share 45 % and
80 % sequence identity with hP2X7 respectively, were solved providing further evidence
for this dolphin-like subunit structure and trimeric chalice-like shape. Moreover,
McCarthy et al. (2019) revealed the ATP-bound (open) state of rP2X7 and examined the
cytosolic domains of P2X7 in more detail than previous studies. Within the C-terminal
cytosolic domain, a C-cysteine anchor, which can prevent P2X7 desensitisation (Allsopp
et al., 2015) by linking to the cell membrane, and a ballast domain, with a guanosine
nucleotide binding region and zinc-ion complex, have been identified (McCarthy et al.,
2019). The C-terminus also contains a lipopolysaccharide (LPS) binding domain
(Denlinger et al., 2001), and the cytosolic N-terminus is involved in Ca 2+ influx (Liang
et al., 2015) and regulation of P2X7 channel gating (Allsopp et al., 2015).
Studies of mammalian P2X1, P2X2 and P2X4 identified a group of relatively conserved
hydrophilic residues, K64, K66, T189, N292, R294 and K311, that were essential for
receptor activation (Jiang et al., 2021b). The solved structure of ATP-bound rP2X7
confirmed that ATP binds to an extracellular inter-subunit pocket of P2X7, and the
phosphate groups on ATP interact with the same residues mentioned above (McCarthy et
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al., 2019). Other residues, R276 (Adriouch et al., 2009; Stokes et al., 2010), D280
(Allsopp et al., 2015), L191 and E186 (Roger et al., 2010), within or near the binding
pocket also regulate the sensitivity of P2X7 to ATP, as mutations that alter these amino
acids can reduce or increase ATP sensitivity and receptor activity. Once ATP binds to
P2X7, the binding pocket tightens and the lower section moves outward opening the
transmembrane ion pathway (Jiang et al., 2021b).
Karasawa et al. (2016) described an inter-subunit allosteric drug binding pocket in
pdP2X7 that structurally unrelated compounds, A740003, A804598, AZ10606120,
GW91343 and JNJ-47965567, all bind to. This drug binding pocket is in close proximity
to, but not in direct contact with, the ATP-binding site and is surrounded by thirteen
residues that are part of the surrounding β-strands, with drug binding mediated
predominately by hydrophobic amino acids F95, F103, M105, F293 and V312 (Karasawa
et al., 2016). Structural modelling and point mutations identified a similar inter-subunit
drug binding pocket for AZ10606120 on hP2X7 and implicated additional residues, T90
and T94, in antagonist binding (Allsopp et al., 2017). Moreover, this study demonstrated
that increasing or decreasing the size of the allosteric pocket, by substituting with
different sized residues of similar hydrophobicity, increased or decreased antagonist
affinity, respectively (Allsopp et al., 2017). Both studies concluded that the antagonists
tested bind to this allosteric pocket which prevents the pocket from narrowing and inhibits
the conformational change required for P2X7 activation. Additionally, point mutations
and chimeras indicated that larger antagonists, including KN-62, Brilliant Blue G (BBG)
and calmidazolium, bind to the same allosteric inter-subunit pocket but also interact with
residues in the central upper vestibule region to facilitate binding (Bin Dayel et al., 2019).
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1.1.2. P2X7 splice variants
Additional to full length P2X7 (P2X7A), eleven transcripts of splice variants (hP2X7B
through hP2X7J, hP2X7L and an unnamed variant) have been defined for hP2X7 (Di
Virgilio et al., 2017; Skarratt et al., 2020; Sluyter, 2017), although protein subunits have
only been identified for hP2X7B, hP2X7H, hP2X7J and hP2X7L (Adinolfi et al., 2010;
Cheewatrakoolpong et al., 2005; Feng et al., 2006; Skarratt et al., 2020) of which
hP2X7B is the most published.
hP2X7B is the result of the deletion of the C terminus by the inclusion of an intron
(containing a stop codon) between exons 10 and 11. This results in the deletion of the
original residues from residue 347 onwards, and the addition of 18 new amino acids from
residues 347-364 (Cheewatrakoolpong et al., 2005). hP2X7B can form a functional ion
channel, but not large pores, and likely plays a role in cell proliferation (Adinolfi et al.,
2010). hP2X7B expression is increased during osteogenesis (Carluccio et al., 2019).
Moreover, hP2X7B expression in the absence of full length hP2X7A has been linked to
increased growth and reduced mineralisation of osteosarcomas, but when expressed
alongside hP2X7A cell growth is similar and mineralisation is increased compared to
hP2X7A alone (Giuliani et al., 2014). Treatment of glioblastoma stem cells with
2’(3’)-O-(4-benzoylbenzoyl) ATP (BzATP) increased the expression of hP2X7B in these
cells, suggesting a role for hP2X7B in the recurrence and invasiveness of this cancer
(Ziberi et al., 2019). Upregulation of hP2X7B expression in tumour immune cells in
patients with lung adenocarcinoma was linked to non-inflamed tumours (Benzaquen et
al., 2020). Additionally, hP2X7B expression is increased in leukaemic cells in newly
diagnosed acute myeloid leukaemia (AML) patients compared to patients with
myelodysplastic syndrome who had not developed AML (Pegoraro et al., 2020).
Moreover, increased hP2X7B expression protected cells from the chemotherapeutic agent
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daunorubicin due to the inability of this splice variant to produce a macropore (Pegoraro
et al., 2020). hP2X7B expression is also upregulated in the brains of patients with
Huntington’s disease, although the effect this splice variant has in this disease is unknown
(Ollà et al., 2020).
hP2X7H occurs due to the inclusion of an intron (containing a start codon) between exons
2 and 3, which deletes the first transmembrane domain, resulting in a non-functional
protein subunit with 504 amino acids (Cheewatrakoolpong et al., 2005). hP2X7J results
from a transcript lacking exon 8, except for one nucleotide, resulting in a unique coding
frame which generates a protein subunit of 258 amino acids that lacks the cytoplasmic
C-terminus, second transmembrane domain and a third of the extracellular loop (Feng et
al., 2006). hP2X7J was first identified in cervical cancer cells and is thought to inhibit
apoptosis by combining with hP2X7A subunits to form a non-functional heterotrimer,
limiting the formation of normal hP2X7 homotrimers (Feng et al., 2006). hP2X7J has
also been identified in the corneal (Mankus et al., 2011) and conjunctival (GuzmanAranguez et al., 2017) epithelium where it also protects against ATP-mediated apoptosis.
hP2X7L is the most recently identified variant and occurs due to a specific P2RX7
haplotype that results in the skipping of exons 7 and 8 which leads to the deletion of key
residues in the ATP binding pocket (Skarratt et al., 2020). hP2X7L subunits can form
either homotrimers, which lack channel and pore function, or heterotrimers with fulllength hP2X7A subunits, which have reduced pore function (Skarratt et al., 2020). It is
unclear why the authors designated this new variant hP2X7L instead of continuing
alphabetically, perhaps due to a previously reported unnamed variant resulting from the
deletion of exon 2 (Sun et al., 2010) or to avoid being confused with the mouse variant
mP2X7K.
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Similar to hP2X7, splice variants have also been identified for mP2X7 with four variants
(mP2X7B, mP2X7C, mP2X7D and mP2X7K) described to date (Sluyter, 2017).
mP2X7B transcripts have a much shorter exon 13 region that encodes only one residue
before the stop codon, resulting in a protein subunit of 431 amino acids that is missing a
large portion of the C terminal cytoplasmic domain and has low receptor activity (Masin
et al., 2012). mP2X7B subunits can combine with full length mP2X7A subunits to reduce
mP2X7-mediated responses (Kido et al., 2014; Masin et al., 2012). Similar to mP2X7B,
mP2X7C is also a truncated form of mP2X7 arising from a shortened exon 13 with a
length of 442 amino acids and reduced receptor activity (Masin et al., 2012). mP2X7D is
much shorter than the aforementioned variants, with only 153 amino acids, but like
mP2X7B it can suppress the activity of full length mP2X7 subunits (Kido et al., 2014).
mP2X7K occurs due to an alternative exon 1 that deletes some and alters most of the first
40 residues of mP2X7A, resulting in a subunit of 492 amino acids with increased activity
compared to mP2X7A (Nicke et al., 2009). As mP2X7K occurs due to an altered exon 1,
GlaxoSmithKline mP2X7 -/- mice generated by deletion of exon 1 can still have functional
receptors (Nicke et al., 2009). In contrast, Pfizer (Solle et al., 2001) and Lexicon Genetics
(Basso et al., 2009) mP2rx7 -/- mice, generated by disrupting exon 13 or exons 2 and 3,
respectively, do not have functional receptors and have been used to study P2X7 in
disease and inflammation (Gonçalves et al., 2006; Sinadinos et al., 2015; Wilhelm et al.,
2010).
1.1.3. P2X7 single nucleotide polymorphisms
Sixteen missense single nucleotide polymorphisms (SNP) within hP2RX7 have been
characterised (Sluyter, 2017). Early studies in human leukocytes indicated that
differences in P2X7 activity between donors could not be explained by variation in
cell-surface expression of this receptor (Gu et al., 2000). Additionally, studies in
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macrophages (Lammas et al., 1997) and lymphocytes (Wiley et al., 1992) indicated that
some human donors have negligible P2X7 activity. Since these early studies, two
gain-of-function (GOF), twelve loss-of-function (LOF) and two neutral SNPs in hP2RX7
have been characterised (Sluyter, 2017). A number of hP2RX7 SNPs have been associated
with various diseases including Alzheimer’s (Sanz et al., 2014), multiple sclerosis
(Oyanguren-Desez et al., 2011), depression (Lucae et al., 2006), rheumatoid arthritis (AlShukaili et al., 2011), leukaemia (Zhang et al., 2021), pericarditis in systemic lupus
erythematosus patients (Hu et al., 2020b), gout arthritis (Tao et al., 2017) and tuberculosis
(Zheng et al., 2017).
The activity-SNP relationship for hP2X7 is complicated by the heterozygous inheritance
of SNPs, where coinheritance of the neutral rs2230912 (Q460R) SNP with a LOF SNP,
either rs3751143 (E496A) or rs16536624 (I568N), can increase P2X7 activity compared
to wild type (Q460) and LOF SNP coinheritance (Denlinger et al., 2006). SNPs are also
inherited in linkage disequilibrium (non-random allelic association) which results in five
distinct haplotypes in Caucasian populations, further complicating the relationship
between individual SNPs and P2X7 activity (Fuller et al., 2009; Husted et al., 2013;
Wesselius et al., 2013). Another study divided these five Caucasian haplotypes into 17
unique haplotypes and predicted the relative function of each haplotype (Jørgensen et al.,
2012). Haplotype analysis in other populations remains limited, although ten haplotypes
have been identified in Japanese (Ide et al., 2014) and four in Chinese Han (Zhou et al.,
2018) populations.
SNPs in mP2rx7 appear to be rarer, or at least less studied, than those for h P2RX7, as
only one has been characterised (Sluyter, 2017). The LOF SNP P451L occurs in some
mouse strains (C57BL, DBA and CSH) but not others (BALB/c, NOD and 129)
(Adriouch et al., 2002; Syberg et al., 2012). This SNP has been associated with reduced
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bone density and strength (Syberg et al., 2012) and impaired glucose tolerance (Todd et
al., 2015). Interestingly, introduction of a P451L mutation in hP2RX7 does not alter
activity of hP2X7 (Adamczyk et al., 2015).
1.1.4. P2X7 distribution
At first, P2X7 was primarily thought to exist on haematopoietic cells, including mast cells
(Cockcroft et al., 1979), lymphocytes (Di Virgilio et al., 1989) and macrophages (elMoatassim et al., 1992); and has since been identified on a variety of immune cell types
including dendritic cells (DC) (Ferrari et al., 2000b), eosinophils (Ferrari et al., 2000a),
B cells (Gu et al., 1998; Wang et al., 2004), T cells (Wang et al., 2004), including both
CD4 + (Yip et al., 2009) and CD8 + (Heiss et al., 2008) subsets and regulatory T cells
(Treg) (Schenk et al., 2011), and neutrophils (Karmakar et al., 2016), although expression
of P2X7 on neutrophils was originally contested (Martel-Gallegos et al., 2010). Early
evidence suggested P2X7 was present on other cell types in many organs/tissues
including the gut, kidney, urinary tract, heart, reproductive tissues, hormonal glands,
central nervous system (CNS), muscle, bone and cartilage (Burnstock et al., 2004). It is
now well established that P2X7 is expressed on many non-immune cell types including
erythrocytes (Sluyter, 2015), mesenchymal stem cells (Jiang et al., 2017), bone cells
(Agrawal et al., 2015), oligodendrocytes (Kaczmarek-Hajek et al., 2018), renal cells
(Booth et al., 2012), skin cells (Geraghty et al., 2016), exocrine cells (Novak et al., 2010),
eye cells (Sanderson et al., 2014), and cancer cells (Lara et al., 2020).
1.1.5. P2X7 activation and positive modulation
P2X7 is activated by extracellular ATP with species specific sensitivity and half maximal
effective concentrations (EC50) between 50 μM and 2.5 mM, depending on the species
and assay used (Sluyter, 2017). Importantly, it is now well established that extracellular
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ATP is a major biochemical component of the inflammatory microenvironment and can
reach concentrations sufficient to stimulate P2X7 in vivo (Di Virgilio et al., 2017). As
mentioned above (Section 1.1.1), activation of P2X7 by ATP induces a conformational
change to open the transmembrane cation channel (Jiang et al., 2021b). This channel
allows the influx of small cations including Ca2+ and Na 2+ and efflux of K+ (Egan et al.,
2004; Rassendren et al., 1997). Prolonged activation of P2X7 induces pore formation to
allow the uptake of larger organic cations, including dyes such as ethidium + or YO-PRO1 2+ (Surprenant et al., 1996; Wiley et al., 1993). Two different mechanisms for P2X7mediated pore formation have been hypothesised (Di Virgilio et al., 2018). The first of
these suggested that P2X7 recruits an accessory molecule, such as pannexin-1, to act as a
macropore and this mechanism is supported by a number of studies which demonstrated
P2X7 alone was insufficient to produce this pore (Locovei et al., 2007; Pelegrin et al.,
2006; Petrou et al., 1997). However, this hypothesis has been challenged by studies
indicating that macrophages from pannexin-1 knockout mice display normal dye uptake
(Qu et al., 2011) and blockade of pannexin-1 does not alter dye uptake (Alberto et al.,
2013).
The second hypothesis, based on observations that cation permeability increased with
activation time (Virginio et al., 1999; Yan et al., 2008), suggested that prolonged
activation of P2X7 dilates the transmembrane pore to allow passage of larger organic
cations (Di Virgilio et al., 2018). However, other evidence indicated that the pore opens
immediately following P2X7 activation (Harkat et al., 2017; Pippel et al., 2017),
disagreeing with this mechanism. Recently, Karasawa et al. (2017) demonstrated that
P2X7 alone can induce dye uptake in liposomes, but that pore formation is heavily
dependent on membrane lipid composition, with cholesterol inhibiting pore formation in
C-terminus truncated P2X7. Moreover, this study indicated that palmitoylated cysteines
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in the C-terminus of full length P2X7 counteract this inhibitory cholesterol to allow pore
formation, and the authors concluded that this may explain the inconsistent results in
previous studies (Karasawa et al., 2017). It should be noted that neither of these
hypotheses are mutually exclusive and it is likely that multiple pores are involved in
P2X7-mediated cation uptake (Coutinho-Silva et al., 1997; Marques-da-Silva et al.,
2011).
Despite these differing hypothesis, dye uptake over time (Wiley et al., 1993) or at fixed
time points (Georgiou et al., 2005) can be measured by flow cytometry, fluorescence
spectroscopy or fluorescent microscopy, and is widely used to study activation and
inhibition of P2X7 by our laboratory (Adhikary, 2020; Bartlett et al., 2013; Bartlett et al.,
2017b; Farrell et al., 2010; Geraghty et al., 2017) and others (Gonzaga et al., 2019;
Pislyagin et al., 2021; Piyasirananda et al., 2021).
The synthetic ATP analogue BzATP is also an agonist for P2X7 in most species (Sluyter,
2017), and activates both hP2X7 (Rassendren et al., 1997) and mP2X7 (Chessell et al.,
1998b) 10-fold more potently than ATP.

Additionally, 2-methylioadenosine

5’-triphosphate (2MeSATP) and adenosine 5’-[γ-thio] triphosphate (ATPγS) can also
activate hP2X7, with EC50 values approximately two-and-half- or two-fold greater,
respectively, than ATP (Donnelly-Roberts et al., 2009). Notably, this study indicated that
both 2MeSATP and ATPγS showed weak, or absent, agonist activity against mP2X7 from
both BALB/c and C57BL/6 mice (Donnelly-Roberts et al., 2009). Other nucleotides,
including adenosine 5’-diphosphate (ADP), adenosine 5’-monophosphate (AMP) and
uridine 5’-triphosphate (UTP), do not activate either hP2X7 or mP2X7 (DonnellyRoberts et al., 2009). However, activation of mP2X7 with ATP or BzATP made the
receptor sensitive to high (mM) concentrations of ADP and AMP, and both nucleotides
induced currents through P2X7 (Chakfe et al., 2002). However, this observation has not

36

been reproduced by others, so confirmation of this action of ADP and AMP is still
required.
Nicotinamide adenine dinucleotide (NAD) can activate mP2X7 receptors due to the
presence of ADP-ribosyltransferases (ART) enzymes, ART2.1 and ART2.2, on the cell
surface (Hong et al., 2009; Seman et al., 2003). These enzymes transfer a ribose moiety
from NAD to the R125 residue, located near the ATP binding pocket of P2X7, to activate
mP2X7 (Adriouch et al., 2008). Of note, NAD directly activated mP2X7 in lymphocytes,
which express relatively high levels ART enzymes, but only potentiated ATP-mediated
P2X7 activation in naive macrophages, which express low-levels of ART (Hong et al.,
2009). As such, it is still unclear if NAD is a true agonist or a positive modulator of
mP2X7 (Di Virgilio et al., 2018).
A number of other positive modulators of both, or either, hP2X7 and mP2X7 have been
described (Stokes et al., 2020). The bactericidal peptide cathelicidin LL-37 was originally
shown to activate hP2X7, inducing dye uptake into and interleukin (IL)-1β release from
human monocytes, and these effects can be inhibited by P2X7 antagonists (Elssner et al.,
2004). However, other studies indicated that LL-37 acts as a positive modulator of P2X7,
as it enhances BzATP-mediated hP2X7 activation (Tomasinsig et al., 2008) and
ATP-mediated mP2X7 activation (Pochet et al., 2006). Similarly, the antibiotic
polymyxin B is also a positive allosteric modulator of P2X7 as it enhances
ATP-induced P2X7 responses, including Ca 2+ influx, plasma membrane permeabilization
and cytotoxicity, in both murine and human macrophages and P2X7 transfected cell lines
(Ferrari et al., 2004; Ferrari et al., 2007). The anti-inflammatory drug tenidap is another
positive modulator that increases the sensitivity of murine macrophages to ATP and
increases P2X7-mediated responses (Sanz et al., 1998). Clemastine, an antihistamine,
also acts as an allosteric positive modulator of P2X7 and increases the sensitivity of P2X7
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to ATP in human and murine macrophages (Nörenberg et al., 2011). Ivermectin is a
broad-spectrum anti-parasitic that was originally shown to act as a positive modulator of
P2X4 (Khakh et al., 1999) and has since been shown to have a similar effect on hP2X7,
but not mP2X7, as it increases ATP-induced currents and Ca 2+ influx (Nörenberg et al.,
2012). Ginsenosides are naturally occurring plant-derived compounds which potentiate
ATP-induced P2X7 currents, Ca 2+ influx and dye uptake (Helliwell et al., 2015).
Molecular modelling and computational docking identified a novel allosteric binding site
for these ginsenosides involving residues S60, A318 and L320 in the β -strands which
connect the ATP binding site to the transmembrane domain (Bidula et al., 2019).
P2X7 activation and LPS have long been tied together in the activation of macrophages
and release of IL-1β (Ferrari et al., 1997b). More recently, intracellular LPS has been
shown to increase extracellular ATP, through the cleaving of the ATP-release channel
pannexin-1, which leads to P2X7 activation (Yang et al., 2015). Intracellular LPS lowers
the threshold required for P2X7 activation (Yang et al., 2015), potentially due to LPS
binding to the intracellular LPS-binding domain of P2X7 mentioned above (Section
1.1.1) (Denlinger et al., 2001) and inducing a conformational change in the receptor,
although this is yet to be confirmed.
1.1.6. P2X7 inhibition
Oxidised ATP (oATP) was the first P2X7 antagonist published (Murgia et al., 1993) and
was utilised widely in the early study of P2X7 function (Di Virgilio, 2003). Since then, a
number of selective and non-selective P2X7 antagonists have been identified and
characterised, and several have been tested in clinical trials, although none of these drugs
have been adopted clinically (Bartlett et al., 2014; Gelin et al., 2020; Park et al., 2017).
Many P2X7 antagonists have been examined against both hP2X7 and mP2X7 and
species-specific potencies have been observed (Donnelly-Roberts et al., 2009; Hibell et
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al., 2001). As mentioned above (Section 1.1.1), an allosteric binding pocket for multiple
hydrophobic P2X7 antagonists, A740003, A804598, AZ10606120, GW91343 and JNJ47965567, was identified in pdP2X7 (Karasawa et al., 2016) with a similar pocket
described in hP2X7 (Allsopp et al., 2017). Moreover, an overlapping allosteric pocket
that can accommodate larger antagonists, including BBG, has also been identified (Bin
Dayel et al., 2019). In contrast, other inhibitors, including oATP and pyridoxalphosphate6-azophenyl-2',4'-disulfonic acid (PPADS) (Huo et al., 2018), bind directly to the ATPbinding site of P2X receptors to block activity. However, this renders them relatively nonselective for P2X7 as these compounds can also inhibit other P2X and some P2Y
receptors (Sluyter, 2017). The remainder of this section will focus on the antagonists used
in this thesis, which are summarised in Table 1.1.
Table 1.1 Summary of the P2X7 antagonists used throughout this thesis.
hP2X7
IC50 (nM)

mP2X7
IC50 (nM)

Off-target effects
and inhibition

Reference(s)

BBG

~250-2000 ~200-500

Protein stain,
pannexin-1

Jiang et al. (2000),
Donnelly-Roberts et al.
(2009), Qiu et al. (2009)

PPADS

~3000

~40 000

P2X1, P2X2, P2X3,
P2Y1

Donnelly-Roberts et al.
(2009)

JNJ-47965567

~5-30

~30

Melatonin 1
receptor, serotonin
transporter

Bhattacharya et al.
(2013)

Amiloride

> 106

Unknown

Most sodium
transporters, uPA

Wiley et al. (1990),
Kleyman et al. (1988),
Sun et al. (2020),
Vassalli et al. (1987)

HMA

~20000

Unknown

Some sodium
transporters, uPA

Wiley et al. (1993),
Kleyman et al. (1988),
Matthews et al. (2011)

IC50, half maximal inhibitory concentration BBG, Brilliant Blue G; PPADS, pyridoxalphosphate-6azophenyl-2',4'-disulfonic acid; uPA, urokinase-type plasminogen activator; HMA, 5-(N, NHexamethylene) amiloride.
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BBG was first, and still is, used to stain polyacrylamide gels (Diezel et al., 1972) but was
also identified as an antagonist for purinergic receptors (Soltoff et al., 1989). Following
this early study, BBG was characterised as a non-competitive P2X7 antagonist, inhibiting
BzATP-induced currents with half maximal inhibitory concentration (IC 50) values of
265 nM and 10 nM against hP2X7 and rP2X7, respectively, displaying species-dependent
specificity (Jiang et al., 2000). BBG is 10-fold less potent against hP2X4, compared to
hP2X7, with an IC50 of 3000 nM and did not appear to inhibit hP2X1 or hP2X3 in this
study (Jiang et al., 2000). In another study, BBG blocked ATP-induced YO-PRO-12+ dye
uptake with an IC50 of 2000 nM for hP2X7 and 200-500 nM for mP2X7, although the
effect of BBG on Ca 2+ responses was minimal (Donnelly-Roberts et al., 2009). Moreover,
this study provided conflicting evidence that BBG does not inhibit hP2X4 and confirmed
that it does not inhibit other hP2X receptors, hP2Y1 or hP2Y2 (Donnelly-Roberts et al.,
2009). BBG also inhibits the ATP-release channel pannexin-1 (Qiu et al., 2009),
hindering the use of this compound for studying P2X7 responses in vivo and in vitro.
Despite this non-selectivity, BBG is one of the most published in vivo P2X7 antagonists
due to its long history of use and relatively low cost (Bartlett et al., 2014), making it a
prime ‘proof of concept’ antagonist.
PPADS was first described as a P2 receptor inhibitor (Lambrecht et al., 1992) and has
since been shown to inhibit P2X1, P2X2, P2X3, P2X7 and P2Y 1 (Charlton et al., 1996;
Donnelly-Roberts et al., 2009). PPADS inhibits ATP-induced Ca2+ responses with similar
potencies against hP2X7, hP2X1 and hP2Y1 with IC50 values of 3.2 μM, 1.3 μM and
2.0 μM, respectively, but is approximately 10-fold less potent against hP2X2 and hP2X3
(Donnelly-Roberts et al., 2009). Moreover, PPADS is 10 times more potent for hP2X7
than mP2X7, inhibiting Ca 2+ responses with IC50 values of 3 μM and 40 μM, respectively
(Donnelly-Roberts et al., 2009). Despite the relatively poor selectivity of this compound,
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PPADS has been used to study P2X7 in vivo in a range of diseases including neurological
and inflammatory disorders (Bartlett et al., 2014).
Early P2X7 antagonists, including BBG and PPADS, were useful for identifying roles for
P2X7 in disease, however the lack of selectivity hindered the use of these compounds in
the clinic. As such, a range of more specific P2X7 antagonists have been developed over
the past ten years (Bartlett et al., 2014; Gelin et al., 2020). One such antagonist is
JNJ-47965567 which inhibits hP2X7- and mP2X7-mediated Ca 2+ flux with IC50 values
of 5 nM and 30 nM, respectively (Bhattacharya et al., 2013). This compound also inhibits
ATP-induced IL-1β release from human whole blood and human peripheral blood
mononuclear cells (PBMC) with IC 50 values of 30 nM and 200 nM, respectively
(Bhattacharya et al., 2013). JNJ-47965567 appeared to inhibit hP2X7 and rP2X7 in a
competitive manner (Bhattacharya et al., 2013), however another study indicated that this
compound inhibits pdP2X7 in a non-competitive manner, and binds to the allosteric
binding pocket (Karasawa et al., 2016). Whether one of these studies is incorrect, or if
the mode of inhibition of JNJ-47965567 is species-dependent is unknown. As such, it is
unknown if JNJ-47965567 inhibits mP2X7 in a competitive or non-competitive manner.
JNJ-47965567 is specific for P2X7 and does not inhibit other P2X receptors, or other ion
channels and transporters, except for a melatonin 1 receptor and a serotonin transporter
at 10 μM (Bhattacharya et al., 2013). Furthermore, this compound is CNS permeable
(Bhattacharya et al., 2013) and can be used to examine the role of P2X7 in the CNS in
models of neurological diseases such as amyotrophic lateral sclerosis (ALS).
Amiloride, a commonly used diuretic that inhibits sodium transporters (Kleyman et al.,
1988; Sun et al., 2020), and amiloride derivatives also act as P2X7 antagonists. Amiloride
partly inhibits ATP-mediated Na + fluxes in lymphocytes with a 50 % reduction at 1 mM,
while 5-(N-ethyl-N-isopropyl) amiloride (EIPA) and 5-(N, N-hexamethylene) amiloride
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(HMA) are more potent P2X7 antagonists, inhibiting ATP-induced Na + fluxes by 72 %
and 95 %, respectively, at 40 μM (Wiley et al., 1990). Likewise, HMA can also inhibit
ATP-mediated ethidium + uptake in human lymphocytes (approximately 50 % blockade
at 20 μM) but concentrations > 100 μM are required for complete inhibition (Wiley et al.,
1993; Wiley et al., 1998). Further, another study demonstrated that HMA inhibits
BzATP-induced inward currents in human embryonic kidney (HEK)293 cells stably
transfected with hP2X7 (30 % reduction at 10 μM) and this inhibition appeared to be
non-competitive (Chessell et al., 1998a), although it should be noted that only two
concentrations of HMA were used and BzATP responses did not plateau so this evidence
is inconclusive. Similarly, HMA (40 μM) partially inhibits ATP- and BzATP-induced
currents in Xenopus oocytes injected with mouse macrophage BAC1.2F5 cell mRNA,
however only Li+, N-methyl-D-glucamine+ and Tris+ currents were assessed (Nuttle et al.,
1994). HMA inhibits BzATP-induced uptake with reduced potency against mP2X7
compared to hP2X7, and at a relatively low concentration (16 μM) of BzATP, HMA
potentiated mP2X7 dye uptake (Hibell et al., 2001). Despite the inhibitory effects of
amiloride and HMA against P2X7 observed in these studies, these compounds have not
been further pursued as P2X7 antagonists. Recently, our laboratory has gained access to
a library of novel amiloride and HMA analogues (Buckley et al., 2018; Buckley et al.,
2021). Therefore, it is possible a derivative of either amiloride or HMA may provide a
more potent and selective P2X7 antagonist than either of these parent compounds.
1.1.7. P2X7 on immune cells and in inflammation
As mentioned above (Section 1.1.4), P2X7 is expressed on the cell surface of many
immune cell subtypes including antigen presenting cells (APC), and effector and
suppressive immune cells. As such, P2X7 plays several roles during inflammation (Di
Virgilio et al., 2017) including the assembly of the NOD-like receptor family pyrin
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domain containing 3 (NLRP3) inflammasome and subsequent release of IL-1β (Dubyak,
2012). Pathogen-associated molecular patterns (PAMP), including LPS, interact with
Toll-like receptors to induce the production and cytoplasmic accumulation of pro-IL-1β
(Dubyak, 2012). Activation of P2X7 by extracellular ATP leads to the efflux of K+, and
this decrease in intracellular K+ is involved in the activation of the NLRP3
inflammasome, leading to the formation of mature caspase-1, which converts pro-IL-1β
to mature IL-1β, although this process is typically coupled with cell death (Laliberte et
al., 1999; Muñoz-Planillo et al., 2013; Perregaux et al., 1994). Other studies suggest that
IL-1β release can occur in the absence of K + fluxes and cell death through the involvement
of reactive oxygen species (Heid et al., 2013; Zhou et al., 2011), although neither of these
studies examined the role of P2X7 in this mechanism. The release of IL-1β is thought to
occur through the exocytosis of secretory lysosomes or autophagosomes, the release of
microvesicles or exosomes, or direct efflux following caspase-1 mediated cell death, or a
combination of these pathways (Dubyak, 2012). More recent studies indicate that
caspase-1 and/or caspase-11 mediate cleavage of gasdermin D and subsequent pore
formation leading to IL-1β release (He et al., 2015). ATP/P2X7-mediated release of IL1β has been shown in human and mouse monocytes and macrophages (Ferrari et al.,
1997a; Laliberte et al., 1997; Qu et al., 2007), microglia (Ferrari et al., 1996; Ferrari et
al., 1997b) and DCs (Ferrari et al., 2000b). IL-1β is a pro-inflammatory cytokine that
plays multiple roles in inflammation including driving T cell responses. IL-1β enhances
antigen-primed CD4 + and CD8 + T cell expansion and cytokine production (Ben-Sasson
et al., 2013), promotes the induction and differentiation of pathogenic T helper (Th)17
cells (Chung et al., 2009; Sutton et al., 2006), induces the production of IL-17 and IL-21
by γδ T cells (Sutton et al., 2009) and primes interferon (IFN)γ-producing CD8 + T cells
against tumour cells (Ghiringhelli et al., 2009). The latter of these studies showed a direct
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role for P2X7 on APCs in this process. Together these studies indicate that P2X7
activation on APCs leads to IL-1β release which promotes inflammation by enhancing T
cell responses (Figure 1.1). Additionally, IL-1β drives the differentiation of monocytes
into macrophages with enhanced antigen presenting capabilities (Schenk et al., 2014) and
promotes B cell proliferation (Lipsky et al., 1983).

Figure 1.1: P2X7 activation on antigen presenting cells (APCs) promotes T cell activation.
Extracellular adenosine 5’-triphosphate (ATP) activates P2X7 on antigen presenting cells (APC)
which leads to the activation of these cells. Activated APCs directly interact with T cells and
release pro-inflammatory cytokines, including interleukin (IL)-1β, to promote T cell activation,
proliferation and ATP release. This process also directs the differentiation of naive CD4+ T cells
to T helper (Th)17 cells and primes interferon (IFN)γ producing CD8 + T cells. Created in
BioRender.com.

P2X7 is also involved in other pro-inflammatory events including the release of
pro-inflammatory cytokines; such as IL-6 from mouse microglia (Shieh et al., 2014) and
mast cells (Kurashima et al., 2012), and human fibroblasts (Solini et al., 1999), tumour
necrosis factor (TNF) from mouse microglia (Shieh et al., 2014) and human DCs (Ferrari
et al., 2000b), and IL-23 from human lamina propria (Atarashi et al., 2008) and migratory
skin DCs (Killeen et al., 2013). P2X7 is also involved in the expression of chemokines
including monocyte chemoattractant protein-1 (MCP-1) in mouse mast cells (Kurashima
et al., 2012), CC ligand (CCL)3 in mouse microglia (Kataoka et al., 2009) and chemokine
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(C-X-C motif) ligand (CXCL)2 in mouse microglia (Shiratori et al., 2010) and mast cells
(Kurashima et al., 2012). Activation of P2X7 also leads to the activation of
pro-inflammatory metalloproteases, such as A disintegrin and metalloprotease
(ADAM)-10, which induce the shedding of cell surface molecules (Pupovac et al., 2016),
including CD23 from human chronic lymphocytic leukaemia lymphocytes (Gu et al.,
1998). P2X7 activation is involved in the shedding of CD23 from human DCs (Sluyter et
al., 2002) and Langerhans cells (Georgiou et al., 2005) and human and mouse B cells
(Pupovac et al., 2015). Once shed, CD23 exists in a soluble form that has a range of
cytokine-like effects (Acharya et al., 2010), such as promoting the differentiation of
myeloid precursors (Mossalayi et al., 1990) and T cells (Bertho et al., 1991), sustaining
B cell growth (Cairns et al., 1990) and driving cytokine release from monocytes
(Hermann et al., 1999).
Alongside the release of pro-inflammatory molecules, many of which are involved in
T cell activation and differentiation, P2X7 also plays direct roles on CD4 + and CD8+
T cells (Rivas-Yáñez et al., 2020). The P2X7-mediated activation of metalloproteases
may be involved in T cell migration. L-selectin (CD62L) is essential for T cell migration
as it binds to addressins on endothelial cells, allowing entry into secondary lymph tissues
(Arbonés et al., 1994; Masopust et al., 2013), however to leave the lymph node T cells
must reduce cell surface CD62L expression (Mueller et al., 2013). ATP-induced CD62L
shedding was first shown on chronic lymphocytic leukaemia lymphocytes (Jamieson et
al., 1996) and subsequently on human T and B cells (Sengstake et al., 2006) and human
CD4 + and CD8 + T cells (Sluyter et al., 2014) . Stimulation of P2X7 activates ADAM-10
and ADAM-17 both of which induce the shedding of CD62L, although ADAM-17 is the
predominant metalloprotease involved (Le Gall et al., 2009; Le Gall et al., 2010).
Moreover, the ability of ATP/P2X7 to induce CD62L shedding is dependent on the
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activation state of the T cell as recently activated T cells had decreased CD62L shedding
compared to effector T cells, indicating that these recently activated T cells cannot leave
secondary lymphoid tissues as readily as effector T cells (Safya et al., 2018). Together
these studies indicate a potential role for P2X7 activation in the migration of activated
T cells from lymphoid tissues.
P2X7 activation also directly stimulates CD4 + T cells to drive the activation of these cells.
T cell receptor (TCR)-stimulation on CD4 + T cells (Schenk et al., 2008; Woehrle et al.,
2010a; Yip et al., 2009) or hypertonic stress of CD4 + T cells (Woehrle et al., 2010b) leads
to the release of ATP through pannexin-1 from these cells. This extracellular ATP
activates P2X receptors including P2X1, P2X4 and P2X7 to promote Ca2+ influx and
T cell activation (Woehrle et al., 2010a; Yip et al., 2009). Moreover, TCR activation
upregulates P2RX7 expression, and the subsequent ATP release increases nuclear factor
of activated T cells (NFAT) activation which promotes IL-2 production in CD4 + T cells
(Woehrle et al., 2010a; Yip et al., 2009). Inhibition of P2X7 or removal of extracellular
ATP with apyrase reduces CD4 + T cell activation (Yip et al., 2009), supporting a role for
autocrine stimulation of P2X7 during T cell activation. Extracellular ATP released from
CD4 + T cells also promotes mitogen-activated protein kinase signalling (MAPK), which
is involved in cell proliferation, differentiation, survival and apoptosis (Pearson et al.,
2001), while oATP reduces MAPK activation (Schenk et al., 2008). Although this study
did not directly demonstrate that P2X7 was responsible for MAPK activation, as oATP
can inhibit other P2X receptors (Sluyter, 2017), a subsequent study demonstrated that the
more specific P2X7 antagonist KN-62 can also reduce ATP-mediated MAPK activation
in CD4 + T cells (Yu et al., 2010). Regardless, P2X1 and P2X4 are likely to also play a
role in the activation of T cells as inhibition or silencing either of these receptors inhibits
NFAT activation and IL-2 synthesis (Woehrle et al., 2010a; Woehrle et al., 2010b).
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Together these studies demonstrate that P2X7, and other P2X receptors, on CD4 + T cells
play a direct role in the activation of these cells.
CD4 + Tregs, which have the ability to suppress immune responses and inflammation
(Grover et al., 2021), express higher levels of P2X7 and are more susceptible to
ATP-induced cell death than other T cells (Rivas-Yáñez et al., 2020). Following contact
with ATP, or NAD or BzATP, mouse Tregs can undergo necrotic lysis with in seconds
while conventional T cells are relatively resistant to this rapid death (Aswad et al., 2005),
Additionally, Treg proportions are increased in P2rx7 -/- mice, and NAD or BzATP does
not induce the death of Tregs from these mice (Aswad et al., 2005) further supporting the
notion that P2X7 activation can induce the death of Tregs. Tregs express higher levels of
P2rx7 than conventional CD4 + T cells, and Tregs from P2rx7 -/- mice have greater
suppressive capacity than Tregs from wild type mice, likely due to P2X7 activation
reducing forkhead box P3 (FOXP3), promoting extracellular signal–regulated kinase
activity (ERK) and enhancing responses to IL-6, including ATP synthesis, within these
cells (Schenk et al., 2011). This reduction in FOXP3, alongside increased ATP release,
decreases Treg stability and allows the conversion of Tregs to Th17 cells, with similar
effects observed following BzATP stimulation of Tregs (Schenk et al., 2011).
Additionally, blockade of P2X7 with oATP promotes the conversion of conventional
CD4 + T cells into Tregs, a process which is dependent on a reduction in ERK activation,
due to P2X7 blockade, and transforming growth factor (TGF)β (Schenk et al., 2011).
Notably, blockade of P2X7 increases Tregs in mouse models of inflammatory bowel
disease (Schenk et al., 2011), renal ischemia-reperfusion injury (Koo et al., 2017) and
muscular dystrophy (Gazzerro et al., 2015) leading to reduced disease severity. Together
these studies indicate that P2X7 activation on Tregs reduces the number and suppressive
capabilities of these cells to promote inflammation and furthers the notion that blockade
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of P2X7 may present a viable strategy for increasing Tregs, and immune suppression, in
inflammatory diseases.
Mouse CD4 + Follicular helper T (Tfh) cells, which promote B cell antibody responses
(Song et al., 2019), also highly express P2rx7 (Iyer et al., 2013; Proietti et al., 2014).
P2X7 mediates Tfh cell death and controls the number of these cells in Peyer’s patches
(Proietti et al., 2014). This study demonstrated that P2rx7 -/- mice have increased
Tfh cells in Peyer’s patches, and that these increases in Tfh cells are associated with
increased germinal centre reactions and immunoglobulin (Ig)A secretion. P2X7 also
promotes Tfh cell death in mouse models of malaria (Salles É et al., 2017), autoimmune
arthritis (Felix et al., 2019), and systemic lupus erythematosus (Faliti et al., 2019) to
reduce disease. Together these studies paint a beneficial role for P2X7 activation in
controlling potentially pathogenic Tfh cell numbers, which may complicate targeting the
P2X7 receptor to reduce inflammation in diseases involving these cells.
P2X7 is also involved in the generation of long-lived central memory and tissue resident
memory CD8 + T cells (Wanhainen et al., 2019). Borges da Silva et al. (2018)
demonstrated that P2rx7 -/- mice have impaired central memory and tissue resident
memory CD8 + T cell generation compared to wild type mice. The authors then
demonstrate that P2X7 acts through AMP-activated protein kinase to promote metabolic
function and mitochondrial homeostasis of memory CD8 + T cells, with blockade of P2X7
in vitro and in vivo reducing the fitness and compromising the production of these cells
(Borges da Silva et al., 2018). A subsequent study demonstrated that P2X7 promoted
tissue resident memory CD8 + T cell generation by inducing expression of TGF receptors
to enhance CD8 + T cell responsiveness to TGFβ (Borges da Silva et al., 2020). This study
also demonstrated that P2X7 was needed for the long-term maintenance of these tissue
resident memory CD8 + T cells. Long-lived memory CD8 + T cells with a
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CD44 highCD45RBhigh phenotype are resistant to ATP-induced responses (Mellouk et al.,
2019) and CD45RBhigh CD8 + T cells display increased survival, compared to their
CD45RBlo counterparts, in vivo (Krummey et al., 2020). Together these studies indicate
that activation of P2X7 promotes the development of memory CD8 + T cells, with a subset
of these cells becoming resistant to ATP-induced responses, including cell death.
In summary, P2X7 has various pro-inflammatory roles on immune cells during
inflammation. The studies discussed above form a model in which activation of P2X7 on
APCs results in the activation of these cells and subsequent release of multiple
pro-inflammatory molecules to stimulate T cells. Additionally, activation of P2X7
directly on T cells is involved in the generation, activation, migration, differentiation,
maintenance, and death of these T cells, including Tregs (Figure 1.2). As such, targeting
P2X7 presents a potential multifaceted therapy for treating inflammatory diseases.

1.2.Graft-versus-host disease
Haematological disorders arise from the abnormal transformation of blood, bone marrow
or lymphatic cells, and allogeneic (allo) haematopoietic stem cell (HSC) transplantation
(HSCT) is a curative therapy for these diseases. Unfortunately, allo-HSCT induces a
severe, and often lethal, T cell mediated inflammatory response against host tissues
known as graft-versus-host disease (GVHD). Current treatments for GVHD rely mainly
on immunosuppression or T cell depletion, however neither of these strategies completely
ablates disease and these treatments have been associated with cancer relapse and an
increased risk of infection. Therefore, new and better therapeutics, such as P2X7
blockade, are required to treat GVHD. The following section will briefly introduce
haematological malignancies and allo-HSCT before focusing on GVHD, including the
role of P2X7 in this disease.
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Figure 1.2: P2X7 activation directly on T cells promotes the migration, differentiation,
proliferation, and either survival or death of these cells. P2X7 activation on T cells can
mediate T cell migration through A disintegrin and metalloprotease (ADAM)-17 mediated
shedding of L-selectin (CD62L). P2X7 activation enhances nuclear factor of T cell (NFAT)
activation, interleukin (IL)-2 release and mitogen-activated protein kinase signalling (MAPK) in
CD4+ T cells to promote the differentiation, proliferation and survival of these cells. Contrarily,
P2X7 activation can induce cell death of regulatory T cells (Treg) and follicular helper T (Tfh)
cells and promote the conversion of Tregs to T helper (Th)17 cells through the downregulation of
forkhead box P3 (FOXP3) and upregulation of adenosine 5’-triphosphate (ATP) synthesis.
Additionally, P2X7 activation increases the expression of transforming growth factor (TGF)
receptors on CD8+ T cells to promote the generation of memory CD8 + T cells and further P2X7
activation on these cells increases the metabolic function and survival of these cells. Created in
BioRender.com.
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1.2.1. Haematological malignancies
Haematological disorders are a complex group of diseases that include malignant blood
cancers, like leukaemia, lymphoma and myeloma which account for 10 % of worldwide
cancers (Siegel et al., 2016), and other non-malignant disease including myelodysplastic
syndrome (Swerdlow et al., 2017). Treatments for malignant blood cancers include
chemotherapy and radiotherapy (Terwilliger et al., 2017), while treatments for
non-malignant disease such as myelodysplastic syndrome include hypomethylating
agents (Arslan et al., 2021). Moreover, allo-HSCT is an alternate curative therapy for
both malignant and non-malignant haematological disorders, and often follows the
treatments mentioned above (Arslan et al., 2021; Khorochkov et al., 2021; Shanbhag et
al., 2018; Takami, 2018).
1.2.2. Allogeneic haematopoietic stem cell transplantation
Allo-HSCT was first used 50 years ago to treat immunodeficiency (Bach et al., 1968) and
anaemia (Thomas et al., 1972), and is now a well-established therapy for a range of
haematological disorders (Appelbaum, 2007). Prior to allo-HSCT, recipients receive
myeloablative chemotherapy and/or radiotherapy to destroy any malignant cells and
remaining immune cells, to prevent immunologically mediated HSCT rejection
(Bacigalupo et al., 2009; Gyurkocza et al., 2014). Peripheral blood HSCs or bone marrow
cells are collected from a healthy donor and infused into the recipient, and the HSCs
present in the infusion migrate to the bone marrow (Copelan, 2006). These HSCs engraft
and replace the recipient’s haematopoietic system and blood counts are fully recovered
in as little as 3 to 4 weeks (Bishop et al., 2000; Lapidot et al., 2005).
Autologous (auto)-HSCT, in which HSCs are derived from the recipient themselves, can
also be used to reconstitute the immune system following myeloablative treatment
(Passweg et al., 2012), however this therapy is often unsuitable for patients whose blood
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or bone marrow is contaminated with cancer cells, or if they have history of
chemotherapy/radiotherapy (Hosing et al., 2002).
The graft-versus-tumour (GVT) effect is a major therapeutic benefit provided by
allo-HSCT, but not auto-HSCT (Welniak et al., 2007). GVT occurs when donor T cells
recognise host tumour cells and mount an effector response against them (Blazar et al.,
2020). Both CD4 + and CD8 + T cells are primed by interacting with major
histocompatibility complex (MHC) molecules, alongside costimulatory molecules, on
host haematopoietic APCs (Matte-Martone et al., 2008). Once primed, these T cells
interact with MHC molecules and/or minor histocompatibility antigens (mHA) on tumour
cells directly (Goulmy, 2004; Matte-Martone et al., 2008), and produce a GVT response
that involves multiple cytolytic pathways (Blazar et al., 2020), including the secretion of
IFNγ by effector T cells to enhance antigen presentation and recognition of tumour cells
(Matte-Martone et al., 2017). Unfortunately, host APCs also prime donor
T cells against host tissues, initiating a severe and often lethal inflammatory response
known as GVHD (Fowler, 2006).
1.2.3. GVHD pathophysiology
Early studies of bone marrow transplantation in mice observed a fatal wasting disease
characterised by diarrhoea and skin lesions (Barnes et al., 1957), which was later
described as a graft-versus-host reaction (Barnes et al., 1962) and is now known as
GVHD. Despite the various prophylactic treatments and therapies available (Zeiser et al.,
2017), GVHD is still a major problem with 30 to 50 % of recipients, receiving HSCs from
a matched sibling or an unrelated donor, respectively, developing acute GVHD (Saber et
al., 2012). Moreover, 30 to 70 % of recipients develop chronic GVHD (Lee et al., 2002).
Acute and chronic GVHD were originally defined by the time at which they occurred,
with acute GVHD occurring within 100 days of allo-HSCT and chronic GVHD occurring
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at least 100 days after allo-HSCT (Martin et al., 1990; Sullivan et al., 1991). Acute and
chronic GVHD are now defined by their differing pathologies (Ramachandran et al.,
2019; Schultz et al., 2020). Acute GVHD is mediated mainly by donor T cells and
presents as tissue damage mainly in the liver, gut, skin, and lungs while chronic GVHD
is mediated by a variety of both innate and adaptive immune cells and results in tissue
damage, abnormal repair and fibrosis. Moreover, cases in which acute and chronic GVHD
overlap and patients display pathologies of both forms have been identified (Lee, 2017).
As this thesis focuses on the acute form of GVHD, future use of GVHD will be referring
to the acute form of disease, unless otherwise stated.
GVHD is mediated primarily by donor T cells in a three stage process: the afferent phase
in which host APCs become activated, the efferent phase in which host APCs activate
donor T cells, and the effector phase in which activated donor T cells mediate tissue
destruction (Ferrara et al., 1999) (Figure 1.3).
The afferent phase of GVHD is initiated following damage to host tissues from either pretransplant conditioning, allo-HSCT itself or early GVHD (Ferrara et al., 2006). Early
tissue damage causes the release of damage-associated molecular patterns (DAMP) and
PAMPs, such as ATP (Wilhelm et al., 2010) and LPS (Hill et al., 1997), respectively, as
well as pro-inflammatory cytokines, including TNFα and IL-1α and IL-6 (Xun et al.,
1994). Together these molecules serve to activate host APCs, which are essential for the
development of GVHD (Shlomchik et al., 1999). Additionally, lower intensity
pre-transplant conditioning regimes minimise APC activation, reducing but not
eliminating GVHD (Baron et al., 2012; Nakasone et al., 2015).
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Figure 1.3: Graft-versus-host disease (GVHD) has a three-stage pathophysiology. The
afferent phase occurs when initial tissue damage from pre-transplant conditioning or early GVHD
initiates the release of damage-associated molecular patterns (DAMP), pathogen-associated
molecule patterns (PAMP) and cytokines. These pro-inflammatory molecules, including
adenosine triphosphate (ATP), lipopolysaccharide (LPS), interleukin (IL)-1 and tumour necrosis
factor (TNF)α, activate host antigen presenting cells (APC). Next, host APCs initiate the efferent
phase of disease by activating donor T cells to drive their differentiation and proliferation. Finally,
the effector phase occurs when activated donor T cells migrate to host tissues and cause severe
inflammatory damage, promoting the further release of pro-inflammatory molecules in a positive
feedback cycle. Created in BioRender.com.

The efferent phase of GVHD begins when host APCs activate alloreactive donor T cells.
Donor CD4 + and CD8 + T cells recognise host MHC class II and MHC class I on APCs,
respectively, and genetic mismatches in these molecules between the host and donor
stimulates T cells (Sprent et al., 1988). Additionally, and in cases where MHC molecules
are matched, differences in mHAs between the host and donor can also result in the
activation of T cells (Goulmy et al., 1996). Following their stimulation and activation,
donor T cells proliferate and differentiate into a variety of subsets (Jiang et al., 2021a).
For example, CD4 + cells can differentiate into effector Th1 and Th17 subtypes following
TCR stimulation and cytokine co-stimulation, relying on IL-12 (Magram et al., 1996) and
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TGFβ, IL-6 and IL-23 (Singh et al., 2013), respectively. Like CD4 + T cells, TCR and
cytokine stimulation during GVHD also directs the proliferation and differentiation of
donor CD8 + T cells into various subsets (Jiang et al., 2021a), including central memory
and effector memory CD8 + T cells (Khandelwal et al., 2020).
Finally, the effector phase of GVHD occurs when activated alloreactive donor T cells
migrate to host tissues, including the liver, gut, lung and skin, and initiate severe
inflammatory damage through multiple pathways (Ferrara et al., 2006). T cell migration
is influenced by the cell surface expression of homing molecules which can interact with
addressins on host cells (Mackay, 1993). Cutaneous lymphocyte antigen (CLA)
(Tsuchiyama et al., 2009) and β7 integrin (Petrovic et al., 2004) are two such homing
molecules which direct T cells to the skin and gut respectively. Moreover, expression of
CLA (Tsuchiyama et al., 2009) and integrin β7 (Chen et al., 2013) on T cells correlates
with worsened skin and gut GVHD, respectively, while increased expression of either
molecule on Tregs is associated with reduced GVHD in the respective tissues (Engelhardt
et al., 2011). Likewise, CCR5 is associated with increased infiltration of CD8 + T cells in
the liver during GVHD (Murai et al., 1999), however transplantation of donor cells from
Ccr5 -/- mice increases GVHD compared to transplanted wild type cells (Welniak et al.,
2004). As such, the use of CCR5 as a marker for liver homing T cells may be limited.
Following migration to target tissues, activated donor CD4 + T cells are thought to lyse
target host cells mainly through the Fas/FasL pathway while activated donor CD8+
T cells, including effector memory CD8 + T cells (Khandelwal et al., 2020), operate via
the perforin/granzyme pathway (Ferrara et al., 2006). Additional to these direct cytolytic
pathways, Th1 and Th17 cells produce the pro-inflammatory cytokines IFNγ (Mosmann
et al., 1986) and IL-17 (Park et al., 2005), respectively, to promote GVHD development.
IFNγ interacts with host cells in the gut and skin to make these tissues more susceptible
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to GVHD damage (Dickinson et al., 1991; Mowat, 1989), a response due in part to IFNγ
and LPS priming of macrophages (Nestel et al., 1992). IL-17 likely contributes to GVHD
by increasing the production of other cytokines, including IFNγ and IL-6 (Kappel et al.,
2009), possibly promoting Th1 responses to increase inflammation (van der Waart et al.,
2014).
1.2.4. GVHD in target tissues
As mentioned previously (Section 1.2.3), the classic target organs of GVHD include the
gut, liver and skin, with increasing evidence that the lung can also be affected by GVHD.
Additionally, other non-classical target organs including the CNS, ovaries, testis, thymus,
bone marrow and kidney can also be affected (Zeiser et al., 2021), although these will not
be discussed further.
The gut is affected in the majority (60 %) of GVHD cases and damage in this tissue is
one of the major causes of GVHD related mortality (McDonald, 2016). As mentioned
above, integrin β7 can direct donor T cells towards the gut (Petrovic et al., 2004) at which
point these activated donor T cells attack intestinal crypt cells and epithelial cells
(Teshima et al., 2016). Continued destruction of the protective epithelial layer, due to
pretransplant conditioning and GVHD, allows the entry of microbial products, like LPS,
into these tissues and eventually systemic circulation (Nestel et al., 1992). Serum
regenerating islet-derived 3 (REG3)α has emerged as a clinical biomarker of gut GVHD
(Ferrara et al., 2011). In normal circumstances REG3α is an antimicrobial peptide
secreted by intestinal crypt cells that helps to maintain the mucosal barrier and prevent
gut microbiota from infecting intestinal cells (Sanos et al., 2011). However, during
GVHD, damage to the mucosal barrier allows REG3α to cross into systemic circulation,
and increased concentrations of REG3α are associated with worsened gut GVHD (Ferrara
et al., 2011). Interestingly, IL-22, which can be produced by Th1 and Th17 cells at sites
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of inflammation (Dudakov et al., 2015), induces the expression of REG3 peptides in
intestinal epithelial cells (Zheng et al., 2008), and protects the gut from GVHD mediated
damage (Hanash et al., 2012). Furthermore, expression of mReg3g, which encodes the
mouse homologue (REG3γ) of REG3α, is increased in villous enterocytes in a mouse
model of GVHD and corresponds with increased serum REG3γ (Eriguchi et al., 2013).
Despite this, the presence of REG3γ in other mouse models of GVHD has not been
reported.
Similar to the gut, liver complications occur in up to 50 % of GVHD cases (Farthing et
al., 1982), however true liver involvement can be hard to distinguish from damage caused
by pretransplant conditioning, GVHD prophylaxis or infection (Matsukuma et al., 2016).
The key features of histological liver GVHD include early-stage lymphocyte infiltration
of portal tracts and destruction of bile duct epithelium, and late-stage bile duct destruction
and fibrosis (Fujii et al., 2001; Matsukuma et al., 2016; Snover et al., 1984). Although,
Matsukuma et al. (2016) note that there is some evidence of damaged bile ducts healing.
Regardless, liver GVHD is associated with poor survival (Modi et al., 2019; Robin et al.,
2009), elevated levels of bilirubin, which promotes jaundice, and liver enzymes, like
alkaline phosphatase (McDonald et al., 1986). Additionally, liver GVHD increases
plasma levels of hepatocyte growth factor (Paczesny et al., 2009) and cytokeratin
fragment 18 (Luft et al., 2007), both of which are biomarkers of liver GVHD and predict
nonresponse to treatment, although only hepatocyte growth factor is predictive of
nonrelapse mortality (Harris et al., 2012). As mentioned above, CCR5 is a poor choice
for identifying liver homing T cells and other liver homing molecules remain poorly
defined. Moreover, early evidence suggested lymphocyte function-associated antigen-1
(LFA-1) directs activated donor T cells to the liver in GVHD (Sato et al., 2006), however
other studies indicate LFA-1 could direct lymphocytes to the lungs (Thatte et al., 2003;
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Xu et al., 2003), thyroid (Jungheim et al., 2004) and lymph nodes (Wang et al., 2009) in
other diseases, making LFA-1 a poor marker for liver homing T cells.
The skin is the most often, and typically the earliest, affected organ in GVHD, and is
involved in up to 90 % of GVHD cases (Martin et al., 1990; Saliba et al., 2007). GVHD
induces a rash that begins on the face, palms and soles but skin lesions can spread to the
entire body and progress to erythroderma, which involves severe inflammation, redness
and scaling of the skin (Strong Rodrigues et al., 2018). The same histopathological
grading system for skin GVHD has been used for almost 50 years (Lerner et al., 1974;
Strong Rodrigues et al., 2018). Mild to moderate histological skin GVHD presents as
vacuolar alteration of basal cells involving lymphocytic infiltration as well as
dyskeratosis and spongiosis of epidermal cells. More severe skin GVHD has similar
histopathology but also results in the formation of subepidermal clefts and the loss of
epidermis.
Lung complications, both infectious and non-infectious, following allo-HSCT have long
been observed and occur in up to 55 % of recipients (Yanik et al., 2006). Lung GVHD
occurs in up to 25 % of allo-HSCT recipients (Yanik et al., 2002) and presents as
idiopathic pneumonia syndrome which involves widespread alveolar injury,
inflammation and abnormal pulmonary function in the absence of infection (Clark et al.,
1993; Crawford et al., 1993). Histopathological lung GVHD presents as diffuse alveolar
damage with interstitial and alveolar infiltrates, denudation of alveolar septa with
eosinophil and neutrophil aggregates, and occasionally alveolar haemorrhage, in the
absence of apoptosis (Yousem, 1995). The lung was not originally recognised as a classic
GVHD target organ due to the lack of epithelial apoptosis, however increasing evidence
of the involvement of T cells and inflammatory cytokines in mediating lung injury post
allo-HSCT shifted this paradigm (Yanik et al., 2006). Various studies in mice have
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implicated Th1 (Hildebrandt et al., 2004), Th2 (Yi et al., 2009) and Th17 (Carlson et al.,
2009; Ma et al., 2018) cells, and the cytokines they produce, in the development of lung
GVHD.
1.2.5. Tregs in GVHD
Tregs act as suppressor cells to limit inflammation and allow for tolerance to
host-antigens following allo-HSCT (Romano et al., 2017). A variety of Treg
subpopulations have been identified (Edozie et al., 2014; Shevyrev et al., 2019),
including CD8 + Tregs (Bézie et al., 2018), however this thesis will focus on CD4 + Tregs
as these are the most well characterised, and of most interest in GVHD. Any future
reference to Tregs will refer to CD4 + Tregs, unless otherwise stated. Tregs were first
identified as CD4 +CD25 + T cells that could prevent autoimmune responses (Sakaguchi et
al., 1995) and it was subsequently established that these cells could be identified by their
expression of intracellular FOXP3, which controls the development of these cells (Hori
et al., 2003). In humans, intracellular FOXP3 expression is inversely correlated with cell
surface CD127 expression (Liu et al., 2006). As such, Tregs can be identified by the
presence of high CD25 and low CD127 surface expression (Fazekas de St Groth et al.,
2011).
Tregs can be either thymically-derived (natural), selected based on recognition of
self-antigens (Jordan et al., 2001), or peripherally-derived (induced), which are induced
from naïve CD4 + T cells and require multiple factors including antigen stimulation,
TGFβ, IL-2 and potentially TNFα (Goldstein et al., 2013). Regardless of lineage, both
natural and induced Tregs display a variety of similar suppressive mechanisms (Vignali
et al., 2008). Tregs can act as a cytokine sink and consume IL-2, due to their high
expression of CD25, preventing the activation and proliferation of reactive T cells (Levine
et al., 2014; Sakaguchi et al., 1995). High levels of IL-2 are associated with worsened
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GVHD (MacMillan et al., 2003), and the use of an anti-IL-2 antibody can reduce GVHD
in mice (Via et al., 1993). Paradoxically, administration of low-dose IL-2 increases Tregs
in vivo and reduces GVHD (Kennedy-Nasser et al., 2014). Tregs express high levels of
two ectonucleotidases, CD39 (Borsellino et al., 2007) and CD73 (Kobie et al., 2006).
Together these enzymes allow Tregs to convert pro-inflammatory extracellular ATP to
anti-inflammatory adenosine (Deaglio et al., 2007). Adenosine, through activation of P1
receptors, has suppressive roles and reduces the activation of T cells, which decreases
cytokine release and tissue damage in GVHD (Lappas et al., 2010). Additionally, Tregs
can release immunosuppressive cytokines, including TGFβ (Wan et al., 2007), IL-35
(Sawant et al., 2015) and IL-10 (Chaudhry et al., 2011), to prevent APC maturation and
T cell proliferation, and reduce GVHD (Banovic et al., 2005; Ulbar et al., 2020).
Together, these studies indicate an immunosuppressive role for Tregs in GVHD and
highlight the importance of these cells in disease.
1.2.6. Mouse models of GVHD
Mouse models are routinely used to investigate GVHD due to similarities in GVHD
development in mice and humans, although like all models there are limitations due to
species differences (Schroeder et al., 2011). Both allogeneic (mouse to mouse transplant)
and humanised (human to mouse “xenogeneic” transplant) mouse models are used to
study GVHD. Allogeneic mouse models have been the most used models of GVHD to
date and typically involve the transfer of bone marrow alongside other lymphocytes,
including splenocytes or specific lymphocyte subsets, from one mouse strain into a
different mouse strain (Schroeder et al., 2011). Allogeneic mouse models differ in disease
severity based on the level of MHC or mHA mismatch, with complete MHC mismatch
mice displaying worsened disease compared to mHA mismatched mice (Bäuerlein et al.,
2013). mHA mismatched models more closely reflect clinical allo-HSCT as complete

60

MHC mismatched transplantation does not occur. GVHD severity in allogeneic models
is also controlled by the pretransplant conditioning regime employed (Hill et al., 1997;
Schwarte et al., 2005; Schwarte et al., 2007) as well as the number and type of
transplanted lymphocytes (Hülsdünker et al., 2015).
Allogeneic mouse models have long be used to study GVHD and the use of these models
identified reactive donor T cells as the mediators of GVHD (Korngold et al., 1978) and
both host and donor APCs as stimulators of T cells in disease (Anderson et al., 2005).
Moreover, these models have been used to trial various therapeutic strategies to prevent
or treat GVHD, including treatment with IL-11 (Hill et al., 1998; Teshima et al., 1999),
or targeting pro-inflammatory cytokines with neutralising antibodies, such as TNFα
(Cooke et al., 1998). However, despite reducing GVHD in allogeneic mice these therapies
do not always translate to the clinic. For example, administration of IL-11 increased fluid
retention and worsened mortality in allo-HSCT recipients (Antin et al., 2002). These
differences between allogeneic mouse models and the clinical setting may be reflective
of the homogenous versus heterogenous response exhibited by T cells from inbred mice
versus humans, respectively (Hülsdünker et al., 2015). As such, mouse models that better
reflect human T cell responses may provide improved preclinical models of GVHD.
Humanised mouse models involve the transplantation of human immune cells into
immunodeficient mice. Early attempts at creating these models involved severe combined
immunodeficiency (SCID) mice but resulted in relatively low (<20 %) engraftment due
to the presence of natural killer (NK) cells (Hoffmann-Fezer et al., 1993; Mosier et al.,
1988). Recombination activating gene 2 (RAG2) (Rag2 -/-)- and IL-2Rγ (Il2rg -/-)-deficient
mice showed increased engraftment of human cells (up to 98 %) as they lack functional
T cell, B cell and NK cell subsets, and these mice consistently developed GVHD (van
Rijn et al., 2003). Two other immunodeficient mouse strains were developed by crossing
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NOD/SCID mice with IL-2Rγ-deficient mice. NOD.Cg-PrkdcscidIl2rg tm1Wjl/SzJ (NSG)
mice are the result of backcrossing Il2rg null (complete null) mice onto NOD/ShiLtSzPrkdcscid mice (Shultz et al., 2005). Similarly, NOD.Cg-PrkdcscidIl2rg tm1Sug/ShiJic (NOG)
mice are the result of backcrossing Il2rg null (truncation of intracellular domain) mice onto
NOD/ShiJic-Prkdcscid mice (Ito et al., 2002). Both mouse strains lack functional T cells
and B cells, have defective NK cells, macrophages, and DCs, and have defective
complement function (Sluyter et al., 2020). As briefly noted, these mouse strains differ
in the fact that NSG mice do not express IL-2 receptors while NOG mice express IL-2
receptors that can bind cytokines but cannot signal (Shultz et al., 2014). Both mouse
strains readily engraft human T cells and develop GVHD following hPBMC injection (Ito
et al., 2009; King et al., 2009). The rest of this section will focus on humanised NSG
mice as these will be used throughout this thesis.
The humanised NSG mouse model of GVHD was first established by King et al. (2009)
and has since been established and utilised in our laboratory (Geraghty et al., 2017;
Geraghty et al., 2019a; Geraghty et al., 2019b; Geraghty et al., 2019c, 2019d). Humanised
NSG mice are typically generated by injecting mice with 5 – 20 x 10 6 hPBMCs either
intraperitoneal (i.p.) or intravenous (i.v.), with i.v. injection allowing engraftment of
lower hPBMC doses (Ehx et al., 2018; King et al., 2008). The use of pretransplant
conditioning is not a requirement for the development of GVHD but does quicken disease
development (Hess et al., 2021). Humanised mice begin showing signs of GVHD from
as early as 2 weeks post-hPBMC injection when preconditioned (Ehx et al., 2018; King
et al., 2009), while signs of GVHD begin to appear from 3-4 weeks post-hPBMC injection
in the absence of preconditioning (Geraghty et al., 2017; King et al., 2009). GVHD in
these mice is heterogenous and can cause hunching, fur loss, weight loss, reduced activity
and scaling or denudation of skin, although the later occurs rarely and only in the late
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stages of disease (Geraghty et al., 2017). Therefore, better, and earlier, indicators of skin
GVHD would be helpful. Humanised mouse studies often report histological involvement
of the liver (Bruck et al., 2013; Geraghty et al., 2019b; Gregoire-Gauthier et al., 2012;
King et al., 2009), however histological GVHD in the skin, gut and lung is underreported,
particularly in the absence of preconditioning. As such, there is a need to better
characterise which organs are most affected in our, and other, preclinical models of
GVHD.
Like in human disease, GVHD in humanised NSG mice is mediated by human donor
T cells. hCD4 + and hCD8 + T cells can recognise mouse MHC class II (Tary-Lehmann et
al., 1994) and MHC class I molecules (King et al., 2009), respectively. Moreover, MHC
class I (β2mnull)- or MHC class II (Ab null)-deficient NSG mice display delayed GVHD,
with a more pronounced effect in the former strain, indicating that hCD8 + are the main
mediators of disease but hCD4 + cells contribute as well (King et al., 2009). However,
NSG mice lack functional APCs, including DCs, macrophages and B cells (Shultz et al.,
2005), which may indicate that APCs present in donor hPBMCs are enough to stimulate
donor T cells against mouse antigens, similar to donor APCs in allogeneic mice
(Anderson et al., 2005). Although, this is yet to be confirmed. Our laboratory has
demonstrated that hCD45+ leukocytes make up 40-80 % of the total leukocyte population
in humanised NSG mice, and that this population is composed primarily (80-100 %) of
T cells (Geraghty et al., 2017; Geraghty et al., 2019b). Additionally, and contrary to King
et al. (2009), we have shown that an increased hCD4 +:hCD8 + T cell ratio is associated
with worsened GVHD, implying that hCD4 + T cells contribute more to disease (Geraghty
et al., 2019b). Additional to effector T cells, small proportions (0-5 %) of hTregs are often
observed in this model (Adhikary, 2020; Geraghty et al., 2019a; Geraghty et al., 2019c)
and are inversely correlated with GVHD severity (Achita et al., 2018; Bruck et al., 2013).
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Humanised NSG mice also engraft relatively small proportions (<2 %) of human
monocytes and DCs (Geraghty et al., 2019a; Geraghty et al., 2019c), but do not appear
to engraft hB cells. Like allogeneic mouse models, humanised NSG mouse models have
been used to study the pathophysiology of GVHD and are also used to test new
therapeutic strategies (Hess et al., 2021).
1.2.7. Current treatments for GVHD
Current clinically accepted treatments for GVHD include general immunosuppression,
inhibition of alloreactive T cells or depletion of T cells (Villa et al., 2016). However,
many of these treatments do not completely prevent GVHD and some are associated with
increased risk of infection or cancer relapse.
Systemic corticosteroids, which provide general immunosuppression (Coutinho et al.,
2011), have been a first line treatment for GVHD for a number of years (Quellmann et
al., 2008). However, nearly 50 % of patients develop steroid-refractory GVHD
(MacMillan et al., 2002) and those with steroid-refractory GVHD show mortality rates
greater than 90 % (Westin et al., 2011). While corticosteroids were not associated with
increased relapse (Quellmann et al., 2008), some studies have noted an increased risk of
infection (Sayer et al., 1994) and prednisone treatment was associated with increased
rates of chronic GVHD (Kumar et al., 2001). As corticosteroid therapy only prevents or
reduces GVHD in 50 % of patients, second line treatments are often adopted, although
many of these cause additional side effects including increased risk of infection and have
varying success rates (10-90 %) (Malard et al., 2020).
Another treatment strategy for GVHD involves the use of calcineurin inhibitors including
cyclosporine A (Powles et al., 1980) and tacrolimus (Fay et al., 1996) to suppress T cells.
Calcineurin inhibitors prevent the calcineurin-mediated activation of NFAT signalling,
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which is involved in the activation and proliferation of T cells in health and disease (Park
et al., 2020). Methotrexate, which inhibits proliferating T cells, has been used alone and
in combination with cyclosporine but reduced GVHD only when used in combination
(Storb et al., 1986). Additionally, mycophenolate mofetil, which has a cytostatic effect
on T cells (Allison et al., 2000), has also been used in combination with cyclosporin and
increased the rate of engraftment, but did not alter GVHD compared to the combination
of cyclosporine and methotrexate (Bolwell et al., 2004). Similarly, sirolimus, which
suppressed T cells by binding to mammalian target of rapamycin (Sehgal, 2003) and
increased Tregs in mouse models of GVHD (Palmer et al., 2010), was used in
combination with tacrolimus and was associated with rapid engraftment and a low
incidence of GVHD (Antin et al., 2003; Cutler et al., 2007).
T cell depletion is used as a prophylactic therapy to prevent GVHD and can be done
ex vivo or in vivo. Ex vivo strategies include the negative selection of T cells or positive
selection of CD34 + progenitor cells (Villa et al., 2016). Early attempts at ex vivo T cell
depletion used soybean agglutin and rosetting with sheep red blood cells to fractionate
bone marrow cells, and this prevented GVHD but cancer relapse occurred (Reisner et al.,
1981). Technological improvements, including the use of magnetic beads and/or
antibodies, allowed for more accurate sorting of immune cells. Positive selection of
CD34 + cells by immunomagnetic separation allows these haematopoietic progenitor cells
to be transplanted in the absence of T cells. Transplantation of CD34 + cells allowed
prompt engraftment with only a slight risk of mild GVHD (Aversa et al., 1998; Butt et
al., 2003; Larocca et al., 2006). Additionally, depletion of T cells by negative selection
with CD3/CD19 monoclonal antibodies (mAb) is a viable strategy for high-risk
(refractory disease, relapse or cytogenetics) patients, although it does not completely
prevent GVHD (Bethge et al., 2006; Federmann et al., 2012). Selective depletion of
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αβ T cells allowed the engraftment of CD34 + cells along with γδ T cells and did not cause
severe GVHD (Bertaina et al., 2014; Rådestad et al., 2019). Moreover, this therapy
allowed αβ T cells to recover over time (Bertaina et al., 2014). Unfortunately, ex vivo
T cell depletion does not prevent cancer relapse in 20-30 % of patients and infection is
still a major issue and cause of mortality (40 %) (Ciceri et al., 2008).
In vivo T cell depletion strategies involve the use of antibodies and other agents which
target alloreactive T cells. The anti-CD52 mAb Alemtuzumab, which targets mature
alloreactive T cells, improved GVHD in 70-80 % of steroid-refractory recipients but was
associated with infections in the majority of cases (Gómez-Almaguer et al., 2008;
Khandelwal et al., 2014) and another study indicated it did not improve survival
(Martínez et al., 2009). Other studies have demonstrated that preconditioning with
alemtuzumab decreased GVHD, but again was associated with viral infection,
particularly cytomegalovirus (CMV), and delayed engraftment (Chakrabarti et al., 2002;
Chakrabarti et al., 2004; Kottaridis et al., 2001).
Cyclophosphamide was originally developed as a chemotherapeutic, however it is now
the most common T cell depletion prophylactic therapy for GVHD (Kanakry et al.,
2016b). Post-transplant cyclophosphamide (PTCy) was first shown to reduce GVHD and
prolong survival in an allogeneic mouse model (Luznik et al., 2001). PTCy has been
tested further in allogeneic (Ganguly et al., 2014; Wachsmuth et al., 2019) and humanised
(Adhikary, 2020; Kanakry et al., 2013) mouse models of GVHD, where it reduced disease
and prolonged survival, but it did not prevent disease in humanised mice. Nevertheless,
PTCy has been adopted clinically, being used for more than 10 years (Kanakry et al.,
2014; Luznik et al., 2008). Cyclophosphamide is typically given on days 3 and 4
post-transplant at a dose between 10-50 mg/kg (Kanakry et al., 2016b). Clinical studies
have indicated that PTCy provides similar survival benefits to calcineurin inhibitors,
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including decreased GVHD and prolonged survival, and PTCy also decreased the risk of
chronic GVHD (Ghosh et al., 2016; Kanate et al., 2016). Moreover, these studies along
with Ciurea et al. (2015) demonstrated that PTCy therapy lead to similar outcomes for
haploidentical (50 % match) allo-HSCT, which typically carries greater risk (Bertaina et
al., 2018), and human leukocyte antigen (HLA)-matched allo-HSCT transplant recipient.
Thus, PTCy widens the donor pool for allo-HSCT, increasing the likelihood of identifying
a suitable donor and treating the underlying condition. Despite such benefits, PTCy is
associated with increased CMV infection (Mulroney et al., 2021), and cancer relapse can
still occur (Ruggeri et al., 2017).
Cyclophosphamide is processed by the liver into phosphoramide and acrolein and these
products intercalate with DNA to disrupt cell division (Al-Homsi et al., 2015). As such,
proliferating reactive donor T cells are particularly susceptible to cyclophosphamide.
Early studies in skin allograft models indicated that cyclophosphamide depleted
proliferating T cells (Eto et al., 1990; Eto et al., 1991). However, a more recent study in
an allogeneic mouse model of GVHD indicated that PTCy did not eliminate reactive
donor T cells but reduced the proliferation and function of these cells (Wachsmuth et al.,
2019). Additionally, recent work from our group indicated that PTCy depleted reactive
hT cells, but also reduced hTreg engraftment and delayed but did not prevent GVHD, in
a humanised mouse model (Adhikary, 2020). Regardless of the mechanism, PTCy cannot
always prevent disease and PTCy-mediated reductions of GVHD are reliant on the
presence of Tregs as removal of Tregs in either humanised (Kanakry et al., 2013) or
allogeneic (Ganguly et al., 2014) models of GVHD leads to worsened disease. As such,
increasing Tregs following PTCy may improve this therapy to better prevent GVHD.
Moreover, current strategies for the treatment or prophylaxis of GVHD have limitations,
so new therapeutics are required.
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1.2.8. P2X7 in GVHD
There is increasing evidence that ATP and P2X7 play important roles in GVHD
development as discussed in detail below. This evidence comes from studies examining
the effects of ATP degradation, P2X7 expression in mouse models of GVHD and clinical
GVHD, P2X7 receptor blockade, and comparisons in P2X7 knockout mice or humans
with P2XR7 SNPs. Together the evidence indicates that the ATP/P2X7 signalling axis
initiates pro-inflammatory effects by activating host DCs and implies a potential role for
P2X7 in the dysfunction and/or destruction of cells with suppressor activity.
Studies of allogeneic and humanised mouse models indicate a role for extracellular ATP
in promoting GVHD (Table 1.2). ATP is increased in the peritoneal fluid of allo-HSCT
recipients with GVHD compared to allo-HSCT recipients without GVHD (Wilhelm et
al., 2010). ATP is also increased in the peritoneal fluid shortly after pre-conditioning and
is increased in the gut during disease progression in an allogeneic mouse model of GVHD
(Koehn et al., 2019; Wilhelm et al., 2010). Apyrase, a soluble ATP diphosphohydrolase,
injected during the first week post-transplantation reduced apoptosis and inflammation in
target organs and serum IFNγ, and increased survival in an allogeneic mouse model of
GVHD (Koehn et al., 2019; Wilhelm et al., 2010) indicating a direct role for extracellular
ATP in mediating GVHD progression following preconditioning and transplantation.
Indirect evidence for extracellular ATP in GVHD is also revealed through the
pharmacological blockade of the CD39/CD73 pathway, which results in increased or
sustained extracellular ATP concentrations. Blockade of CD39/CD73 with α,β-methylene
ADP (APCP) (days 0-6 or twice weekly) reduced survival, increased T cell proliferation
and pro-inflammatory cytokines, and strengthened GVT immunity in an allogeneic
mouse model (Tsukamoto et al., 2012; Wang et al., 2013). Furthermore, treatment with
APCP (days 0-6) in a humanised mouse model of GVHD, which does not involve
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Table 1.2. Extracellular ATP degradation and blockade of CD39 and CD73 in mouse models of GVHD
Model
Allogeneic

Allogeneic

Allogeneic

Graft
5 x 106 TCD BM cells +
1.6 x 106 (FVB/N) or 1 x
106 CD4+ /CD8+ (C57BL/6)
(i.v.)
10 x 106 CD25 depleted T
cells (C57BL/6) (injection
route not disclosed)
5 x 106 BM cells and 2 x
105 CD4+/CD8+ splenic T
cells (i.v.)
5 x 106 BALB/c
splenocytes ± BM cells or
splenocytes (i.v.)
10 x 106 hPBMCs (i.p.)

Host
BALB/c

Target
ATP

Drug Regime
4U Apyrase (hydrolysis
catalyst) i.p. days 0-2, 68

Outcomes
↑ Survival
↓ Apoptosis and inflammation in
the gastrointestinal tract
↓ Serum IFNγ
↑ Survival

BALB/c

ATP

4U Apyrase (hydrolysis
catalyst) i.p. days 0-4

C57BL/6

CD73

50 mg/kg APCP
↑ Mortality
(antagonist) i.p. days 0-6

Reference
Wilhelm et al. (2010)

Koehn et al. (2019)

Tsukamoto et al. (2012)

↑ Mortality
Wang et al. (2013)
↑ Splenic CD4+ and CD8+ T cells
↑ Serum IFNγ and IL-6.
Humanised
NSG
CD39 and
↑ Weight loss
Geraghty et al. (2019c)
CD73
↑ Histological damage
↑ Serum human IL-2
APCP, α,β-methylene adenosine diphosphate; ATP, adenosine 5’-triphosphate; BM, bone marrow; hPBMC, human peripheral blood mononuclear cells; IFN,
interferon; IL, interleukin; i.p., intraperitoneal; i.v., intravenous; NSG, NOD.Cg-PrkdcscidIl2rgnull; TCD, T cell depleted; Treg, regulatory T cell; ↑, increased;
↓, decreased.
Allogeneic

C57BL/6

CD73

20 mg/kg APCP
(antagonist) i.v. twice
weekly
50 mg/kg APCP
(antagonist) i.p. days 0-6

69

preconditioning, resulted in worsened disease with increased weight loss, liver apoptosis
and serum human IL-2 (Geraghty et al., 2019c). This latter finding supports the notion
that ATP is released during GVHD progression and that the initial preconditioning re gime
used in allogeneic mouse studies is not essential for ATP release.
The majority of studies to date indicate that P2X7 is the major P2X receptor involved in
GVHD progression following ATP release. Human P2RX7 expression is increased in the
PBMCs of human patients with GVHD, compared to allo-HSCT recipients without
GVHD or healthy controls (Wilhelm et al., 2010). mP2rx7 expression is increased in
theliver, spleen and thymus of allogeneic mice with GVHD (Wilhelm et al., 2010; Zhong
et al., 2016), whilst the expression of mP2rx7 and hP2RX7 in humanised mouse models
requires better characterisation. P2X7 protein is increased on APCs in Peyer’s patches
and in the colon of patients with GVHD (Wilhelm et al., 2010). This increase in P2X7 on
APCs may be dependent on mir-188 expression, as deficiency of this microRNA (miR)
results in decreased P2rx7 in murine DCs, corresponding to decreased GVHD in
mir-188 -/- recipients (Chen et al., 2015).
Pharmacological blockade of P2X7 reduces GVHD in both allogeneic and humanised
mouse models of disease (Table 1.3). The P2X7 antagonists PPADS (days 0-10), KN62
(days 0-10) or A-438079 (days 0-4) increased survival in an allogeneic mouse model of
GVHD (Koehn et al., 2019; Wilhelm et al., 2010). PPADS treatment also decreased
serum IFNγ and tissue inflammation, which coincided with increased Tregs in some mice
(Wilhelm et al., 2010). Treatment with stavudine (days -1-9), a nucleoside reverse
transcriptase inhibitor that also impairs P2X7 pore formation but not chann el activity,
increased survival and decreased serum pro-inflammatory cytokines, including IFNγ, in
an allogeneic mouse model of GVHD (Fowler et al., 2014). The P2X7 antagonist BBG
(twice weekly for 4 weeks) also reduced weight loss, liver inflammation and
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Table 1.3. P2X7 blockade in mouse models of GVHD
Model
Allogeneic

Graft
5 x 106 TCD BM cells + 1.6 x
106 (FVB/N) or 1 x 106 CD4+
/CD8+ (C57BL/6) (i.v.)

Host
BALB/c

Target
P2X7

Allogeneic

5 x 106 TCD BM cells + 1 x
BALB/c
106 CD4+ /CD8+ (C57BL/6)
(i.v.)
10 x 106 CD25 depleted T
BALB/c
cells (C57BL/6) (injection
route not disclosed)
10 x 106 TCD BM cells + 2.5 BALB/c
x 106 CD4+ T cells (C57BL/6)
(injection route not disclosed)

P2X7

Allogeneic

5 × 106 BM cells + 5 × 106
splenic cells (C57BL/6) (i.v.)

Humanised

Humanised

Allogeneic

Allogeneic

Drug Regime
Outcomes
10 µmol PPADS i.p. days ↑ Survival
0-10
↑ Tregs
↓ Serum IFNγ
↓ GVHD severity
1 µmol KN62 i.p. days 0- ↑ Survival
10

Reference
Wilhelm et al. (2010)

Wilhelm et al. (2010)

P2X7

80 mg/kg A-438079 i.p.
days 0-4

↑ Survival

Koehn et al. (2019)

P2X7

25 mg/kg Stavudine
(d4T) i.p. twice daily
from day -1 or 0

Fowler et al. (2014)

BALB/c

P2X7

50 mg/kg or 75mg/kg
BBG i.p. twice weekly
for 4 weeks

10 x 106 hPBMCs (i.p.)

NSG

P2X7

50 mg/kg BBG i.p. days
0, 2, 4, 6, 8, 10

10 x 106 hPBMCs (i.p.)

NSG

P2X7

↑ Survival (when started from day
-1)
↓ Serum IFNγ, TNFα and IL-6
↓ Liver inflammation
↓ Weight loss
↓ Liver inflammation
↓ CXCL8 and CCL2, Il1B and
Il18
↓ Serum IFNγ
↓ Liver, skin and small intestine
inflammation
↓ Liver inflammation

Zhong et al. (2016)

Geraghty et al. (2017)

50 mg/kg BBG i.p. thrice
Geraghty et al. (2019d)
weekly until endpoint
BBG, Brilliant Blue G; BM, bone marrow; hPBMC, human peripheral blood mononuclear cells; IFN, interferon; IL, interleukin; i.p., intraperitoneal; i.v.,
intravenous; NSG, NOD.Cg-Prkdcscid Il2rgnull ; PPADS, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid; TCD, T cell depleted; TNF, tumour necrosis
factor; Treg, regulatory T cell; ↑ increased; ↓, decreased.
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inflammatory cytokine expression or release, as well as decreasing P2 X7 in allogeneic
mice with GVHD (Zhong et al., 2016). BBG (days 0, 2, 4, 6, 8, 10) also reduced serum
IFNγ and inflammation in the liver, skin and small intestine, but did not alter clinical
symptoms or survival, in a humanised mouse model of GVHD (Geraghty et al., 2017).
However, long-term treatment with BBG (thrice weekly until endpoint) only reduced
liver inflammation but not serum IFNγ (Geraghty et al., 2019d). These differences
suggest that timing of P2X7 antagonism may alter disease outcomes in GVHD. As such,
using a modified P2X7 antagonist regime may be able to provide greater clinical benefits
and better elucidate the role of P2X7 in the humanised mouse model of GVHD.
Genetic studies in mice confirm that P2X7 is involved in GVHD progression and provide
further insight into the potential mechanism of this receptor in this disease. Comparisons
of P2rx7 -/- and wild type mice as either the source of donor cells or recipient mice
indicated that host, but not donor, P2X7 contributes to GVHD progression in an
allogeneic mouse model (Wilhelm et al., 2010). Furthermore, bone marrow chimeras in
P2rx7 -/- or wild type mice demonstrated that P2X7 in the host haematopoietic system, but
not non-haematopoietic tissues, influenced GVHD in allogeneic mice (Wilhelm et al.,
2010). Finally, bone marrow chimeras with a host P2rx7 -/- haematopoietic system
including P2rx7 -/- DCs had reduced disease compared to mice with a host P2rx7 -/haematopoietic system but wild type DCs, indicating that P2X7 on host DCs is
contributing to GVHD development in allogeneic mouse models of GVHD (Wilhelm et
al., 2010).
The importance of host P2X7 in GVHD is indirectly supported by studies of human
P2RX7 SNPs in mice and humans. NSG mice injected with hPBMCs from donors with
either a LOF or GOF P2RX7 haplotype display similar GVHD development (Adhikary et
al., 2019). Likewise, donor P2RX7 genotype did not influence rates or severity of GVHD
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in allo-HSCT recipients (Koldej et al., 2020). Conversely, the LOF rs3751143 SNP in the
host was associated with improved survival, however, other LOF SNPs in the host were
not associated with reduced GVHD and the LOF rs1653624 SNP was associated with
increased GVHD (Koldej et al., 2020).
The above studies indicate that host P2X7 is important in GVHD development however,
they do not exclude the potential contribution of donor P2X7 influencing disease. As
discussed in detail previously (Section 1.1.7), P2X7 activation can promote the activation
and proliferation of CD4 + T cells (Yip et al., 2009) and can help promote the metabolic
fitness, maintenance and survival of memory CD8 + T cells (Borges da Silva et al., 2018;
Borges da Silva et al., 2020), thus the possibility remains that P2X7 may contribute to the
activation and survival of donor effector T cells in GVHD. Additionally, P2X7 activation
can inhibit the suppressive action and stability of Tregs, promoting their conversion to
Th17 cells (Schenk et al., 2011). This may potentially cause P2X7 activation to be a
“double edged sword” in GVHD progression, both impairing Tregs and promoting
pathogenic Th17 cells. Consistent with this notion is that PPADS increased donor Treg
proportions in an allogeneic model of GVHD (Wilhelm et al., 2010). However, this study
only examined Tregs in three mice from each group, and only showed representative
examples. Moreover, BBG did not alter hTregs in humanised mice (Geraghty et al., 2017;
Geraghty et al., 2019d). As such it remains undetermined if a modified P2X7 regime can
increase hTregs in a humanised mouse model of GVHD. Finally, studies of donor myeloid
derived suppressor cells (MDSCs) in an allogeneic mouse model of GVHD provide
indirect evidence for donor P2X7 in promoting this disease. Transplantation of donor
MDSCs can impair GVHD development (Koehn et al., 2015), however P2X7 activation
of these cells prior to transplantation limited their capacity to reduce GVHD in vivo
(Koehn et al., 2019). Thus, this study suggests P2X7 on MDSCs present in the donor
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graft may impair the action of these suppressor cells to help promote GVHD in allo -HSCT
recipients.
Together these studies indicate a model in which extracellular ATP, released during
GVHD, activates P2X7 on host APCs to promote cytokine release and T cell activation
(Figure 1.4). Moreover, these studies indicate a potential role for P2X7 on donor T cells,
particularly Tregs, but this is yet to be conf irmed in GVHD. Characterising P2X7
expression and trialling a modified P2X7 antagonist regime in a humanised mouse model
of GVHD will increase our understanding of the role of P2X7 in GVHD, particularly on
human donor cells.

Figure 1.4. Known roles of P2X7 in graft-versus-host disease (GVHD). Tissue damage from
pretransplant conditioning or GVHD results in the release of adenosine triphosphate (ATP).
Extracellular ATP activates P2X7 on host antigen presenting cells (APC) which stimulate donor
T cells. This leads to enhanced donor T cell activation, proliferation, and survival and worsened
GVHD. Created with BioRender.com.
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1.3.Amyotrophic lateral sclerosis
ALS is a neurodegenerative disorder that worsens over time and leads to muscle weakness
and paralysis (Brown et al., 2017). Despite significant efforts to identify new therapies
for ALS, current treatment options are very limited and offer only small benefits,
therefore new therapeutics are still required (Jaiswal, 2019). ALS pathology includes
inflammatory components and increasing evidence has implicated the peripheral immune
system in disease (McCombe et al., 2020). P2X7 plays a myriad of roles both in the
periphery and the CNS (Volonté et al., 2020) and understanding how these roles influence
ALS pathology are key to determining whether P2X7 will be an effective target for
disease treatment. As such, the following section will introduce ALS, describe current
treatment options, introduce the superoxide dismutase 1 (SOD1) G93A mouse model of
ALS and highlight the role of the peripheral immune system in ALS, before focusing on
the role of P2X7 in ALS.
1.3.1. ALS pathophysiology
ALS is a heterogenous neurodegenerative disease involving both upper and lower motor
neurons. ALS is characterised by the progressive loss of motor neurons in the cerebral
cortex, brainstem, and spinal cord, with disease worsening over time (Brown et al., 2017).
The loss of motor neurons leads to skeletal muscle atrophy which results in muscle
weakness and paralysis (Štětkářová et al., 2021), and cognitive and behavioural
impairment (Phukan et al., 2012). ALS is classified into familial (family history of
disease) or sporadic (no family history of disease) (Al-Chalabi et al., 2016) disease and
these represent 10 % and 90 % of ALS cases, respectively (Harikrishnareddy et al., 2015).
ALS is primarily an age-related disease with incidence rates peaking between 65-75 years
of age in a European population (Logroscino et al., 2010). Survival time from disease
onset varies between populations, with Asian cohorts having increased median survival
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(48 months) compared to European cohorts (24 months) (Marin et al., 2016), but few
patients survive more than 5 years (Wijesekera et al., 2009). At least 30 genes are
associated with a major risk for ALS (Brown et al., 2017) and of these genes C9orf72,
TDP43, SOD1 and FUS are associated with approximately 70 % of familial ALS cases
(Chiò et al., 2012; Millecamps et al., 2012). Other lifestyle and environmental factors,
including smoking, physical activity and cyanobacterial blooms, have been linked to ALS
progression, however many of these studies were deemed inconclusive or incomplete
(Brown et al., 2017).
Like other neurodegenerative disorders, including Alzheimer’s disease, Huntington’s
disease, and Parkinson’s disease, a hallmark of ALS is the presence of protein inclusions
in motor neurons (Argueti-Ostrovsky et al., 2021). These inclusions occur due to
impaired protein homeostasis which involves the misfolding and aggregation of various
proteins, including SOD1 (Bruijn et al., 1998). SOD1 proteins normally have antioxidant
effects but mutations in the SOD1 gene lead to misfolding of the protein and are
associated with ALS (Rosen et al., 1993; Urushitani et al., 2002). SOD1 mutations are
associated with 20 % of familial and 2 % of sporadic ALS cases and the D90A mutation
is the most common, although the G93A mutation was the first identified ALS mutation,
and is the most studied due to widespread use of the human SOD1 G93A transgenic mouse
model (Kaur et al., 2016). Additional to protein inclusions, alterations in mRNA
metabolism (Zhou et al., 2014), nucleocytoplasmic transport (Zhang et al., 2015),
endosomal trafficking (Schwenk et al., 2016), axon structure and function (Puls et al.,
2003; Wu et al., 2012), DNA repair (Kenna et al., 2016) and mitochondrial function
(Vande Velde et al., 2011), and neuroinflammation are also associated with ALS.
Activated microglia induce neuroinflammation in patients with ALS (Corcia et al., 2012).
Microglia are CNS resident macrophages and are the main players in CNS immune
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responses (Filiano et al., 2015). Like other macrophages, microglia become activated in
response to tissue damage and once activated these cells proliferate, release cytokines and
present antigens to promote neuroinflammation (Aloisi, 2001; Gehrmann et al., 1995).
Microglia can have neuroprotective (M2) or neurotoxic (M1) phenotypes during ALS
(Geloso et al., 2017). M2 microglia release anti-inflammatory cytokines, including IL-4,
IL-10 and IL-13, while M1 microglia release pro-inflammatory cytokines, such as TNFα,
IL-1β and IL-6 (Tang et al., 2016). In a mouse model of ALS, M2 microglia were
prevalent at disease onset and protected motor neurons from cells death, while M1
microglia became more prevalent as disease progressed and directly damaged motor
neurons (Liao et al., 2012). The majority of studies examining neuroinflammation have
focused on immune cells in the CNS, but increasing evidence indicates that the peripheral
immune system is also involved in ALS development and progression (Liu et al., 2020)
1.3.2. Current treatments for ALS
There is no known cure for ALS and current therapies are extremely limited. More than
50 drugs have been trialled for the treatment of ALS but only riluzole and eda ravone have
been approved for use (Jaiswal, 2019). In the original clinical trial riluzole increased
18-month survival by up to 7 %, although it did not alter muscle function (Lacomblez et
al., 1996), and has since been shown to increase median survival time by 3 months (Miller
et al., 2012). Edaravone showed efficacy in a small subset of patients, but the authors
concluded it would likely be ineffective in the wider ALS population (Abe et al., 2017).
Additionally, edaravone is expensive and requires daily infusions which further limits its
use (Yeo et al., 2018). Other therapies for ALS focus simply on reducing symptoms to
improve the quality of life for patients (van Es et al., 2017). As such, new treatment
options which reduce ALS and prolong survival are desperately required, so a better
understanding of the factors that contribute to disease is needed.
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1.3.3. SOD1 G93A mouse model of ALS
A number of animal models have been used to study ALS and the most commonly used
mouse model is the human SOD1 G93A transgenic model (Tan et al., 2017). These
transgenic mice overexpress multiple copies of mutant human SOD1 and typically
develop clinical signs of ALS from days 70-140 (Pfohl et al., 2015). SOD1 G93A mice are
the most widely used as they mimic human disease and display the typical features of
ALS including motor neuron loss, microgliosis, axonal and neuromuscular dysfunction,
muscle wasting and paralysis, which lead to weight loss and eventually death
(McGoldrick et al., 2013). SOD1 G93A mice have long been used as a preclinical model to
investigate therapeutic strategies for ALS and to characterise the mechanisms underlying
disease (Julien et al., 2006).
1.3.4. ALS and the peripheral immune system
Roles for CNS immune cells, like microglia, in ALS are well studied but increasing
evidence has put a spotlight on the peripheral immune system in ALS. Immune profiling
revealed substantial alterations in the immune systems of ALS patients compared to
healthy individuals, with differences in monocytes and multiple T cell phenotypes
(Gustafson et al., 2017). Moreover, increased total leukocyte counts were associated with
ALS (Murdock et al., 2017). As such, interest is growing in how the peripheral immune
system is able to interact with the CNS to alter ALS progression.
The blood-brain-barrier (BBB) limits the ability of peripheral molecules from entering
the CNS. However, during both the pre-symptomatic and symptomatic stages of ALS
physical damage to the BBB allows the passage of peripheral molecules into the CNS in
rodent models of disease (Garbuzova-Davis et al., 2007a; Garbuzova-Davis et al., 2007b;
Nicaise et al., 2009). Moreover, the disruption of the BBB is associated with motor
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neuron impairment and dysfunction, and recovery of the barrier delayed motor neuron
injury (Winkler et al., 2014). This suggests that peripheral molecules can play a role in
ALS when the BBB is disrupted.
The role of CNS macrophages (microglia) in ALS was described above, however
increasing evidence suggests circulating macrophages, monocytes and DCs also
contribute to disease. Macrophages are activated and infiltrate nerve bundles prior to
symptomatic ALS, where they clear cellular debris from axonal degradation, in SOD1 G93A
mice (Chiu et al., 2009). Moreover, circulating monocytes from ALS patients are skewed
towards a pro-inflammatory phenotype (Zhao et al., 2017) and are more easily activated,
after which the production of IL-6 and TNFα is increased and is associated with worsened
disease (Du et al., 2020). Moreover, evidence indicates that peripheral monocytes and
DCs can infiltrate, and are elevated in, the CNS of ALS patients (Henkel et al., 2004).
However, some evidence indicates that increasing peripheral monocyte infiltration of the
CNS can protect against ALS (Zondler et al., 2016). As such, further research is required
to understand whether these peripheral cells are harmful or beneficial during ALS.
T cells have varying roles in ALS with some cell types contributing to neuroinflammation
and others providing neuroprotective benefits. CD4 + T cells are increased in the blood of
ALS patients (Mantovani et al., 2009; Zhang et al., 2005) but CD8 + T cells are reduced
(Gustafson et al., 2017), although another study reported reduced CD4 + T cells and
unchanged CD8 + T cells (Chen et al., 2014). Both CD4 + and CD8 + T cells have been
detected near ALS-affected areas, including in damaged corticospinal tracts and ventral
horns, of ALS patients (Engelhardt et al., 1993; Kawamata et al., 1992). As described
previously in the context of GVHD, CD4 + T cells release a number of pro-inflammatory
cytokines to enhance immune responses and CD8 + T cells can directly kill other cells.
Despite a general pro-inflammatory role, CD4 + T cells protect mice from ALS (Chiu et
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al., 2008) and disease progression is accelerated in mice lacking functional CD4 + T cells
(Beers et al., 2008). However, these studies did not distinguish between conventional
CD4 + T cells and Tregs, so it is possible these protective effects are due solely to the
presence of Tregs. CD8 + T cells can assert a cytotoxic effect to kill motor neurons through
Fas and granzyme pathways in mice (Coque et al., 2019; Nardo et al., 2018). In contrast,
the infiltration of CD8 + T cells alongside macrophages is associated with myelin
regeneration on motor neurons which delays ALS and prolongs survival (Nardo et al.,
2016). Further research is required to determine the exact roles of CD8 + T cells, and to
investigate whether these differential effects are mediated by different CD8 + T cell
subsets.
Tregs are perhaps the most well characterised T cell subset in ALS, with reduced Tregs
repeatedly associated with disease progression (Giovannelli et al., 2020). Circulating
Tregs are decreased in patients with ALS (Henkel et al., 2013; Mantovani et al., 2009;
Rentzos et al., 2012) and decrease as disease progresses in SOD1 G93A mice (Beers et al.,
2011). Tregs are increased early in disease development in SOD1 G93A mice early and
suppress microglia responses, through the release of IL-4, and effector T cell responses,
through the release of IL-4, IL-10 and TGFβ (Zhao et al., 2012). However, this study also
indicated that as ALS begins to rapidly progress, Tregs numbers decrease, and Tregs are
unable to suppress effector T cell proliferation. Moreover, the adoptive transfer of Tregs
into SOD1 G93A mice delays ALS and extends survival (Beers et al., 2011). Since these
studies in mice, similar results have been observed in ALS patients with Treg numbers
negatively correlated with disease progression and survival (Beers et al., 2017; Rentzos
et al., 2012). Moreover, Treg function in ALS patients appears to be decreased, as
FOXP3, IL4, and TGFB1 mRNA expression in leukocytes from these patients was
reduced (Henkel et al., 2013). Notably, in vivo treatment with an IL-2/IL-2 mAb complex
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and rapamycin increases Tregs in SOD1 G93A mice and prolongs their survival (Sheean et
al., 2018). Moreover, this study demonstrated that treatment decreases microgliosis and
increases spinal cord M2 microglia. Altogether this evidence indicates a clear protective
role for Tregs in ALS and demonstrates that increasing Tregs in disease can provide
protective benefits against ALS.
A handful of peripheral cytokines have also been implicated in ALS development. TNFα
and soluble TNF receptors 1 and 2 are increased in the blood of ALS patients compared
to healthy individuals (Babu et al., 2008; Cereda et al., 2008). TNF contributes to spinal
cord inflammation (Brohawn et al., 2016) but reports differ on whether this
neuroinflammation is harmful or beneficial (McCombe et al., 2020). Signalling through
TNF receptor 2 on motor neurons and astrocytes contributes to motor neuron death
(Tortarolo et al., 2015) while stimulation of TNF receptor 1 on astrocytes protects motor
neurons (Brambilla et al., 2016). IL-1β is also increased in ALS patients (Hu et al., 2017;
Lu et al., 2016) and the NLRP3 inflammasome and IL-1β worsen disease in mouse
models by promoting neuroinflammation (Deora et al., 2020; Meissner et al., 2010).
IL-6 levels are increased in the blood of ALS patients (Hu et al., 2017) and allelic
variation in IL6 alters disease severity in patients (Wosiski-Kuhn et al., 2019). However,
IL-6 deficiency does not alter disease progression in a SOD1 G93A mouse model (Han et
al., 2016). Additionally, a number of other serum cytokines are altered in ALS patients,
including IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13, IL-17, IL-18, IL-23, IL-33 and
IFNγ (Babu et al., 2008; Hu et al., 2017; Italiani et al., 2014; Lin et al., 2012; Lu et al.,
2016; Rentzos et al., 2010), but the role of these cytokines in clinical disease is poorly
understood. Moreover, it is largely unknown which of these cytokines are involved in
ALS progression in SOD1 G93A mice.
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1.3.5. P2X7 in ALS
P2X7 plays roles both in the CNS and periphery during ALS (Volonté et al., 2020). P2X7
expression is increased on immunoreactive spinal cord microglia from ALS patients
(Yiangou et al., 2006) and SOD1 G93A mice (D'Ambrosi et al., 2009) and activation of
P2X7 on microglia and astrocytes leads to motor neuron death in SOD1 G93A mice
(D'Ambrosi et al., 2009) and rats (Gandelman et al., 2010). P2X7 can induce the
transcription of multiple immune related miRs, including miR-22, miR-155, miR-125b
and miR-146b, in microglia which leads to increased TNFα release from these cells and
motor neuron death (Parisi et al., 2013; Parisi et al., 2016). Similarly, the activation of
P2X7 on microglia can also enhance reduced nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase 2 activity to promote oxidative stress and damage (Apolloni
et al., 2013b). Moreover, direct activation of P2X7 on motor neurons induces the death
of these cells via a heat-shock protein and Fas pathway (Franco et al., 2013; Gandelman
et al., 2013).
Due to these P2X7-mediated pro-inflammatory responses which worsen ALS, P2X7
blockade has been trialled in mouse models of ALS. BBG (from pre-onset, day 90, to
endpoint) improves motor function in SOD1 G93A mice with a larger effect in male mice
compared to female mice (Cervetto et al., 2013). Moreover, this BBG regime delays
weight loss in male, but not female, mice but does not extend survival. Likewise, BBG
(from late pre-onset, day 100, to endpoint; but not asymptomatic, day 40, or pre-onset,
day 70) improves motor performance and delays ALS in SOD1 G93A mice (Apolloni et al.,
2014). This BBG regime also reduces motor neuron loss, spinal cord microgliosis and
IL-1β mRNA, and increases spinal cord IL-10 mRNA. Our group also trialled BBG (from
pre-onset, day 62-64, to endpoint) in SOD1 G93A mice and demonstrated that P2X7
blockade reduces weight loss and prolongs survival in female, but not male, mice (Bartlett
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et al., 2017a). MCP-1 is a biomarker of ALS (Huang et al., 2020) that is upregulated in
ALS patients (Henkel et al., 2004) and mice (Kawaguchi-Niida et al., 2013), and P2X7
activation is involved in the expression of this chemokine (Kurashima et al., 2012).
Despite this, BBG increases MCP-1 in SOD1 G93A ALS mice (Bartlett et al., 2017a).
Notably, BBG does not readily cross the BBB (Bhattacharya et al., 2016) which may
suggest the benefits observed in these studies occurred due to the blockade of peripheral
P2X7. As such, using a CNS penetrant P2X7 antagonist, like JNJ-47965567
(Bhattacharya et al., 2013), may increase our understanding of the role of P2X7 in ALS.
To this end, recent work from our group indicated that the CNS-penetrant P2X7
antagonist JNJ-47965567 (from disease onset, day 97-104, to endpoint) does not alter
clinical score, weight loss, motor coordination or survival in SOD1 G93A mice (Dongol,
2018), but other molecular and cellular effects of P2X7 blockade were not examined.
Bartlett et al. (2017a) demonstrated that BBG does not alter immune cell proportions in
the spleens of SOD1 G93A mice, but other lymphoid tissues were not investigated. As
highlighted in previous sections of this chapter, P2X7 activation can alter the function
and survival of immune cells, including T cells and DCs, but it remains to be determined
if P2X7 blockade can alter peripheral immune cells outside of the spleen in SOD1 G93A
mice.
Contrary to previous studies using BBG, the P2X7 antagonist A804598 (from pre-onset,
day 100) does not alter motor performance or survival in SOD1 G93A mice (Fabbrizio et
al., 2017). Additionally, P2rx7 knockout in SOD1 G93A mice worsens ALS (Apolloni et
al., 2013a). These knockout mice have increased astrogliosis, microgliosis, motor neuron
loss and pro-inflammatory markers at endpoint. This suggests that under certain
circumstances P2X7 may play a beneficial role in disease. Indeed, stimulation of P2X7
with BzATP improves the metabolism and innervation of myofibers and prevents the
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atrophy of skeletal muscles in SOD1 G93A mice (Fabbrizio et al., 2020). This highlights
differential roles for P2X7 in ALS and indicates that targeting of P2X7 in ALS may be
more complicated than initially thought. If the dual roles of P2X7 in ALS are better
understood, P2X7 therapy could be targeted towards certain tissues or cell types to better
prevent disease.

1.4. Summary and Key Aims
In summary, P2X7 is an ATP-gated ion channel found on multiple cell types including
most immune cells, with activation of this receptor generally resulting in
pro-inflammatory events. As such P2X7 has been implicated in multiple inflammatory
diseases including GVHD and ALS. Targeting P2X7 in these diseases will allow us to
better understand what roles P2X7 plays during inflammation and may allow the
development of better therapeutics for both diseases. Furthermore, development of novel
P2X7 antagonists will also assist in understanding how this receptor is involved in health
and disease and provide novel P2X7 therapeutics. As such, the general aim of this thesis
is to investigate P2X7 as a therapeutic target in inflammatory disorders.
The specific aims of this thesis are:
1) To examine mP2rx7 and hP2RX7 expression in the gut, skin, liver and lung of the
humanised NSG mouse model of GVHD, and to further characterise disease
impact in these tissues;
2) To determine if a modified P2X7 blockade treatment regime with BBG can
improve outcomes in a humanised NSG mouse model of GVHD;
3) To investigate if a second P2X7 antagonist, PPADS, can improve outcomes in a
humanised NSG mouse model of GVHD;
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4) To determine if combinational therapy of PTCy and P2X7 blockade with BBG
can better prevent GVHD than PTCy alone in humanised NSG mice;
5) To elucidate the mechanism of action of JNJ-47965567 against mouse P2X7, and
analyse data and tissues from a recently completed preclin ical trial using
JNJ-47965567 in SOD1 G93A ALS mice (Dongol, 2018);
6) To identify and characterise a novel P2X7 antagonist from a library of amiloride
and HMA analogues.
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Chapter 2: Methods
2.1. Materials and reagents
D-glucose, ethidium bromide, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), KCl and NaCl were from Amresco (Solon, USA). Vacutainer Plus lithium
heparin tubes, needles and syringes were from Becton Dickinson (BD) (San Diego, USA).
Precision count beads and zombie near-infrared (NIR) dye were from BioLegend (San
Diego, USA). TRIsure was from Bioline (London, UK). Foetal calf serum (FCS) was
from Bovogen Biologicals (East Keilor, Australia) and heat inactivated before use (56oC,
30 min). MgCl2 and MgSO4 were from Chem-Supply (Gillman-Australia). Clear
flat-bottomed 6-, 24- or 96- well plates were from Corning (Durham, USA) unless
otherwise stated. Cell filters and plastic tubes were from Falcon Biosciences (New York
City, USA) unless otherwise stated. Ficoll-Paque PLUS was from GE Healthcare
(Uppsala, Sweden). VACUETTE lithium heparin tubes, black-walled, clear/flatbottomed 96-well plates and vented 75 cm 2 cell culture flasks were from Greiner
Bio-One (Frickenhausen, Germany). Saline (0.9 % w/v) was from Pfizer (Sydney,
Australia). Haematoxylin and eosin were from POCD Scientific (Artarmon, Australia).
10 % neutral-buffered formalin, amiloride, ampicillin, ATP, BBG, CaCl2, collagenase A,
cyclophosphamide, dimethyl sulphoxide (DMSO), DNase I (grade II from bovine
pancreas), ethanol, HCl, kanamycin, LPS (Escherichia coli serotype 055:B5),
Luria-Bertani (LB) agar, LB broth, NaOH, pluronic F-127 acid and sodium citrate
solution (4 % w/v), were from Sigma-Aldrich (St Louis, USA). Dulbecco’s modified
phosphate-buffered saline (D-PBS), Dulbecco’s Modified Eagle Medium: Nutrient
Mixture F12 (DMEM/F12), fura-2-acetoxymethyl ester (Fura-2AM), geneticin,
GlutaMAX, 2-mercaptoethanol, Opti-MEM, penicillin-streptomycin, RNAlater, RPMI-
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1640 medium, TaqMan Universal Master Mix II, TRIzol and YO-PRO-1 iodide were
from Thermo Fisher Scientific (Waltham, USA). KHCO 3, Na2CO3, NH4Cl, PPADS and
JNJ-47965567 were from Tocris Biosciences (Minneapolis, USA).
2.1.1. Antibodies
Brilliant Violet (BV) 711-conjugated anti-hCD3 (clone UCHT1), allophycocyaninconjugated anti-hCD3, peridinin chlorophyll protein complex (PerCP) cyanine (Cy)
5.5-conjugated anti-hCD4 (clone SK3), R-phycoerythrin (PE)-conjugated anti-hCD4
(clone SK3), PE-Cy7-conjugated anti-hCD8 (clone RPA-T8), allophycocyaninconjugated anti-hCD19 (clone HIB19), PE-conjugated anti-hCD25 (clone M-A251),
PE-conjugated anti-hCD27 (clone M-T271), allophycocyanin-conjugated anti-hCD39
(clone TU66), fluorescein isothiocyanate (FITC)-conjugated anti-hCD45 (clone HI30),
PE-Cy7-conjugated anti-hCD56 (clone B159), BV405-conjugated anti-hCD127 (clone
HIL-7R-M21), BV421-conjugated anti-hβ7 (clone FIB504), BV605-conjugated
anti-hCLA (clone HECA-452) and PerCP-conjugated anti-mCD45 (clone 30-F11) mAbs
were obtained from BD.
2.1.2. Quantitative polymerase chain reaction primers
FAM-labelled mP2rx7 (Mm01199503_m1), mReg3g (Mm01181783_g1), mP2rx1
(Mm01251971_g1), mP2rx4 (Mm00501790_g1), mIl22 (Mm01226722_g1), mNqo1
(Mm01253561_m1), hP2RX7 (Hs00175721_m1), hP2RX7B (custom, Forward sequence:
5’GGAAAATGGTTTGGAGAAGGAAGTG3', Reverse sequence: 5’CGATGAGG
AAGTCGATGAACACA3'), hIFNG (Hs00989291_m1) or hIL22 (Hs01574154_m1),
and VIC-labelled mGapdh (Mm99999915_g1) and hHPRT1 (Hs99999909_m1)
primer/probes were obtained from Thermo Fisher Scientific.
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2.1.3. Agonist and antagonist stock solution preparation
ATP powder was dissolved in low-divalent medium (LDM) (145 mM NaCl, 2 mM KCl,
0.2 mM CaCl2, 13 mM D-glucose, 10 mM HEPES, pH 7.5) at >100 mM. ATP solutions
were titrated to a pH of 7 with NaOH (5 M) and diluted to a final concentration of
100 mM. Solutions were stored (-80 oC) for up to a year prior to use in in vitro assays.
BBG powder was dissolved at 5 mg/mL in sterile saline (0.9 % w/v). PPADS powder was
dissolved at 60 mg/mL in sterile saline (0.9 % w/v). Solutions were filter sterilised
(0.22 μm filter) and stored (-20 oC). Sterile BBG and PPADS solutions were stored for up
to six or one month(s), respectively, prior to use in mice. BBG and PPADS solutions were
stored for up to two years prior to use in in vitro assays. Cyclophosphamide at 40 mg/mL
in water was diluted to 6.6 mg/mL with D-PBS, filter sterilised (0.22 μm filter) and stored
(4 oC) for up to a week prior to use in mice. JNJ-47965567 powder was dissolved at
30 mM in DMSO and stored (-20 oC) for up to two years prior to use in in vitro assays.
Amiloride derivatives, including HMA, were previously synthesised as described
(Buckley et al., 2018; Buckley et al., 2021). Amiloride and its derivatives were dissolved
at 10-30 mM in DMSO and stored (-20 oC) for up to a year prior to use in in vitro assays.
Compounds used in in vitro assays were diluted as indicated.

2.2. hPBMC isolation
Human blood was acquired and used as approved by the Human Ethics Committee of the
University of Wollongong (Wollongong, Australia). Whole blood was collected from
healthy donors into VACUETTE or Vacutainer Plus lithium heparin tubes with informed
written consent from all donors. Whole blood was mixed with an equal volume of D-PBS,
under laid with Ficoll-Paque PLUS, and centrifuged (560 xg, 30 min, deceleration set to
0). hPBMCs were collected from the plasma/Ficoll-Paque interface and washed twice
with D-PBS (440 xg, 10 min, followed by 330 xg, 10 min). hPBMCs were suspended in
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a known volume of D-PBS, counted with a haemocytometer (Boeco, Hamburg, Germany)
according to the manufacturer’s instructions, washed (330 xg, 5 min) and suspended in
D-PBS at the desired concentration.

2.3. Humanised mouse model of GVHD
All animal procedures were carried out as approved by the University of Wollongong
Animal Ethics Committee within the Rodent Research Facility of the University of
Wollongong. Female NSG mice (aged 4-6 weeks) were obtained from Australian
BioResources (Moss Vale, Australia) and housed in ventilated cages (Techniplast,
Buggugiate, Italy) with a 12 h light/12 h dark cycle and provided with autoclaved food
and water provided ad libitum. Mice were acclimatised for 1-2 weeks.
NSG mice were injected i.p. (23-gauge (G) needle) with 10 x 10 6 (Chapters 3-5) or
20 x 10 6 (Chapter 6) hPBMCs (day 0). Control NSG mice in Chapter 3 were injected i.p.
(23G needle) with an equal volume (200 L) of D-PBS. In Chapters 4-6, humanised mice
also received daily (days 0-10) i.p. injections (30G needle) of BBG (50 mg/kg), PPADS
(300 mg/kg) or an equivalent volume (200 μL) of saline (0.9 % w/v) as indicated. In
Chapter 6, humanised mice received two i.p. injections of cyclophosphamide (33 mg/kg)
(days 3, 4). Mice were monitored for signs of GVHD at least thrice weekly from day 0
until endpoint using a clinical scoring system (Table 2.1). Ear thickness was measured
up to thrice weekly using Interapid spring-loaded callipers (Rolle, Switzerland).
Humanised mice were euthanised by slow-fill CO2 at day 21, day 70 or ethical endpoint
(see Table 2.1 for details) and tissues (duodenum, jejunum, ileum, colon, skin, ear,
spleen, liver, lung and/or blood) were collected into sodium citrate, D-PBS, RPMI-1640
medium, 10 % neutral-buffered formalin and/or RNAlater as indicated.
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Table 2.1: Clinical scoring criteria for the assessment of GVHD in humanised mice.

Score1

0

1

2

3

<5 %

5 to 9.9 %

10 to 15 %

>15 %

Posture

Normal

Hunching noted at
rest only

Hunching noted at
rest and movement

Severe hunching

Activity

Normal

Mild to moderately
decreased

Stationary unless
stimulated

Permanently stationary

Fur

Normal

Mild to moderate
ruffling

Severe ruffling and
hair loss (thinning)

Areas of hair loss
(balding)

Skin Integrity

Normal

Weight loss2,3

Scaling of paws
Scaling at
Areas of denuded skin
and/or tail
additional areas
(loss of surface layers)
1 Mice were euthanised if they scored a 3 in any category (excluding fur) or a total score ≥10.
2 Weight loss was determined as percentage loss from starting weight (weight on day 0).
3 Mice with >10 % (Chapter 3) or >15 % (Chapters 4-6) weight loss over a 7 day period were
assigned a score of 3 for weight, and euthanised. All mice euthanised in Chapter 3 were euthanised
due to 10 % acute weight loss despite many (14 of 26) of these mice having only mild (score <3
excluding acute weight loss) clinical signs of GVHD. As such, Chapters 4-6 used 15 % acute
weight loss as an ethical endpoint.
Table adapted from (Adhikary et al., 2019)

2.4. SOD1 G93A mouse model of ALS
Chapter 7 includes a retrospective analysis of previously acquired data from a mouse
model of ALS (Ly et al., 2020). Briefly, SOD1 G93A mice were scored and weighed at least
three times a week from 60 days of age. From disease onset (day 97-104) mice were
treated thrice weekly with 30 mg/kg JNJ-47965567 or an equivalent volume of
2-(hydroxypropyl)-beta-cyclodextrin (β-CD) (vehicle control). Endpoint was defined as
≥20 % body weight loss from the maximum pre-treatment weight or when a mouse was
unable to right itself within 10 s of being placed on its side. Endpoint mice were
euthanised by slow-fill CO2 and whole blood (via cardiac puncture), spleen, CNS draining
and non-draining lymph nodes and spinal cords were collected. Serum was extracted from
whole blood by centrifugation (1700 xg, 10 min) and stored until required (-80 oC). Lymph
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tissues were processed for immunophenotyping on the day of euthanasia. Spinal cords
were stored in RNAlater until required (-20 oC).

2.5. Humanised mouse blood preparation for serum and immunophenotyping
Blood was collected via the tail vein by pricking with a needle (29G) and collecting blood
(Chapter 3) or cardiac puncture with a needle (23G) (Chapters 3-6) at day 21 or endpoint
as indicated. On day 21, 50 μL of blood collected via the tail vein or cardiac puncture was
mixed with 200 μL of sodium citrate solution to prevent coagulation. Alternatively, the
remaining blood collected via cardiac puncture on day 21 (Chapters 4 -6) or all blood at
endpoint (Chapters 3-6) was allowed to coagulate for at least 30 min in microfuge tubes.
Coagulated blood was centrifuged (1700 xg, 5 min) and serum collected and stored
(-80 oC) until required. If serum volume was <100 μL, remaining blood was centrifuged a
second time (1700 xg, 5 min) to increase yield.
Blood in concentrated sodium citrate was diluted with D-PBS, centrifuged (300 xg,
5 min) and the supernatant was removed. Cells were incubated (5 min) with ammonium
chloride potassium (ACK) lysis buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM Na2CO3)
to lyse red blood cells and washed with 10 volumes D-PBS (300 xg, 5 min). If samples
still had considerable red blood cells present ACK lysis was repeated, otherwise cells
were suspended in a known volume of D-PBS, counted with a haemocytometer as above
(Section 2.2) and resuspended at 1 x 10 6 cells/mL in D-PBS.

2.6.Humanised mouse spleen preparation for immunophenotyping
Mouse spleens collected in D-PBS were manually homogenised using a flat syringe base,
passed through a 70 μm nylon filter and centrifuged (300 xg, 5 min). Cells were incubated
with ACK lysis buffer (5 min) and washed with 10 volumes of D-PBS (300 xg, 5 min).
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Cells were suspended in a known volume of D-PBS, counted with a haemocytometer as
above (Section 2.2) and resuspended at 1 x 10 6 cells/mL in D-PBS.

2.7. Humanised mouse liver preparation for immunophenotyping
Mouse livers collected in RPMI-1640 medium were manually homogenised a flat syringe
base and digested with 1.4 mg/mL collagenase A (dissolved in RPMI-1640 medium) and
0.4 mg/mL DNase I (dissolved in RPMI-1640 medium) (37 oC, 45 min, shaking, 200 rpm)
(Bioline 8160 Orbital Shaker). Incubations were extended for a further 15 min if tissue
was not fully digested. Once digested the cell suspension was passed through a 70 μm
nylon filter, washed with D-PBS (300 xg, 5 min) and red blood cell were lysed with ACK
lysis buffer (5 min). Cells were washed with 10 volumes D-PBS (300 xg, 5 min),
suspended in a known volume of D-PBS, counted with a haemocytometer as above
(Section 2.2) and resuspended at 1 x 10 6 cells/mL in D-PBS.

2.8. Immunophenotyping
In some experiments (as indicated) cells isolated from mouse blood, spleens and/or livers,
or hPBMCs were incubated with Zombie NIR dye (15 min on ice, dark) prior to antibody
staining. Cells were washed with D-PBS containing 2 % FCS (300 xg, 5 min) and stained
with fluorochrome-conjugated mAbs as indicated (15 min, on ice, dark). Labelled cells
were washed with D-PBS (300 xg, 5 min), resuspended in D-PBS. In some experiments
(as indicated) precision count beads were added. Data was collected using a LSR Fortessa
X-20 flow cytometer (BD). In Chapter 7, flow cytometry data was previously acquired
by Dr Diane Ly (University of Wollongong); for experimental details see (Ly et al.,
2020). All flow cytometric data was analysed with FlowJo software (version 8.7.1) (BD).
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2.9. Humanised mouse histology
Mouse tissues collected in 10 % neutral-buffered formalin were stored for at least three
days before being processed in a Leica Biosystems tissue processor (Leica, Wetzlar,
Germany) and embedded in paraffin wax (Leica). Embedded tissues were sectioned at
3–5 μm using a microtome (Leica) and stained with haematoxylin and eosin (Table 2.2).
Stained tissues were imaged using a Leica DM750 inverted light microscope and Leica
application suite software (version 4.7). Representative images of each tissue for each
mouse were taken and histological grades in liver, skin (flank and ear) and duodenum
were determined in a blinded fashion as described previously (Hu et al., 2020a) (Table
2.3). Percent clear alveoli of total lung was determined from measurements of clear and
nonclear areas in lung images with Fiji (Schindelin et al., 2012) in a blinded fashion.
Table 2.2 Haematoxylin and eosin staining of tissue sections
Step. Reagent

Time (sec)

Step. Reagent

Time (sec)

1. Xylene substitute

150

7. Water

60

2. 100 % ethanol

100

8. Scott’s bluing reagent
(45 mM NaHCO3 , 166 mM
MgSO4 )

60

3. Water

120

9. Water

60

4. Haematoxylin

100

10. Eosin

20

5. Water

120

11. 100 % ethanol

105

12. Xylene substitute

70

6. Acid alcohol
(1 % HCl in 70 %
1*
ethanol)
*Slides were dipped once in acid alcohol
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Table 2.3: Histological grading system to assess GVHD in humanised mouse tissues.
Grade
0
0.5
1
2
3
4

Tissue
Skin and Ear
Normal
Rare single basilar vacuolar necrosis with/without rare infiltrating lymphocytes
Several foci of single basilar vacuolar necrosis with rare infiltrating lymphocytes
Contiguous single cell necrosis or multiple necrotic cells in proximity with mild
lymphocytic infiltrate
Confluent loss of cells with cleft formation or loss of skin appendages with heavy
lymphocytic infiltrate
Loss of epidermis or epithelium with or without granulation tissue response

3
4

Intestine
Normal
Rare infiltrating lymphocytes and rare necrotic cells in glands or crypts
Mild lymphocytic infiltrates, multiple focal necrotic cells in glands or crypts, or
focal surface colonocyte lesions and villous blunting
Heavy lymphocytic infiltrates, necrosis involving several crypts or glands,
colonocyte lesions and villous blunting
Crypt loss and focal glandular destruction
Loss of mucosa with granulation tissue response

0
0.5
1
2
3
4

Liver
Normal
Focal and rare portal lymphocytic infiltrate
Widespread focal and mild portal lymphocytic infiltrate
Heavy lymphocytic infiltrates with focal bile duct invasion or cellular injury
Multiple foci of bile duct injury and regeneration
Widespread injury and destruction of bile ducts

0
0.5
1
2

Table adapted from Hu et al. (2020a).

2.10.

Gene expression analysis

2.10.1. RNA isolation and cDNA synthesis
Duodenum, jejunum, ileum, colon, spleen, liver, and/or lung stored in RNAlater (-20oC)
were thawed on ice, manually homogenised in TRIzol (Chapter 3) or TRIsure (Chapters
4-6) using flat syringe base and RNA was isolated according to the manufacturer’s
instructions. Skin (flank and ear) and spinal cords stored in RNAlater (at -20 oC) were
thawed on ice then homogenised using a Precellys 24 tissue homogeniser (2 x 20 sec
cycles at 5500 rpm) with CK14 beads (Bertin Instruments, Montigny -le-Bretonneux,
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France) and RNA was isolated using an ISOLATE II RNA Mini Kit (Bioline) according
to the manufacturer’s instructions. Complementary DNA (cDNA) was synthesised from
isolated RNA using a qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA,
USA) according to the manufacturer’s instructions.
2.10.2. Quantitative polymerase chain reaction
Relative gene expression was determined using TaqMan Universal Master Mix II
(Thermo Fisher Scientific) according to the manufacturer’s instructions. Quantitative
polymerase chain reactions (qPCR) were conducted with the following primer/probes:
FAM-labelled mP2rx7, mReg3g, mP2rx1, mP2rx4, mIl22, mNqo1, hP2RX7, hP2RX7B,
hIFNG or hIL22 with either VIC-labelled mGapdh or hHPRT1 as the housekeeping gene
for murine or human genes respectively. qPCR was conducted using a QuantStudio 5 real
time PCR System (Thermo Fisher Scientific) with an initial step of 50 oC (2 min), followed
by 95 oC (10 min) then 40 cycles of 95 oC (15 sec) and 60 oC (1 min). Reactions were
conducted in triplicate and analysed with QuantStudio Design and Analysis Software
(version 1.5.1) (Thermo Fisher Scientific). Gene expression was quantified using the
ΔΔCt method to normalise to a housekeeping gene and mouse tissue. mP2rx7 was made
relative to the same non-humanised NSG mouse spleen (Chapters 3-5) or a control
(vehicle) SOD1 G93A mouse spinal cord (Chapter 7). mP2rx1, mP2rx4 and mReg3g were
made relative to the same non-humanised NSG mouse duodenum (Chapters 3-5). mNqo1
was made relative to a control SOD1 G93A mouse spinal cord (Chapter 7). hP2RX7,
hP2RX7B and hIFNG were made relative to a randomly selected humanised mouse spleen
(Chapter 3) or a saline-treated humanised mouse liver (Chapters 4, 5).
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2.10.3. NanoString Analysis
Differential gene expression in

the spinal cords of control (vehicle) or

JNJ-47965567-treated SOD1 G93A mice was assessed with a nCounter Mouse
Neuropathology Panel (NanoString Technologies, Seattle, USA) using a nCounter
SPRINT Profiler (NanoString) according to the manufacturer’s instructions. RNA was
isolated and gene expression data was acquired by Dr Diane Ly as described (Ly et al.,
2020). Data was analysed using nSolver Advanced Analysis software (version 4.0)
(NanoString Technologies). Background thresholding was set to 40 based on negative
control counts. Housekeeping genes with average counts below 100 (Asb7 and Supt7l)
were excluded prior to normalisation to the remaining housekeeping genes, Aars,
Ccdc127, Cnot10, Csnk2a2, Fam104a, Lars, Mto1 and Tada2b. Samples were partitioned
by treatment and differences in gene expression between JNJ-47965567-treated and
control mice were calculated by the program.

2.11. Mouse serum cytokine analysis
Serum mREG3γ concentrations were measured using a Murine REG3γ ELISA kit
(MyBioSource, San Diego, USA) according to the manufacturer’s instructions (Chapter
3). Serum hIFNγ concentrations were determined using a Human IFNγ ELISA Kit (Life
Technologies) (Chapter 3) or a Human IFNγ ELISA Kit (Invitrogen) (Chapters 4 and 5)
according to the manufacturer’s instructions. Serum hIL-2, hIL-6, hIL-10, hIL-17A and
hTNFα concentrations were measured using a LEGENDplex Human Th1 Panel (5-plex)
kit (BioLegend) according to the manufacturer’s instructions (Chapter 5). Serum hIFNγ,
hIL-2, hIL-4, hIL-5, hIL-6, hIL-9, hIL-10, hIL-13, hIL-17A, hIL-17F, hIL21, hIL-22, and
hTNFα concentrations were determined using a LEGENDplex Human Th Cytokine Panel
(13-plex) kit (BioLegend) according to the manufacturer’s instructions (Chapter 6).
Serum m granulocyte macrophage colony stimulating factor (GM-CSF), mIFNβ, mIFNγ,
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mIL-1α, mIL-1β, mIL-6, mIL-10, mIL-12p70, mIL-17A, mIL-23, mIL-27, mMCP-1 and
mTNFα concentrations were measured using a LEGENDplex Mouse Inflammation Panel
(13-plex) (BioLegend) according to the manufacturer’s instructions (Chapter 7). Cytokine
concentrations below, or above, the detection limit (variable) were set to the detection
limit for statistical analysis in each experiment.

2.12. Cell culture
2.12.1. Established cell lines and culturing conditions
All established cell lines were maintained in 75 cm 2 flasks at 37 oC 95 % air/5 % CO2.
Cells were passaged when they reached 70-90 % confluency. Murine macrophage J774
cells (American Type Culture Collection (ATCC), Manassas, USA) and human multiple
myeloma RPMI8226 cells (European Collection of Authenticated Cell Cultures, Porton
Down, UK) were maintained in RPMI-1640 medium supplemented with 2 mM
GlutaMAX and 10 % (v/v) FCS (complete RPMI-1640 medium). J774 cells were
detached from flasks by mechanical scraping and RPMI8226 cells are grown in
suspension. HEK293 cells (ATCC) and HEK293 cells stably transfected with hP2X7
(HEK-hP2X7) (Bhaskaracharya et al., 2014) (kindly provided by Dr Leanne Stokes,
University of East Anglia, Norwich, UK) were maintained in DMEM/F12 medium
supplemented with 2 mM GlutaMAX, 10 % (v/v) FCS, 100 U/mL penicillin, and 100
μg/mL streptomycin (complete DMEM/F12 medium). Medium for HEK-hP2X7 cells
also contained 400 μg/mL geneticin (complete DMEM/F12 medium with geneticin).
HEK293 and HEK-hP2X7 cells were detached from flasks by washing with D-PBS and
incubating with 0.05 % trypsin-EDTA (37 oC, 3-5 min). Trypsin reactions were stopped
by addition of an equal volume of the relevant complete medium. Cell suspensions were
centrifuged (300 xg, 5 min) and cells were resuspended in the relevant complete medium.
Suspended cells were transferred to new 75 cm 2 flasks at the desired dilution for further
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culture. Mycoplasma testing was conducted by technical officers (Illawarra Health and
Medical Research Institute) and cell lines regularly tested negative for mycoplasma using
the MycoAlert Test Kit (Lonza, Basel Switzerland).
2.12.2. hPBMC cultures
Freshly isolated hPBMCs or cryopreserved hPBMCs (kindly provided by Ross Turner,
University of Wollongong) (Turner et al., 2020) were washed once with D-PBS (300 xg,
5 min), twice with RPMI-1640 medium supplemented with 2 mM GlutaMAX, 100 U/mL
penicillin, 100 μg/mL streptomycin, 1 % (v/v) mercaptoethanol and 0-10 % (v/v) FCS (as
indicated) (300 xg, 5 min). hPBMCs were suspended at 1 x10 6 in new supplemented
RPMI-1640 medium, seeded at 2 x 10 6 cells/well in a 24-well plate and incubated with
10 μM BBG or PPADS, or an equivalent volume of saline for 20 h (37 oC, 95 % air/5 %
CO2). Well contents were transferred to tubes, centrifuged (300 xg, 5 min) and washed
twice with PBS (300 xg, 5 min) and immunophenotyped as described above (Section 2.8).

2.13. Transformation and transfection
2.13.1. Plasmid transformation and isolation
mP2rx7 in pPP89 (Bhaskaracharya et al., 2014) (kindly provided by Dr Leanne Stokes)
cP2rx7 (cloned from an English springer spaniel) in Ac-green fluorescent protein
(GFP)-N1 (Jalilian, 2011) and hP2RX4 in p-emerald (Em)GFP-N3 (Sophocleous et al.,
2020) were previously cloned and purified. Plasmid DNA was amplified by
transformation into DH5α competent bacterial cells (Thermo Fisher Scientific) according
to the manufacturer’s instructions. Positive colonies were selected on LB agar plates with
100 μg/mL ampicillin (mP2rx7) or 50 μg/mL kanamycin (cP2rx7 and hP2RX4) and
single colonies were expanded in LB broth with the relevant antibiotic (overnight, 37 oC).
Plasmid DNA was isolated using a Wizard Plus SV Miniprep DNA Purification kit
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(Promega, Madison, USA) according to the manufacturer’s instructions. Plasmid DNA
was suspended in Milli-Q water and the absorbances measured at 260 and 280 nm using
a NanoDrop (Thermo Fisher Scientific). The purity of DNA (A 260/A280 ratio) was
routinely 1.90-1.95. Yields of DNA ranged from 150-400 ng/μL.
2.13.2. HEK293 cell transfection
HEK293 cells were plated at 3.5 x 10 5 cells/well in 2 mL of complete DMEM/F12
medium (Section 2.12.1) overnight (37 oC, 95 % air/5 % CO2). Cells were transfected with
mP2X7-GFP, cP2X7-GFP or hP2X4-EmGFP plasmids, or mock transfected with an
equivalent volume of sterile Milli-Q water, using a Lipofectamine 3000 kit (Thermo
Fisher Scientific) according to the manufacturer’s instructions. In detail, a transfection
mixture of 0.8 μg of plasmid DNA (or an equivalent volume of sterile Milli-Q water for
mock transfections), 1 μL P3000 reagent and 5 μL Lipofectamine 3000 reagent was made
up to 250 μL with Opti-MEM and incubated (15 min). Each well received 250 μL of the
respective transfection mixture in a dropwise fashion and the plate was manually rocked
gently to ensure adequate mixing before incubation (48 h, 37 oC, 95 % air/5 % CO2). Cells
were detached from the plate by trypsinisation as described above (Section 2.12.1). To
determine transfection efficiency, cells were washed twice with D-PBS and data collected
with a LSR Fortessa X-20 flow cytometer. Transfected HEK293 cells were compared to
mock transfected HEK293 cells for the presence of GFP or EmGFP (as indicated) using
FlowJo software. Transfection efficiency in HEK293 cells was regularly between
70-80 % for mP2X7, 80-90 % for cP2X7 and >99 % for hP2X4.

2.14. Flow cytometric dye uptake assays
For all dye uptake experiments, tissue culture cells or hPBMCs were washed thrice with
LDM (300 xg, 5 min) and suspended in this medium at the desired concentration. For all
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experiments ATP was dissolved and diluted in LDM. Compounds or the respective
vehicle were diluted with LDM when necessary.
2.14.1. Traditional (tube-based) flow cytometric uptake assay
For tube-based uptake assays, 1 x 10 6 cells in 1 mL LDM were transferred to individual
tubes. Cells were pre-incubated (37 oC, 5min). In experiments with antagonists, cells were
instead pre-incubated with compounds (or the respective vehicle: saline for BBG and
PPADS, DMSO for JNJ-47965567 and amiloride analogues) at varying concentrations as
indicated (37 oC, 15 min). Following pre-incubation, cells were incubated with ethidium
bromide (25 μM) or YO-PRO-1 iodide (1 μM) in the presence of ATP or an equivalent
volume of LDM (basal) (5 min, 37 oC). An equal volume (1 mL) of ice-cold Mg2+ stopping
solution (145 mM NaCl, 2 mM KCl, 0.2 mM CaCl2, 10 mM HEPES, 20 mM MgCl2, pH
7.5) was then added and cells were centrifuged (300 xg, 5 min) to halt ATP-induced dye
uptake. Cells were washed twice with LDM (300 xg, 5 min), resuspended in LDM and
data collected with a LSR Fortessa X-20 flow cytometer. Mean fluorescent intensity
(MFI) of ethidium + or YO-PRO-1 2+ uptake was determined using FlowJo software. In
some experiments the respective basal fluorescence was subtracted from each sample to
calculate ATP-induced uptake. Samples were normalised to the maximal ATP-induced,
or vehicle, response within their respective experiments as indicated.
2.14.2. Novel (plate-based) flow cytometric uptake assay
For plate-based uptake assays, 1 x 10 5 RPMI8226 cells in 25 μL LDM (final concentration
of 1 x 10 6 cells/mL) were added to each well of a 96-well clear flat-bottomed plate. An
additional 25 μL of LDM was added and plates were pre-incubated (37 oC, 5min). In some
experiments, compounds or the respective vehicle (saline for BBG and PPADS, DMSO
for JNJ-47965567 and amiloride analogues) were diluted with LDM, and 25 μL of diluted
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compound (final concentration of 10 or 5 μM as indicated) or vehicle was added to the
appropriate wells, instead of the additional 25 μL LDM, and pre-incubated (37 oC,
15 min). LDM containing various concentrations of ATP (final concentrations as
indicated) or LDM (basal) with YO-PRO-1 iodide (final 1 μM) were prewarmed (37oC,
5 min) to reduce temperature decreases upon addition to the plate. Then, 50 μL of the
ATP/YO-PRO-1 iodide mixture was added to respective wells and plates were incubated
(37 oC, 4-16 min as indicated). Reactions were halted by the addition of an equal volume
(100 μL) ice-cold Mg2+ stopping solution and centrifugation (300 xg, 5 min). Wells were
washed twice with LDM (300 xg, 5 min), cells were resuspended in LDM and data
collected with an Attune NxT Flow Cytometer and Autosampler (Thermo Fisher
Scientific). MFI of YO-PRO-1 + uptake was determined using FlowJo (version 8.7.1).
ATP-induced uptake and normalisation were calculated as above (Section 2.14.1).
ATP-induced responses during compound screening were normalised to ATP-induced
uptake in vehicle treated wells.

2.15. IL-1β release assays
2.15.1. J774 cells mIL-1β release assay
J774 cells were collected, suspended in supplemented (2mM GlutaMAX and 10 % (v/v)
FCS) RPMI-1640 culture medium, and incubated (20 h, 37 oC, 95 % air/5 % CO2) at
5 x 10 5 cells/well in a 24-well plate. Medium was replaced with fresh medium containing
LPS (1 μg/mL) and incubated (4 h, 37 oC, 95 % air/5 % CO2). Adherent cells were washed
thrice with physiological medium (147 mM NaCl, 2 mM KCl, 2 mM CaCl 2, 1 mM MgCl2
and 10 mM HEPES, pH 7.4) and pre-incubated with compounds (10 μM) or an equivalent
volume of vehicle (saline) (30 min, 37oC, 95 % air/5 % CO2). Cells were incubated in the
presence of 1 mM ATP or an equivalent volume of LDM (20 min, 37 oC, 95 % air/5 %
CO2). Well contents were collected and centrifuged (11000 xg, 30 s) and cell free
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supernatants were stored at -80 oC until required. The concentration of mIL-1β was
determined using a Murine IL-1β ELISA (Invitrogen) according to the manufacturer’s
instructions. Samples above the detection limit (1000 pg/mL) were set at 1000 pg/mL for
statistical analysis.
2.15.2. Whole blood hIL-1β release assay
Whole blood was mixed with serum-free RPMI-1640 medium containing LPS
(200 ng/mL), added to a 96-well plate and incubated (105 min, 37oC, 95 % air/5 % CO2).
Compounds (30 μM), or an equivalent volume of vehicle (DMSO), were added to
respective wells and plates pre-incubated (15 min, 37 oC, 95 % air/5 % CO2). Then 6 mM
ATP or an equivalent volume of LDM was added and plates incub ated (30 min, 37 oC,
95 % air/5 % CO2). Plates were centrifuged (700 xg, 10 min) and the supernatants
collected and stored at -80 oC until required. The concentration of hIL-1β was determined
using a Human IL-1β ELISA (Thermo Fisher Scientific) according to the manufacturer’s
instructions. Samples above the detection limit (7500 pg/mL) were set at 7500 pg/mL for
statistical analysis.

2.16. Fura-2AM Ca 2+ response assay
Harvested cells were plated in a black clear-bottom 96-well plate at 5 x 10 4 cells/well and
allowed to adhere overnight (37 oC, 95 % air/5 % CO2). Cells were washed with
extracellular Ca 2+ solution (ECS) (145 mM NaCl, 2 mM CaCl2, 5 mM KCl, 13 mM
glucose and 10 mM HEPES, pH 7.4) and incubated with Fura-2AM loading buffer
(2.5 μM Fura-2AM and 0.2 % pluronic acid in ECS) (30 min, 37 oC, 95 % air/5 % CO2,
dark). Fura-2AM loading buffer was removed, and cells were washed once with ECS and
incubated in ECS (20 min, 37 oC, 95 % air/ 5% CO2, dark) to allow for Fura-2AM
de-esterification. In some experiments, cells were pre-incubated with antagonists (as
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indicated) or vehicle (DMSO) (30 min, 37 oC, 100 % air, dark). Following this antagonist
incubation, or the 20 min de-esterification, wells were excited at 340 and 380 nm and
Fura-2AM fluorescence at 510 nm was measured (six reads per well) every 5 sec using a
FlexStation 3 (Molecular Devices, San Jose, USA). Baseline recordings were taken for
15 sec and ATP (diluted with ECS) or an equivalent volume of ECS (basal) were added
using the built-in fluidics in the FlexStation 3 (final volume 100 μL per well). Data was
acquired using SoftMax Pro software (version 7.0) (Molecular Devices). Relative
changes in intracellular Ca 2+ were calculated using the ratio of Fura-2AM fluorescence at
510 nm following excitation at 340 nm and 380 nm (F 340nm/380nm). Ca2+ responses were
normalised to the baseline recordings using the formula ΔCa 2+ = ΔF/Frest = (F – Frest)/Frest,
where F is the F340nm/380nm ratio in a well at a particular timepoint and Frest is the mean
fluorescence of a well from 0-15 sec (prior to ATP or ECS addition) (Paredes et al., 2008).
Ca2+ responses over time were plotted in GraphPad Prism software (version 8.4.2)
(GraphPad Software, La Jolla, USA). The area under the curve from 100 -180 sec was
calculated with GraphPad Prism software to determine relative P2X-mediated Ca 2+
responses. The peak response was used to determine P2Y-mediated Ca 2+ responses. In
both cases, ATP-induced responses were calculated by subtracting the relevant basal
response. These responses were normalised to the maximal ATP-induced response within
their respective experiment.

2.17. General data analyses and statistics
Data in this thesis is presented as mean ± standard error of the mean (SEM) unless
otherwise stated. All statistical analysis (excluding NanoString gene expression analysis)
and graphing were conducted using GraphPad Prism (version 8.4.2). Where appropriate,
data sets were tested for normality (Shapiro-Wilk normality test) and equal variance
(F test). Statistical differences for single comparisons were calculated using one of the
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following (as indicated): unpaired or paired Student’s t test (parametric, equal variance),
Welch’s t test (parametric, unequal variance), Mann Whitney test (nonparametric,
unpaired) or Wilcoxon matched-pairs signed rank test (nonparametric, paired). Statistical
differences for multiple comparisons were calculated using a One-way ANOVA with
Tukey’s multiple comparisons correction (parametric) or a Kruskal-Wallis test with
Dunn’s multiple comparisons correction (nonparametric) as indicated. Statistical
differences between treatments in clinical score, weight and ear thickness over time were
calculated using a repeated-measures Two-way ANOVA with the Geisser-Greenhouse
correction. Multiple comparisons with a Sidak correction were used to determine at which
time points significant differences occurred. Statistical differences in survival or mortality
were determined with a log-rank Mantel-Cox test or Chi-squared (χ 2) test, respectively.
P < 0.05 was considered statistically significant. Concentration curves were fitted to
normalised data in GraphPad Prism with either ‘log(agonist) vs normalised response –
variable slope’ or ‘log(inhibitor) vs normalised response – variable slope’ curves to
calculate EC50 or IC50 values respectively. An ‘exponential plateau’ curve was fitted to
ATP-induced uptake over time to aid visualisation of data. For cell-based experiments,
and where possible, plate setup and sample order were altered between independent
experiments to reduce positioning bias.
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Chapter 3: Characterisation of the humanised mouse model of
GVHD
3.1. Introduction
Allo-HSCT is a curative therapy for haematological disorders, including blood cancers
(Copelan, 2006). However, HSCT causes acute GVHD, a potentially lethal complication
that damages the gut, skin, liver and lung (Markey et al., 2014), in the majority of
recipients (Zeiser et al., 2017). GVHD is mediated by donor T cells, which initiate a
massive inflammatory response against host organs (Ferrara et al., 1991). GVHD
develops when host APCs activate donor T cells (Ferrara et al., 1999). These donor
T cells are then directed to target organs by homing molecules such as integrin β7
(Petrovic et al., 2004) and CLA (Tsuchiyama et al., 2009), which direct T cells to the gut
and skin respectively. Activated donor T cells release pro-inflammatory cytokines such
as IFNγ (Yi et al., 2009), propagating a positive feedback loop leading to the further
activation of donor T cells, and increased inflammation and tissue damage (Hill et al.,
2000).
The gut is affected in approximately 60 % of GVHD cases and is a major cause of
mortality (McDonald, 2016). Gut damage arises when donor T cells cause severe
inflammation in the intestines, leading to crypt cell degeneration and destruction of the
villous epithelium (Teshima et al., 2016). Plasma REG3α has emerged as a clinical
biomarker of GVHD progression in humans (Ferrara et al., 2011). Likewise, mRNA for
REG3γ, the murine homologue of REG3α, is increased in villous enterocytes of mice
with GVHD, corresponding with increased circulating REG3γ in these mice (Eriguchi et
al., 2013).
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The skin is affected in approximately 80 % of GVHD cases and is usually the first tissue
to show clinical signs of damage (Martin et al., 1990). Whilst this damage does not
typically result in mortality, it causes significant pain to patients (Ball et al., 2008). The
liver is affected in approximately 50 % of GVHD cases, and is another major cause of
mortality (Farthing et al., 1982). Liver damage occurs when leukocytes infiltrate the area
surrounding the portal vein; leading to hepatocyte death and bile duct destruction (Snover
et al., 1984). In the lung, acute GVHD presents mainly as an idiopathic pneumonia
syndrome, with little to no cell apoptosis (Markey et al., 2014).
Allogenic mouse models are commonly used to study GVHD and have provided
significant insight into the understanding of this disease (Baker et al., 1996), but they do
not fully replicate GVHD in humans. As such, humanised mouse models of GVHD have
been developed to further elucidate the role of human immune cells in this disease.
Common examples of these models involve the injection of hPBMCs into immune
deficient mice, such as NSG (King et al., 2009) or NOG (Ito et al., 2009) mice.
Humanised mouse studies of GVHD often report disease involvement in the liver, but
involvement in the gut, skin or lungs is not always reported (Bruck et al., 2013; Geraghty
et al., 2019b; Gregoire-Gauthier et al., 2012; King et al., 2009). Homing molecules on
donor T cells have shown importance in both humans receiving allo-HSCT (Petrovic et
al., 2004; Tsuchiyama et al., 2009) and allogeneic mouse models (Waldman et al., 2006),
however they have not been extensively examined in humanised mice.
The activation of P2X7 by extracellular ATP plays an important role following
allo-HSCT. In allogeneic mouse models of GVHD, tissue damage leads to the release of
DAMPS including ATP (Wilhelm et al., 2010). This extracellular ATP can activate P2X7
on antigen presenting cells to promote donor T cell activation (Wilhelm et al., 2010).
hP2RX7 and mP2rx7 gene expression has been shown to be increased in human patients
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with GVHD and in mouse models of this disease (Wilhelm et al., 2010), but analysis of
P2RX7 expression in GVHD remains limited. Furthermore, pharmacological studies
blocking P2X7 have shown its importance in mediating GVHD progression in allogeneic
models of this disease (Wilhelm et al., 2010; Zhong et al., 2016) and more recently in a
humanised model of GVHD (Geraghty et al., 2017; Geraghty et al., 2019c, 2019d).
Collectively, this highlights the need for a more thorough analysis of mP2rx7 and
hP2RX7 expression in GVHD target organs. Therefore, this chapter aimed to examine
mP2rx7 and hP2RX7 expression in the gut, skin, liver and lung of humanised NSG mice,
and to further characterise disease impact in these organs.
Flow cytometric and clinical (weight, score and survival) results presented in this Chapter
are a combination of previously obtained (2 human donors) (Cuthbertson, 2017) and new
(2 human donors) data.

3.2. Results
3.2.1. Humanised NSG mice have circulating hCD45 +hCD3 + T cells at day 21
NSG mice typically develop GVHD following hPBMC injection and engraftment (King
et al., 2009). In this chapter NSG mice were injected i.p. with 10 x 10 6 hPBMCs
(humanised) or PBS (control) (Figure 3.1a). To confirm the engraftment of human
PBMCs, tail vein blood was collected from all mice at day 21 post-injection and analysed
by flow cytometry as indicated (Figure 3.1b). As expected, control mice lacked hCD45+
cells, whilst humanised mice engrafted hCD45+ cells (Figure 3.1c), the majority of which
were hCD3 + T cells (Figure 3.1d). Further analysis of the hCD3 + T cell population
revealed similar proportions of hCD4 + or hCD8+ subtypes (P = 0.11) (Figure 3.1e).

107

Figure 3.1: Humanised mice have circulating hCD45+hCD3+ T cells at day 21. (a) NSG mice
were injected i.p. with 10 x 106 human hPBMCs (n = 4 donors) (humanised) or PBS (control) on
day 0. (b-e) Blood from all mice (week 3) was examined by flow cytometry for the presence of
leukocytes. Forward scatter (FSC)-A, FSC-H and side scatter (SSC)-A were used to select single
lymphocytes (not shown). (b) Single lymphocytes were gated as shown and the proportions of (c)
hCD45+ leukocytes, (d) hCD3+ T cells, and (e) hCD4+ or hCD8+ T cell subsets were determined.
(c-e) Data presented as mean ± SEM. (b-d) Symbols represent individual mice. (c-e) n = 4, control
mice; n = 26 humanised mice. (e) Significance was determined by a paired t-test. P value as
shown.

3.2.2. Humanised mice develop clinical signs of GVHD from week 3
All mice were monitored for up to 10 weeks. Weight change was similar between
humanised and control mice until week 3, at which time humanised mice steadily lost
weight (P < 0.05) (Figure 3.2a). Humanised mice developed significant signs of disease
from 3 weeks post-hPBMC injection, with increased clinical score over time compared
to control mice (P < 0.0001) (Figure 3.2b). As a result, humanised mice had significantly
reduced survival (median survival time (MST) = 37.5 days) compared to control mice
(MST > 70 days) over 10 weeks (P < 0.01), with most of the humanised mice succumbing
to disease by 10 weeks, whilst all control mice remained alive during this time (Figure
3.2c). As such, mortality was significantly different between the two groups (P < 0.001).
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Figure 3.2: Humanised mice develop clinical signs of GVHD from week 3. Control and
humanised mice were monitored 3 times a week for up to 10 weeks for (a) weight change, (b)
clinical score and (c) survival. (a, b) Data presented as mean ± SEM or (c) percent survival. (a-c)
n = 4, control mice; n = 26 humanised mice. Significance determined by (a, b) repeated measures
Two-way ANOVA or (c) log-rank (Mantel-Cox) tests or χ2 test for mortality (box). P values as
shown.

3.2.3. Humanised mice engraft mainly hCD45 +hCD3 + T cells in the spleen have
circulating hIFNγ at endpoint
Spleens from all mice at endpoint were examined by flow cytometry (Figure 3.3a). As
above, control mice lacked hCD45 + cells, whilst humanised mice had splenic hCD45+
cells (Figure 3.3b); the majority of which were hCD3 + T cells (Figure 3.3c). In contrast
to the data at day 21, the splenic hCD3 + T cell population contained a significantly greater
proportion of hCD4+ T cells than hCD8 + T cells (P < 0.001) (Figure 3.3d).
P2X7 activation has an emerging role in GVHD in humanised mice (Geraghty et al.,
2017; Geraghty et al., 2019c, 2019d). qPCR analysis of spleens from control and
humanised mice demonstrated similar expression of mP2rx7 (P = 0.84) (Figure 3.3e).
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Figure 3.3: Humanised mice engraft mainly hCD45 +hCD3+ T cells in the spleen and have
circulating hIFNγ at endpoint. (a-d) Spleens from control and humanised mice (endpoint) were
examined by flow cytometry. FSC-A, FSC-H and SSC-A were used to select single lymphocytes
(not shown). (a) Single lymphocytes were gated as shown and the proportions of (b) hCD45+
leukocytes, (c) hCD3+ T cells, and (d) hCD4+ or hCD8+ T cell subsets determined. Relative
expression of (e) mP2rx7, and (f) hP2RX7 and hP2RX7B in spleen at endpoint were determined
by qPCR. (g) Serum hIFNγ at endpoint was measured by ELISA. (b-g) Data presented as mean ±
SEM; symbols represent individual mice (n = 2-4, control mice; n = 8–26, humanised mice).
Significance determined by (d) Wilcoxon matched-pairs signed rank or (e) Mann Whitney test. P
values as shown.

Moreover, qPCR revealed the presence of hP2RX7 in the spleens of humanised mice, as
well as the presence of hP2RX7B (Figure 3.3f), an isoform associated with lymphocyte
proliferation (Adinolfi et al., 2010). The human housekeeping gene (hHPRT1), hP2RX7
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and hP2RX7B were not detected in control mice, despite detection of mGapdh in these
same samples (data not shown).
Human IFNγ is produced by human T cells and has been shown to play important roles
in GVHD development (Yi et al., 2009). Thus, hIFNγ concentrations in sera from
endpoint mice were assessed by ELISA. hIFNγ was detected in all humanised mice tested,
but no control mice (Figure 3.3g).
3.2.4. Humanised mice engraft gut-homing T cells but do not develop gut GVHD
The gastrointestinal tract is a major target of GVHD (Markey et al., 2014). Thus, this
chapter aimed to characterise gut GVHD in humanised mice. Integrin β7 is an important
homing molecule that directs various T cell subsets to the gut an d has been linked to
GVHD progression (Petrovic et al., 2004). To determine if integrin β7 was present on
circulating T cells, hPBMCs were isolated from the blood of seven healthy donors and
integrin β7 expression on hCD4 + or hCD8 + T cell subsets was examined by flow
cytometry. Integrin β7 was expressed on the majority of hCD4+ T cells, but a significantly
smaller proportion of hCD8 + T cells (P < 0.01) (Figure 3.4a). Next, integrin β7
expressing T cells were examined in humanised mice. Again, integrin β7 was expressed
on the majority of hCD4 + T cells and a significantly smaller proportion of hCD8 + T cells
in the blood of humanised mice at day 21 (P < 0.0001) (Figure 3.4b), and in the spleens
of these mice at endpoint (P < 0.0001) (Figure 3.4c).
Tissue from the duodenum, jejunum, ileum and colon were collected from mice at
endpoint, stained with haematoxylin and eosin, and examined for signs of histological
GVHD. There was limited evidence of histological GVHD throughout the gut of
humanised mice with mild immune cell infiltration, no crypt degeneration, and few
apoptotic bodies (Figure 3.4d). As expected, control mice displayed normal gut histology
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(Figure 3.4d). There was also no evidence of diarrhoea from humanised mice over
70 days (results not shown), as occasionally reported in other mouse models of GVHD
(Baker et al., 1996).

Figure 3.4: Humanised mice engraft gut-homing T cells but do not develop gut GVHD.
Human CD4+ or CD8+ T cells from (a) human blood of healthy donors or (b) mouse blood (day
21) and (c) mouse spleen (endpoint) from humanised mice were examined for human integrin β7
(hβ7) expression by flow cytometry. (d) Sections of duodenum, jejunum, ileum and colon from
mice at endpoint were examined for histological evidence of GVHD. (a-c) Data presented as mean
± SEM. Symbols represent individual (a) humans (n = 7) or (b, c) mice (n = 16). Significance
determined by (a, b) paired t-test or Wilcoxon matched-pairs signed rank test. P values as shown
(d) Scale bars represent 100 µm.
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3.2.5. mP2rx7, mP2rx4 and mReg3g expression is upregulated in the duodenum
and ileum, and serum REG3γ concentration is increased in some
humanised mice
Despite limited changes in gut histology between mouse groups, qPCR revealed that
mP2rx7 was significantly upregulated in the duodenum (P < 0.01) and ileum (P < 0.05),
but not jejunum (P = 0.16) or colon (P = 0.53), of humanised mice compared to control
mice (Figure 3.5a). In contrast, hP2RX7 and hP2RX7B expression in each of these
regions of the gut was limited, with no differences between sites or isoforms (P > 0.99)
(Figure 3.5b).
To determine if the increased expression of mP2rx7 in the duodenum and ileum
corresponded to changes in other P2X receptors commonly expressed on murine
leukocytes (Boumechache et al., 2009; Lecut et al., 2009) that are associated with GVHD
(Schwab et al., 2014; Terakura et al., 2015), mP2rx1 and mP2rx4 in these tissues was
assessed by qPCR. There was no difference in mP2rx1 expression in either the duodenum
(P = 0.22) or ileum (P = 0.30) between humanised and control mice (Figure 3.5c). In
contrast, mP2rx4 was significantly increased (approximately three-fold) in the duodenum
(P < 0.001) and partly increased (approximately two-fold) in the ileum (P = 0.089) of
humanised mice compared to control mice (Figure 3.5d).
Despite limited histological evidence of GVHD in the gut, molecular signs of gut GVHD
were examined. REG3α is a clinical biomarker of human gut GVHD (Ferrara et al., 2011),
whilst the murine homologue, REG3γ, is increased in the gut and serum of mice with
allogeneic GVHD (Eriguchi et al., 2013). Therefore, relative mReg3g expression was
measured in control and humanised mice by qPCR. mReg3g expression in the duodenum
(P < 0.01) and ileum (P < 0.05), but not jejunum (P = 0.15) and colon (P = 0.07), was
significantly increased in humanised mice compared to control mice (Figure 3.5e).
ELISA measurements revealed that there was no significant difference in serum REG3γ
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Figure 3.5: mP2rx7, mP2rx4 and mReg3g expression is upregulated in the duodenum and
ileum, and serum REG3γ concentration is increased in some humanised mice. Relative
expression of (a) mP2rx7, and (b) hP2RX7 and hP2RX7B, (c) mP2rx1, (d) mP2rx4, (e) mReg3g,
(g) mIl22 and (h) hIL22 in gut sections (as indicated) at endpoint were determined by qPCR. (f)
Serum REG3γ at endpoint was measured by ELISA. (a-h) Data presented as mean ± SEM;
symbols represent individual mice (n = 4, control mice; n = 7–15, humanised mice); (f) dotted
lines represent two standard deviations (2SD) from control mean. Significance determined by (a:
jejunum and ileum, c: duodenum, d, e: ileum) unpaired t-test, (a: duodenum and colon, c: ileum,
e: duodenum, jejunum and colon, f) Mann Whitney or (b) Kruskal-Wallis test. P values as shown.

concentrations between humanised mice and control mice (P = 0.53) (Figure 3.5f).
Notably, seven of fifteen (47 %) humanised mice had REG3γ concentrations greater than
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two standard deviations above the control mean, whilst three of fifteen (20 %) humanised
mice had REG3γ concentrations two standard deviations below the control mean.
Since IL-22 can regulate REG3γ and is involved in the pathogenesis of various gut
disorders (Parks et al., 2015) including GVHD (Hanash et al., 2012), the expression of
mIl22 and hIL22 in the duodenum and ileum were assessed by qPCR. mIl22 was not
detected in duodenum or ileum from control or humanised mice (Figure 3.5g). Whilst
hIL22 was only detected in the duodenum of one of eight humanised mice, but not in the
ileum (Figure 3.5h).
3.2.6. Humanised mice engraft skin-homing T cells and develop cutaneous
GVHD
The skin is a major target of GVHD and a leading cause of morbidity in allo-HSCT
recipients (Martin et al., 1990). Thus, this chapter aimed to characterise cutaneous GVHD
in humanised mice. CLA is an important skin homing molecule for T cells and has been
linked to cutaneous GVHD (Tsuchiyama et al., 2009). To determine if CLA was present
on circulating T cells, PBMCs were isolated from the blood of seven healthy donors and
hCLA expression on hCD4 + or hCD8 + T cell subsets was examined by flow cytometry.
hCLA was present on approximately half of the hCD4+ T cells, but near absent on hCD8+
T cells (P < 0.001) (Figure 3.6a). Next, hCLA expressing T cells were examined in
humanised mice. Compared to PBMCs directly isolated from human blood, both hCD4+
and hCD8 + T cells in the blood of humanised mice at day 21 post-hPBMC injection
displayed high proportions of hCLA+ T cells, and these mice had significantly higher
proportions of hCLA+ hCD4 + T cells compared to hCLA+ hCD8 + T cells (P < 0.0001)
(Figure 3.6b). In contrast, there was no difference in the proportions of hCLA+hCD4+ or
CLA+hCD8 + T cells in the spleens of these mice at endpoint (P < 0.10) (Figure 3.6c).
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Flank skin and ears from endpoint mice were collected and examined for evidence of
histological GVHD. Both the flank skin and ears of humanised mice displayed signs of
cutaneous GVHD, including the presence of apoptotic bodies, epidermal hyperplasia
(thickening) and separation of the dermal-epidermal junction (Figure 3.6d). As expected,
flank skin and ears from control mice did not display histological evidence of GVHD
(Figure 3.6d).

Figure 3.6: Humanised mice engraft skin-homing T cells and develop cutaneous GVHD.
Human CD4+ or CD8+ T cells from (a) human blood of healthy donors or (b) mouse blood (day
21) and (c) mouse spleen (endpoint) from humanised mice were examined for human cutaneous
lymphocyte antigen (hCLA) expression by flow cytometry. (d) Sections of flank skin and ears at
endpoint were examined for histological evidence of GVHD. (e) Ear swelling was measured using
a spring-loaded calliper three times a week for 10 weeks or until endpoint. (a-c, e) Data presented
as mean ± SEM. Symbols represent individual (a) humans (n = 7) or (b, c) mice (n = 16). (e) n =
4, control mice; n = 26 humanised mice Significance determined by (a-c) paired t-test or (e)
repeated measures Two-way ANOVA. P values as shown. (d) Scale bars represent 100 µm, black
arrowheads indicate dermal-epidermal junction separation, red arrowheads indicate apoptotic
keratinocytes, stars indicate areas with epidermal thickening.
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Measurements of ear swelling have long been used as an assay of cutaneous inflammation
(Asherson et al., 1968), but this assay has not been used to assess GVHD in mice. As
such, ear thickness, as a measure of ear swelling, was assessed thrice weekly in control
and humanised mice for 10 weeks or until endpoint. Mean ear thickness in control mice
remained unchanged but ear thickness was significantly increased from week 3 in
humanised mice, reaching a maximum plateau by week 6 (Figure 3.6e).
3.2.7. mP2rx7 and mP2rx4 expression is upregulated in the skin, and mP2rx7 is
downregulated in the ears, of humanised mice
qPCR analysis revealed mP2rx7 expression was significantly upregulated in the flank
skin of humanised mice compared to control mice (P < 0.05) Figure 3.7a). In contrast,
mP2rx7 expression was decreased in the ears of humanised mice compared to control
mice (P < 0.05) (Figure 3.7a). qPCR analysis also revealed that both hP2RX7 and
hP2RX7B were expressed in the flank skin and ears of humanised mice, with no
significant differences between sites or isoforms (P > 0.57) (Figure 3.7b).
As for gut tissues above, mP2rx1 and mP2rx4 expression in the flank skin of mice was
analysed by qPCR. Like in the duodenum and ileum, there was no difference in mP2rx1
expression in flank skin (P = 0.29) (Figure 3.7c) and mP2rx4 expression was
significantly increased in the flank skin of humanised mice compared to control mice
(P < 0.01) (Figure 3.7d).
3.2.8. Humanised mice develop histological hepatic GVHD and have human T
cells present in the liver
The liver is another major target of GVHD (Farthing et al., 1982). Thus, hepatic GVHD
in humanised mice was examined. Histological analysis revealed that humanised mice
had increased immune cell infiltration in the liver, compared to control mice, and
displayed early signs of bile duct destruction (Figure 3.8a). King et al. (2009)
demonstrated that hCD45 + cells were present in the livers of humanised mice. This
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Figure 3.7: mP2rx7 and mP2rx4 expression is upregulated in the skin, and mP2rx7 is
downregulated in the ears, of humanised mice. Relative expression of (a) mP2rx7, (b) hP2RX7
and hP2RX7B, (c) mP2rx1 and (d) mP2rx4 in (a-d) flank skin or (a-b) ears from control and/or
humanised mice at endpoint were determined by qPCR. (a-d) Data is presented as mean ± SEM.
(a-d) Symbols represent individual mice (n = 4, control mice; n = 7-8 humanised mice).
Significance determined by (d) unpaired t-test, (a, c) Mann Whitney test or (b) One-way ANOVA.
P values as shown.

chapter confirmed, and expanded upon, this earlier finding by using flow cytometry to
show the presence of hCD45 + cells (Figure 3.8b), the majority of which were hCD3+
T cells (Figure 3.8c), in humanised mouse livers. qPCR analysis revealed similar mP2rx7
expression in the livers of humanised and control mice (P = 0.70) (Figure 3.8d).
Moreover, both hP2RX7 and hP2RX7B were expressed in the livers of humanised mice,
with no difference between isoforms (P = 0.82) (Figure 3.8e).
3.2.9. Humanised mice develop histological evidence of pulmonary GVHD
Previous studies have reported involvement of the lung in humanised mice (King et al.,
2009). Therefore, pulmonary GVHD in humanised mice was examined. Histological
analysis

revealed

increased

immune

cell

infiltration

into

the

lungs

of

humanised mice compared to those of control mice (Figure 3.9a). qPCR analysis
revealed similar mP2rx7 expression in the lungs of both control and humanised mice
(Figure 3.9b). Moreover, both hP2RX7 and hP2RX7B were expressed in the lungs of
humanised mice, with no difference between isoforms (Figure 3.9c).
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Figure 3.8: Humanised mice develop histological hepatic GVHD and have human T cells
present in the liver. (a) Sections of liver from control and humanised mice were examined for
histological evidence of GVHD at endpoint. (b) hCD45 + leukocytes and (c) hCD3+ T cells were
examined in the liver of humanised mice by flow cytometry. Relative expression of (d) mP2rx7,
and (e) hP2RX7 and hP2RX7B in the livers of control and/or humanised mice at endpoint were
determined by qPCR. (b-e) Data is presented as mean ± SEM. Symbols represent individual mice
(n = 4, control mice; n = 6–8, humanised mice). Significance determined by (d, e) unpaired t-test.
P values as shown. (a) Scale bar represents 100 µm.

Figure 3.9: Humanised mice develop histological evidence of pulmonary GVHD. (a) Sections
of lung from control and humanised mice were examined for histological evidence of GVHD at
endpoint. Relative expression of (b) mP2rx7, and (c) hP2RX7 and hP2RX7B in the lungs of
control and/or humanised mice at endpoint were determined by qPCR. (b, c) Data is presented as
mean ± SEM. Symbols represent individual mice (n = 4, control mice; n = 8, humanised mice).
Significance determined by (b) unpaired t-test or (c) Mann Whitney test. P values as shown. (a)
Scale bar represents 100 µm.
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3.3.Discussion
3.3.1. Clinical GVHD and engraftment in humanised mice
This chapter aimed to examine mP2rx7 and hP2RX7 expression in the gut, skin, liver and
lung of humanised mice, and to further characterise disease impact in these organs.
Injection of hPBMCs into NSG mice resulted in the development of GVHD with clinical
signs of disease increasing over time, and weight loss commencing from week 3. The rate
of disease progression was slower compared to other studies which involved a similar
injection regime of hPBMCs (Ali et al., 2012; King et al., 2009). This difference is
presumably due to the absence of irradiation in our model, compared to the use of
pre-transplant irradiation in these former studies. In contrast, disease progression closely
matched previous works from our group in which mice were not irradiated (Adhikary et
al., 2019; Adhikary et al., 2020; Geraghty et al., 2017; Geraghty et al., 2019b; Geraghty
et al., 2019c, 2019d). This chapter also confirmed the engraftment of human leukocytes,
predominately hCD4+ and hCD8 + T cells. Engraftment of human leukocytes was similar
to other studies of irradiated and non-irradiated mice which demonstrated that hCD45+
cells make up between 40-80 % of the leukocyte population, and that the majority of these
cells are hCD3 + (Adhikary et al., 2019; Adhikary et al., 2020; Ali et al., 2012; Geraghty
et al., 2017; Geraghty et al., 2019b; Geraghty et al., 2019c, 2019d; King et al., 2009).
Furthermore, the current chapter demonstrated that proportions of hCD4 + T cells were
greater than that of hCD8 + T cells at endpoint, similar to previous studies from our group
(Adhikary et al., 2019; Adhikary et al., 2020; Geraghty et al., 2017; Geraghty et al.,
2019b; Geraghty et al., 2019c, 2019d) and others (Ali et al., 2012; King et al., 2009).
3.3.2. mP2rx7 and hP2RX7 expression in humanised mice
This chapter examined the expression of mP2rx7, hP2RX7 and hP2RX7B in GVHD target
tissues of control and humanised mice. mP2rx7 tended to be higher in humanised mice
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compared to control mice but such increases only reached statistical significance in the
duodenum, ileum and skin. These increases in mP2rx7 expression in the duodenum and
skin, and to a lesser extent the ileum, corresponded to increases in m P2rx4, but not
mP2rx1 expression. This suggests that the increases in mP2rx7 expression in these tissues
may be due to the infiltration of macrophages, which co-express both P2X7 and P2X4
(Boumechache et al., 2009). Notably, mP2rx7 expression in the ear was an exception to
the above tissues with gene expression decreased in humanised mice compared to control
mice. Whether this reflects a compensatory mechanism or possible changes in ear
cartilage, which also express P2X7 (Tanigawa et al., 2018), remains unknown. hP2RX7
and hP2RX7B expression was also observed in all examined tissues. Given the expression
of hP2X7 on T cells (Baricordi et al., 1996) and other human leukocytes (Adhikary et al.,
2019), this indicates that human leukocytes were present in these tissues from most mice.
Finally, it should be noted that relative mP2rx7 expression in tissues from NSG mice
closely resembles hP2RX7 expression profiles seen in humans (Uhlén et al., 2015), with
greatest expression in the skin, followed by the lungs, spleen, liver and gut, as summarised
in Figure 3.10.
3.3.3. Gastrointestinal GVHD in humanised mice
Although flow cytometric analyses in humanised mice in former studies (Adhikary et al.,
2019; Ali et al., 2012; Geraghty et al., 2017; Geraghty et al., 2019b; Geraghty et al.,
2019c, 2019d; King et al., 2009) is extensive, the histological analysis of GVHD tissues
in each is limited. This chapter provides the broadest tissue analysis of this model to date,
including analysis of four regions of the gut; duodenum, jejunum, ileum and colon.
Previous studies have reported blunting of villi (Tobin et al., 2013) and lymphocyte
infiltration of intestinal crypts (King et al., 2009; Tobin et al., 2013). In contrast to
previous studies (King et al., 2009; Tobin et al., 2013), and despite the presence of
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gut-homing integrin β7 + human T cells, histological evidence of gut GVHD was limited
in these humanised mice. Recent evidence suggests that radiation plays a large role in
controlling gut-homing T cells in allogeneic models of GVHD (Zheng et al., 2020).
Furthermore, NSG mice, and other strains encoding the IL-2Rγnull mutation, show reduced
T cell trafficking and infiltration into the gastrointestinal tract (Denton et al., 2012). Thus,
the absence of irradiation in the current model and defects in gut homing in NSG mice
provides an explanation for the limited gut GVHD observed.

Figure 3.10: Comparison of relative expression of mP2rx7 between tissues from control and
humanised mice. Relative mP2rx7 expression shown throughout this chapter was combined to
compare the expression of this gene between tissues. Data presented as mean ± SEM. Symbols
represent individual mice (n = 4, control mice; n = 8, humanised mice).

Despite limited evidence of histological gut GVHD, molecular evidence of gut GVHD
was observed, with increased mReg3g expression in the duodenum and ileum. These
increases did not correspond to an increase in mIl22 or the presence of hIL22, which were
largely absent in these tissues, suggesting that up-regulation of mReg3g expression in
humanised mice may be IL-22-independent. Of note, the increase in mReg3g in the gut
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regions paralleled increases in mP2rx7, suggesting these regions may be more susceptible
to GVHD. Moreover, there was an increased trend in serum REG3γ consistent with gut
GVHD. However, serum REG3γ was increased in only some humanised mice and failed
to correlate with integrin β7 + human T cells or the limited histological damage
(correlations not shown). Increases in serum REG3α/REG3γ concentrations are thought
to be due to damage of the mucosal epithelial cells (Ferrara et al., 2011). However, given
that some humanised mice displayed relatively high concentrations of REG3γ compared
to control mice, this may suggest that this antimicrobial peptide may also enter circulation
in the absence of epithelial cell damage.
3.3.4. Cutaneous GVHD in humanised mice
This chapter also provides the most thorough analysis of cutaneous GVHD in
humanised mice to date. King et al. (2009) originally reported minimal histological
GVHD involvement in the skin of humanised mice; however more recent studies reported
lymphocyte infiltration in the skin of such mice (Ali et al., 2012; Geraghty et al., 2017).
Consistent with these previous findings, extensive lymphocyte infiltration and signs of
apoptosis in flank skin of humanised mice was identified. This was further expanded by
observing the same histological signs of cutaneous GVHD in the ears of these mice.
GVHD damage in the ears was also consistent with increases in ear swelling over time,
shown for the first time in any mouse model of GVHD. Changes in ear thickness provide
a quantitative method for determining cutaneous GVHD in mouse models and could be
used alongside traditional clinical measures such as scaling of skin and fur loss. Although
the proportions of CLA + T cells did not correlate with histological evidence of GVHD or
ear swelling (correlations not shown), others have shown that these cells home to the skin
of humanised mice (Ali et al., 2012).
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3.3.5. Hepatic and pulmonary GVHD in humanised mice
Histological evidence of hepatic GVHD in humanised mice was consistent with previous
findings (Geraghty et al., 2017; King et al., 2009). It was also shown that a large
proportion of leukocytes in the liver were of human origin consistent with King et al.
(2009). This was further expanded with the demonstration that the majority of these
human leukocytes were T cells, as similarly seen in the spleens of humanised mice. Of
note, our previous studies have revealed that activation of P2X7 plays an important role
in hepatic GVHD in humanised mice (Geraghty et al., 2019c, 2019d), despite this the
expression of mP2rx7 was similar between humanised and control mice. This may
suggest activation of P2X7 to mediate hepatic GVHD in this model may be regulated by
P2X7 present elsewhere in these mice.
Finally, it was revealed that the lungs are also a target in this humanised model of GVHD.
Lung involvement following HSCT is used to diagnose chronic GVHD (Jagasia et al.,
2015), however lung involvement has also been reported in patients with acute GVHD
(Liu et al., 2009). Similar to this chapter, previous allogeneic (Varelias et al., 2015) and
humanised (Bruck et al., 2013; King et al., 2009) mouse studies have reported immune
cell infiltration in the lungs of mice with GVHD. Therefore, even though the lung is
involved, this humanised mouse model can still be considered a model of acute GVHD.
3.3.6. Conclusion
In conclusion, this chapter demonstrated that mP2rx7 expression was increased in the
duodenum, ileum and skin of humanised mice supporting a role for P2X7 in these organs.
hP2RX7 is present in target tissues of GVHD, consistent with human leukocyte
infiltration into these tissues. This chapter also demonstrated that the skin, liver and lung
are highly involved in this model, with limited histological gut involvement. Finally,
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increased mReg3g expression and ear swelling in humanised mice are potential indicators
of early-stage gut and later stage skin GVHD, respectively.
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Chapter 4: P2X7 blockade with Brilliant Blue G in a humanised
mouse model of graft-versus-host disease
4.1. Introduction
Allo-HSCT is a curative therapy for blood cancers such as leukaemia, lymphoma and
myeloma (Copelan, 2006); however it causes GVHD in the majority of recipients (Gooley
et al., 2010). Acute GVHD occurs when donor T cells are activated by host APCs,
including DCs,

following transplantation. These activated T

cells

release

pro-inflammatory cytokines, including IFNγ, and attack host tissues including the liver,
skin, lung and gastrointestinal tract (Ferrara et al., 1999). Destruction of these tissues
leads to the release of DAMPs, including purine metabolites like ATP, and further
activation of APCs and T cells, resulting in a positive feedback cycle (Apostolova et al.,
2016). Tregs are able to suppress this positive feedback cycle by limiting the proinflammatory effects of donor CD4 + and CD8 + effector T cells (Ruggeri et al., 2014).
Current therapies for GVHD are limited to broad range immunosuppression or donor
T cells depletion (Hamilton, 2018). However, these therapies do not always prevent
GVHD related mortality, and relapse and infection still occur (Ruggeri et al., 2017).
Extracellular ATP, a DAMP released from dying cells following tissue damage (Di
Virgilio et al., 2020), is well known to activate the P2X7 receptor present on leukocytes
to promote inflammation and immune responses (Di Virgilio et al., 2017; Savio et al.,
2018). Following allogeneic HSCT in humans and mice, ATP released from damaged
tissues activates P2X7 on host DCs to increase the expression of costimulatory molecules
and release of cytokines to promote T cell-mediated inflammation (Wilhelm et al., 2010).
Moreover, host but not donor P2X7 has been shown to contribute to GVHD development
in an allogeneic mouse model of disease (Wilhelm et al., 2010). P2X7 activation can also
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directly promote activation, proliferation and maintenance of CD4 + (Yip et al., 2009) and
CD8 + (Borges da Silva et al., 2018) T cells and reduce the suppressive function and
stability of Tregs (Schenk et al., 2011), but evidence of these roles of P2X7 in GVHD is
lacking. Nevertheless, this receptor represents a potential target to p revent GVHD
development.
The therapeutic potential of P2X7 antagonism has been examined in both allogeneic and
humanised mouse models of GVHD (Sluyter et al., 2020). Treatment with the P2X7
antagonists PPADS (~300 mg/kg, days 0-10), KN-62 (~36 mg/kg, days 0-10) (Wilhelm
et al., 2010) or A-438079 (80 mg/kg, day 0-4) (Koehn et al., 2019) reduces disease and
increases survival in allogeneic mouse models of GVHD. Treatment with the P2X7
antagonist BBG over a longer time period (75 mg/kg, twice weekly for 4 weeks) reduces
weight loss and liver GVHD but does not alter survival in an allogeneic mouse model
(Zhong et al., 2016). Furthermore, BBG (50 mg/kg, days 0, 2, 4, 6, 8, 10) reduces liver
GVHD and serum hIFNγ but does not alter clinical GVHD in a humanised mouse model
(Geraghty et al., 2017). Similarly long-term treatment with BBG (50 mg/kg, thrice
weekly) reduces liver disease but clinical GVHD is unaffected in humanised mice
(Geraghty et al., 2019d). Collectively, these allogeneic and humanised mouse studies
indicate that P2X7 antagonism may be most effective in GVHD when a more frequent
dosing regime is used early after transplantation. Therefore, the current chapter aimed to
examine if a modified BBG treatment regime could improve outcomes in a preclinical
humanised mouse model of GVHD.
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4.2. Results
4.2.1. BBG prevents P2X7 activation in murine macrophages
Prior to investigating BBG in humanised mice, this P2X7 antagonist was tested in vitro
using murine J774 macrophages, which are well known to express functional P2X7
(Coutinho-Silva et al., 2005), by measuring ATP-induced dye uptake (Bartlett et al.,
2013) and mIL-1β release (Sluyter et al., 2016). Pre-incubation of J774 macrophages with
10 μM BBG completely impaired ATP-induced dye uptake into (P < 0.001) (Figure 4.1a
and 4.1b) and IL-1β release from (P < 0.01) (Figure 4.1c) these cells compared to cells
pre-incubated with vehicle control.
4.2.2. BBG reduces clinical score and mortality in humanised NSG mice
To investigate if a more frequent dosing regime with BBG early after transplantation
could prevent GVHD, NSG mice were injected with hPBMCs (day 0) and injected daily
(days 0-10) with BBG (50 mg/kg) or saline and monitored thrice weekly until endpoint
(Figure 4.2a). Weight loss was slightly, but not significantly, reduced in BBG-treated
mice compared to saline-treated mice (P = 0.14) (Figure 4.2b). BBG-treated mice had
significantly reduced clinical score compared to saline-treated mice (P < 0.01) (Figure
4.2c). Ear thickness provides an additional measure of cutaneous GVHD (Chapter 3). Ear
thickness was slightly, but not significantly, reduced in BBG-treated mice compared to
saline-treated mice (P = 0.17) (Figure 4.2d). Despite differences in weight loss and
clinical score there was no difference in overall survival between the two treatment groups
(P = 0.14) (Figure 4.2e). However, mortality at day 70 was significantly reduced in
BBG-treated mice (66 %) compared to saline-treated mice (100 %) (P < 0.05).
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Figure 4.1: BBG blocks P2X7-mediated dye uptake into and IL-1β release from J774 mouse
macrophages. (a, b) J774 cells in low-divalent medium were pre-incubated with BBG (10 μM)
or saline for 15 min, followed by addition of YO-PRO-12+ (1 μM) in the absence or presence of
ATP (0.5 mM) for 5 min. (a) Single cells were identified using FSC-H and FSC-A and J774 cells
were selected with SSC-A and FSC-A. J774 cells were examined for YO-PRO-12+ fluorescence
and (b) YO-PRO-12+ uptake (expressed as MFI) was determined. (c) J774 cells in RPMI-1640
medium containing 10 % FCS were primed with LPS (1 μg/mL) for 4 h. Medium was replaced
with physiological medium, and cells were pre-incubated with BBG (10 μM) or saline for 30 min,
followed by incubation in the absence or presence of ATP (1 mM) for 20 min. mIL-1β
concentrations in cell supernatants were measured by ELISA. (a) The histogram for BBG alone
was not shown for clarity but was similar to saline alone. (b, c) Data presented as mean ± SEM.
Symbols represent independent experiments (n = 3). Significance determined by One-Way
ANOVA with a Tukey’s post-hoc test. P values as shown.

4.2.3. BBG increases splenic human Tregs in some mice at endpoint
The determine if BBG treatment altered human leukocyte engraftment spleens from
BBG- and saline-treated mice were assessed by flow cytometry at endpoint (Figure 4.3a).
Proportions of hCD45 + leukocytes (P = 0.14) (Figure 4.3b) or hCD3 + T cells (P = 0.56)
(Figure 4.3c) were similar in both BBG- and saline-treated mice. Notably, four
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Figure 4.2: BBG reduces clinical score and mortality in humanised mice. (a) Schematic
representation of the humanised mouse model of GVHD. (a-e) NSG mice were injected i.p. with
10 x 106 hPBMCs (n = 3 donors) at day 0, then injected i.p. daily (day 0-10) with 50 mg/kg BBG
(n = 12 mice) or saline (n = 12 mice). Mice were assessed thrice weekly for up to 70 days for (b)
weight change, (c) clinical score, (d) ear thickness and (e) survival. (b-d) Data presented as mean
± SEM. (e) Data presented as percent survival. Significance determined by a (b-d) repeated
measures Two-Way ANOVA or (e) Mantel-Cox log-rank test for survival or χ2 test for mortality
(box). P values as shown.

BBG-treated mice had frequencies of hCD3 + T cells lower than the other eight BBGtreated mice and all twelve saline-treated mice. This reduction in hCD3 + T cells may be
due to increased proportions of human B cells or NK cells, but this was not examined
further at the time. A previous study revealed that an increased splenic hCD4 +:hCD8+
T cell ratio corresponds to clinical GVHD (Geraghty et al., 2019b). There was no
difference in the proportion of hCD4 + or hCD8 + T cells (P = 0.94 and P = 0.95,
respectively) (Figure 4.3d) or the hCD4 +:hCD8 + T cell ratio (P = 0.63) (Figure 4.3e)
between treatments. Notably, the mean proportion of hCD4+hCD25+hCD127 lo Tregs was
two-fold greater in the spleens of BBG-treated mice compared to saline-treated mice,
although this was not statistically significant (P = 0.37) (Figure 4.3f). Proportions of
hCD39 + Tregs, which have the capacity to metabolise extracellular ATP (Borsellino et
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al., 2007) and reduce GVHD in humanised mice (Gu et al., 2017), were similar between
treatment groups (P = 0.69) (Figure 4.3g).

Figure 4.3: BBG increases splenic human Treg proportions in some mice at endpoint. (a-g)
Spleens from humanised mice treated with BBG or saline were examined by flow cytometry to
identify human cell populations at endpoint. Zombie NIR dye, FSC-A, FSC-H and SSC-A were
used to select live single lymphocytes (not shown). (a) Live single lymphocytes were gated as
shown to determine the proportions of (b) hCD45+ leukocytes, (c) hCD3+ T cells, (d) hCD4+ or
hCD8+ T cell subsets, (f) hCD4+hCD25+hCD127lo regulatory T cell (hTreg) or (g) hCD39+ Tregs.
(e) The ratio of hCD4+ to hCD8+ T cells was calculated from (d). (b-g) Data presented as mean ±
SEM. Symbols represent individual mice (n = 12, BBG; n = 12, saline). Significance determined
by (b, c, e-g) Mann Whitney test or (d) One-Way ANOVA. P values as shown.
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Analysis of total splenic cell numbers by flow cytometry provides another method for
investigating if engraftment of human immune cells was altered by BBG at endpoint. The
number of splenic hCD45 + leukocytes (P = 0.35) (Figure 4.4a), hCD3 + T cells (P = 0.44)
(Figure 4.4b) and hCD4 + or hCD8 + T cell subsets (P > 0.99 and P > 0.99 respectively)
(Figure 4.4c) were similar between treatment groups, although within treatment groups
there was large variation in total cell numbers. Notably, the numbers of splenic Tregs
(Figure 4.4d) and CD39 + Tregs (Figure 4.4e) were eight- and six-fold higher,
respectively, in BBG-treated mice compared to saline-treated mice, although neither of
these differences reached significance (P = 0.20 and P = 0.18 respectively).

Figure 4.4: BBG increases splenic human Treg and hCD39 + Treg numbers in some mice at
endpoint. Absolute splenic numbers of (a) hCD45+ leukocytes, (b) hCD3+ T cells, (c) hCD4+ or
hCD8+ T cell subsets, (d) hCD4+hCD25+hCD127lo hTreg or (e) hCD39+ hTregs from Figure 4.3
were quantified using flow cytometric count beads. (a-e) Data presented as mean ± SEM. Symbols
represent individual mice (n =12 BBG; n = 12, saline). Significance determined by (a, b, d, e)
Mann Whitney test or (c) Kruskal-Wallis test. P values as shown.

4.2.4. BBG reduces histological GVHD in the liver, ear and lung of humanised
mice at endpoint
Liver, skin, ear and lung are the major tissues affected by GVHD in this humanised mouse
model (Chapter 3). Therefore, the impact of BBG treatment on histological GVHD was
assessed in these tissues as well as the duodenum (Figure 4.5). Saline-treated mice
displayed moderate to severe inflammation in the liver, skin, ear and lung with significant
immune cell infiltration. Epidermal thickening was prevalent in the skin and ear of
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Figure 4.5: BBG reduces histological GVHD in the liver, ear and lung of humanised mice at
endpoint. Tissues from BBG- or saline-treated humanised mice at endpoint were stained with
haematoxylin and eosin. Sections of liver, skin, ear, lung and duodenum from humanised mice
were examined for evidence of histological GVHD. Histological GVHD in the liver, skin, ear and
duodenum was assessed using a standardised grading system. Histological lung GVHD was
determined as the percent of clear alveoli area of total lung area. Arrowheads indicate epidermal
thickening in the skin and ear. Images representative of 6-8 mice per treatment group. Data
presented as mean ± SEM. Symbols represent individual mice. Significance determined by Mann
Whitney test. P values as shown. Scale bars represent 100 µm.
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saline-treated mice. In contrast, BBG-treated mice had mild inflammation with reduced
immune cell infiltration in the liver, skin, ear and lung compared to saline-treated mice.
Moreover, epidermal thickening was not apparent in either the skin or ear of BBG-treated
mice. Further, histological grades were significantly lower in livers (P < 0.01) and ears
(P < 0.05), but not skin (P = 0.32), of BBG-treated mice compared to saline-treated mice.
Moreover, clear alveoli space (as an inverse measure of inflammation) in the lung was
significantly increased in BBG-treated mice compared to saline-treated mice (P < 0.05).
In contrast to these tissues, GVHD was negligible in the duodenum of both BBG- and
saline-treated mice, with few immune cell infiltrates and minimal crypt degeneration
culminating in relatively low histological grades.
4.2.5. BBG increases mP2rx7 expression in the duodenum and partially reduces
serum hIFNγ at endpoint
Gene expression of mP2rx7 is increased in the duodenum and skin of humanised mice
(Sections 3.2.5 and 3.2.7) so expression of this gene was examined by qPCR in the current
chapter. mP2rx7 expression in the liver (P = 0.14) (Figure 4.6a), skin (P = 0.94) (Figure
4.6b) and lung (P = 0.16) (Figure 4.6c) was slightly, but not significantly, increased in
BBG-treated mice compared to saline-treated mice. mP2rx7 expression was increased
two-fold in the duodenum of BBG-treated mice compared to saline-treated mice
(P < 0.05) (Figure 4.6d).
Gene expression of mReg3g, a potential molecular marker of gut GVHD, is increased in
the duodenum of humanised mice with GVHD (Section 3.2.5). Therefore, expression of
mReg3g in the duodenum was examined by qPCR in the current chapter. mReg3g
expression was reduced by 65 % in the duodenum of BBG-treated mice but this was not
statistically significance (P = 0.32) (Figure 4.6e).
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Figure 4.6: BBG increases mP2rx7 expression in the duodenum and partially reduces serum
hIFNγ at endpoint. RNA isolated from the (a, f, i) liver, (b, g, j) skin, (c, h, k) lung or (d, e)
duodenum of humanised mice treated with BBG (n = 7) or saline (n = 7) was converted to cDNA
and analysed by qPCR. Relative expression of (a-d) mP2rx7, (e) mReg3g, (f-h) hP2RX7 or (i-k)
hIFNG was examined. (a-k) Samples that did not express the relevant housekeeping gene were
excluded from analysis. (l) hIFNγ concentrations in sera from humanised mice were determined
by ELISA (n = 7 BBG; n = 8 saline). (a-l) Data presented as mean ± SEM. Symbols represent
individual mice. Significance was determined by (a-c, e, g-i, l) unpaired t-test or (d, f, j, k) Mann
Whitney test. P values as shown.

BBG-treated mice had reduced histological GVHD in the liver, skin and lung so hP2RX7
expression was examined in these tissues. hP2RX7 expression was unaltered in the liver
(P = 0.81) (Figure 4.6f) but was approximately two-fold greater in the skin (P = 0.41)
(Figure 4.6g) and lung (P = 0.13) (Figure 4.6h) of BBG-treated mice compared to
saline-treated mice, although neither of these differences were significant.
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A previous study demonstrated that a different BBG regime (50 mg/kg, days 0, 2, 4, 6, 8,
10) reduced serum hIFNγ concentration in humanised NSG mice (Geraghty et al., 2017),
therefore this cytokine was assessed in the current chapter. The expression of hIFNG, the
gene encoding hIFNγ, was examined in the same tissues as for hP2RX7 expression above.
hIFNG was reduced (albeit not significantly) by 55 % in the liver (P = 0.12) (Figure 4.6i)
and 35 % in the skin (P = 0.41) (Figure 4.6j) of BBG-treated mice compared to
saline-treated mice. hIFNG expression was marginally increased in the lungs of BBGtreated mice compared to saline-treated mice, but this difference was not significant
(P = 0.34) (Figure 4.6k). ELISA measurements of sera revealed that circulating hIFNγ
was reduced by 55 % in BBG-treated mice compared to saline-treated mice, a difference
which approached statistical significance (P = 0.080) (Figure 4.6l).
4.2.6. BBG increases splenic human Tregs and B cells in humanised mice at day
21
To better understand the therapeutic effects of the new BBG regime trialled in this
chapter, NSG mice were injected with hPBMCs from the same donors as above and
treated with BBG (50 mg/kg) or saline (days 0-10), but euthanised in the early stages of
GVHD development (day 21) (Figure 4.7a). Splenic human leukocyte engraftment was
examined by flow cytometry as described above. Both hCD45 + leukocyte (P < 0.05)
(Figure 4.7b) and hCD3 + T cell (P < 0.01) (Figure 4.7c) proportions were reduced in
BBG-treated mice compared to saline-treated mice. Frequencies of hCD4 + or hCD8+
T cells (P = 0.30 and P > 0.99, respectively) (Figure 4.7d) and hCD4 +:hCD8 + T cell
ratios (P = 0.61) (Figure 4.7e) were similar between treatment groups. Notably,
proportions of hCD4 +hCD25 +hCD127lo Tregs were significantly increased (two-fold) in
BBG-treated mice compared to saline-treated mice (P < 0.01) (Figure 4.7f). However,
there was no difference in hCD39 +Treg proportions between treatment groups (P = 0.20)
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Figure 4.7: BBG increases splenic human Treg and B cell proportions in humanised mice at
day 21. (a) Schematic representation of the humanised mouse model of GVHD. (b-k) Spleens
from humanised mice treated with BBG or saline were examined by flow cytometry to identify
human cell populations at day 21. The proportion of (b) hCD45+ leukocytes, (c) hCD3+ T cells,
(d) hCD4+ or hCD8+ T cell subsets, (f) hCD4+hCD25+hCD127lo Tregs or (g) hCD39+ Tregs were
determined as previously shown (Figure 4.3). (e) The ratio of hCD4+ to hCD8+ T cells was
calculated from (d). (h) hCD45+ leukocytes were gated as shown to determine the proportion of
(i) hCD19+ B cells, (j) hCD27+ memory B cells or (k) hCD56+hCD3-hCD19- NK cells. (b-g, i-k)
Data presented as mean ± SEM. Symbols represent individual mice (n = 12 BBG; n = 12 saline).
Significance was determined by (b, c, f, g) Welch’s t-test, (d) One-Way ANOVA or (e, i-k) Mann
Whitney test. P values as shown.

137

(Figure 4.7g). Since there was a reduction in hCD3 + T cell proportions in some
BBG-treated mice at endpoint (Section 4.2.3), the human cell population was examined
further for B cells and NK cells at day 21 (Figure 4.7h). Notably, the proportion of
hCD19 + B cells was significantly increased in BBG-treated mice compared to
saline-treated mice (P < 0.05) (Figure 4.7i). Preliminary analysis revealed that most of
these B cells expressed hCD27, a marker of memory B cells (Tangye et al., 1998), and
the proportion of these memory B cells was similar between treatment groups (P = 0.45)
(Figure 4.7j). Both BBG- and saline-treated mice had small proportions of
hCD56 +hCD3 -hCD19- NK cells (P = 0.60) (Figure 4.7k).
Further analysis of the above data revealed that the numbers of splenic hCD45 +
leukocytes (P = 0.24) (Figure 4.8a), hCD3 + T cells (P = 0.29) (Figure 4.8b) and hCD4+
or hCD8 + T cell subsets (P > 0.99 for both) (Figure 4.48) were similar between treatment
groups at day 21. Notably, the splenic numbers of Tregs were significantly increased
(two-and-half-fold) in BBG-treated mice compared to saline-treated mice (P < 0.05)
(Figure 4.8d). Splenic hCD39 + Tregs counts were three-fold higher in BBG-treated mice
compared to saline-treated mice, although this did not reach statistical significance
(P = 0.16) (Figure 4.8e). Splenic hCD19 + B cell (P = 0.26) (Figure 4.8f) and hCD27+
memory B cell (P = 0.47) (Figure 4.8g) counts were two-and-half and two-fold,
respectively, higher in BBG-treated mice compared to saline-treated mice, although
neither of these differences were statistically significant. Finally, splenic counts of
hCD56 +hCD3 -hCD19- NK cells were reduced by 70 % in BBG-treated mice; however,
this was not statistically significant (P = 0.38) (Figure 4.8h).
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Figure 4.8: BBG increases splenic human Treg numbers at day 21. Absolute splenic numbers
of (a) hCD45+ leukocytes, (b) hCD3+ T cells, (c) hCD4+ or hCD8+ T cell subsets, (d)
hCD4+hCD25+hCD127lo hTregs, (e) hCD39+ Tregs, (f) hCD19+ B cells, (g) hCD27+ memory B
cells or (h) hCD56+hCD3-hCD19- NK cells from BBG- and saline-treated mice were quantified
using flow cytometric count beads. (a-h) Data presented as mean ± SEM. Symbols represent
individual mice (n =11 BBG; n = 11, saline). Significance determined by (a, b, f-h) Mann Whitney
test, (c) Kruskal-Wallis test or (d, e) unpaired t-test. P values as shown.

4.2.7. BBG does not alter circulating human cell proportions at day 21
Circulating human T cells were unaffected early in GVHD in previous studies using
different BBG regimes in humanised mice (Geraghty et al., 2017; Geraghty et al., 2019d).
Therefore, the current chapter also used flow cytometry to determine if the modified BBG
injection regime altered human cell engraftment in the blood at day 21. The proportion of
hCD45 + cells was decreased by 30 % in the blood of BBG-treated mice compared to
saline-treated mice, but this difference was not significant (P = 0.22) (Figure 4.9a). There
was no difference in the proportions of circulating hCD3 + T cells (P = 0.55) (Figure 4.9b)
or hCD4 + or hCD8 + T cell subsets (P = 0.33 and P = 0.78, respectively) (Figure 4.9c).
Further, while the hCD4:hCD8 ratio was increased two-fold in BBG-treated mice this
was due to one outlier and was not significant (P = 0.27) (Figure 4.9d). There was no
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significant difference in the proportions of circulating hTregs (P = 0.94) (Figure 4.9e) or
hCD39 + hTregs (P = 0.15) (Figure 4.9f) between treatment groups. Event counts for
hCD19 + B cells and hCD56 +hCD3-hCD19- NK cells in the blood were regularly too low
to compare treatment groups. Likewise, event counts were too low to ac curately
enumerate cell numbers in blood (data not shown).

Figure 4.9: BBG does not alter circulating human cell proportions at day 21. Proportions of
(a) hCD45+ leukocytes, (b) hCD3+ T cells, (c) hCD4+ or hCD8+ T cell subsets, (e)
hCD4+hCD25+hCD127lo hTregs or (f) hCD39+ Tregs in the blood were determined by flow
cytometry. (d) The ratio of hCD4+ to hCD8+ T cells was calculated from (c). (a-f) Data presented
as mean ± SEM. Symbols represent individual mice (n = 11, BBG; n =11 saline). Significance
determined by (a, b, d) Mann Whitney test, (c) One-Way ANOVA or (e, f) Welch’s t-test. P
values as shown.

4.2.8. BBG partially reduces histological GVHD in the liver at day 21
The modified BBG regime reduced histological GVHD at endpoint (Section 4.2.5)
Therefore, histological GVHD was assessed in the same tissues at day 21 (Figure 4.10).
Saline-treated mice displayed mild to severe inflammation in the liver at day 21 with
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Figure 4.10: BBG partially reduces histological GVHD in the liver at day 21. Tissues from
BBG- or saline-treated humanised mice at day 21 were stained with haematoxylin and eosin.
Sections of liver, skin, ear, lung and duodenum from humanised mice were examined for evidence
of histological GVHD. Histological GVHD in the liver, skin, ear and duodenum was assessed
using a standardised grading system. Histological lung GVHD was determined as the percent of
clear alveoli area of total lung area. Images representative of 3-8 mice per treatment group. Data
presented as mean ± SEM. Symbols represent individual mice. Significance determined by Mann
Whitney test (liver/skin/ear/duodenum) or unpaired t-test (lung). P values as shown. Scale bars
represent 100 µm.
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some mice having significant immune cell infiltration and bile-duct destruction.
BBG-treated mice only had mild signs of liver GVHD and slightly reduced histological
grades compared to saline-treated mice (P = 0.062). Contrary to the liver, histological
GVHD was not present in the skin, ear, lung or duodenum of almost all BBG- and
saline-treated mice at day 21.
4.2.9. BBG reduces serum hIFNγ concentration and slightly increases mReg3g
expression at day 21
Although there were only slight differences in mP2rx7, mReg3g, hP2RX7 and hIFNG
expression at endpoint, these genes were examined at day 21 to determine if treatment
with BBG altered expression early in disease. mP2rx7 expression was similar between
treatment groups in the liver (P = 0.94) (Figure 4.11a) and lung (P = 0.45) (Figure
4.11b), but slightly decreased in the duodenum (P = 0.12) (Figure 4.11c) of BBG-treated
mice. mReg3g expression was increased in the duodenum of BBG-treated mice at day 21,
a difference which approached statistical significance (P = 0.065) (Figure 4.11d).
Expression of hP2RX7 and hIFNG, and the housekeeping gene hHPRT1, could not be
determined in the majority of mice and tissues at day 21 (data not shown). Finally, serum
hIFNγ was decreased in BBG-treated mice at day 21 (P < 0.05) (Figure 4.11e).
4.2.10. BBG increases human Tregs and B cells in vitro
The above data indicates that BBG reduced clinical and histological GVHD in humanised
mice, and that these effects corresponded to increased proportions of hTregs and hB cells
in these mice. P2X7 may be involved in the induction of cell death in human Tregs
(Hubert et al., 2010) and B cells (Farrell et al., 2010). Therefore, the effects of BBG on
lymphocyte subsets within hPBMCs, using culture conditions that promote cell death,
were examined. A preliminary study revealed that culture of hPBMCs in FCS
concentrations from 2.5-7.5 % or 0 % resulted in a partial or complete loss of lymphocyte
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Figure 4.11: BBG reduces serum hIFNγ concentration and slightly increases mReg3g
expression at day 21. RNA isolated from the (a) liver, (b) lung or (c, d) duodenum of humanised
mice treated with BBG (n = 6) or saline (n = 6) was converted to cDNA and analysed by qPCR.
Relative expression of (a-c) mP2rx7 or (d) mReg3g was examined. (a-d) Samples that did not
express the relevant housekeeping gene were excluded from analysis. (e) hIFNγ concentrations
in sera from humanised mice were determined by ELISA (n = 7 BBG; n = 7 saline). (a-e) Data
presented as mean ± SEM. Symbols represent individual mice. Significance was determined by
(a, d, e) Mann Whitney test, (b) Welch’s t-test, (c) unpaired t-test. P values as shown.

viability, respectively, over 20 h compared to hPBMCs cultured with 10 % FCS
(Figure 4.12a and Figure 4.12b). A low serum concentration of 2.5 % FCS was chosen
for subsequent studies. hPBMCs from five healthy donors were cultured in low serum
conditions to promote cell death in the presence of BBG (10 μM) or saline for 20 h
(Figure 4.12c). The number of live lymphocytes and proportions of lymphocyte subsets
were examined by flow cytometry. Incubation of hPBMCs in RPMI-1640 (2.5 % FCS)
in the presence of saline or BBG resulted in similar numbers of viable lymphocytes at
20 h (P = 0.18) (Figure 4.12d). Amongst these cells, hCD3 + T cell proportions were
similar following incubation with either saline or BBG (P = 0.59) (Figure 4.12e). hCD4+
T cell proportions were significantly increased (P < 0.05) (Figure 4.12f) and hCD8+
T cell proportions slightly, but not significantly, decreased (P = 0.085) (Figure 4.12f) in
hPBMC cultures containing BBG compared to cultures with saline. Subsequently, there
was a significantly increased hCD4 +:hCD8+ T cell ratio in hPBMCs cultured with BBG
compared to hPBMCs cultured with saline (P < 0.05) (Figure 4.12g). Moreover,
hCD4 +hCD25 +hCD127lo Tregs in hPBMCs cultured with BBG were significantly
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Figure 4.12: BBG increases human Tregs and B cells in vitro. PBMCs from (a, b) one or (c-j)
five healthy donor(s) were cultured overnight in RPMI-1640 medium containing (a, b) 0-10 % or
(c-j) 2.5 % FCS with 10 μM BBG or saline as indicated. (a) Live lymphocytes were selected as
shown and the number of (b, d) live lymphocytes was determined using count beads. (c)
Schematic representation of experiment. The proportions of (e) hCD3+ T cells, (f) hCD4+ or
hCD8+ T cell subsets, (h) hCD4+hCD25+hCD127lo Tregs, (i) hCD39+ Tregs and (j) hCD19+
B cells were determined by flow cytometry as previously shown (Figure 4.3 and Figure 4.7). (g)
The ratio of hCD4+ to hCD8+ T cells was calculated from (f). Data presented as mean ± SEM.
Symbols represent individual donors. Significance determined by (d, e, g-j) paired t-test or (f)
repeated measures one-way ANOVA. P values as shown.
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increased compared to saline (P < 0.05) (Figure 4.12h). Conversely, the proportion of
hCD39 + Tregs was significantly lower in hPBMCs cultured with BBG compared to those
with saline (P < 0.001) (Figure 4.12i). Finally, there were significantly higher proportions
of hCD19 + B cells in hPBMCs cultured with BBG compared to hPBMCs cultured with
saline (P < 0.01) (Figure 4.12j).

4.3. Discussion
The current chapter aimed to examine if a modified P2X7 antagonist treatment regime
(daily, days 0-10), which had previously shown efficacy in an allogeneic model of GVHD
(Wilhelm et al., 2010), could improve outcomes in a preclinical humanised mouse model
of GVHD. This chapter demonstrated that frequent dosing with the P2X7 antagonist BBG
reduced clinical GVHD and histological GVHD in multiple tissues in this humanised
mouse model. Previous studies using this model showed that less frequent dosing with
BBG at early time points (days 0, 2, 4, 6, 8, 10) (Geraghty et al., 2017) or longer term
(thrice weekly for 10 weeks) (Geraghty et al., 2019d) did not alter clinical GVHD but
could reduce histological liver GVHD. The improved efficacy of P2X7 antagonism in
this chapter corresponded to an increase in hTreg engraftment, which can suppress GVHD
development in mice and humans (Di Ianni et al., 2011; Ruggeri et al., 2014), as well as
to a reduction in serum hIFNγ, a pro-inflammatory cytokine that promotes GVHD
development (Zhao et al., 2016). These findings parallel similar observations of P2X7
blockade in an allogeneic mouse model of GVHD, in which P2X7 blockade increased the
proportion of donor Tregs and reduced serum IFNγ and GVHD development (Wilhelm
et al., 2010).
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4.3.1. BBG treatment and hTregs in humanised mice
To date the role of P2X7 activation in GVHD development has largely been attributed to
its role on host APCs (Wilhelm et al., 2010). However, this chapter indicates an additional
role for P2X7 activation on donor hTregs in promoting GVHD, with P2X7 blockade
increasing the proportion and count of splenic hTregs in this humanised mouse model of
disease. It is hypothesised that in this model, P2X7 activation results in the loss of hTregs
as a result of cell death. P2X7 activation can mediate the death of Tregs (Hubert et al.,
2010) and the presence of hTregs decreases over time in humanised mice (Hu et al.,
2020a). This loss of hTregs is most likely due to the absence of growth factors and other
molecules that support hTreg survival in mice (Theocharides et al., 2016). Thus, to study
this further, hPBMCs were cultured in the absence or presence of BBG with limited
amounts of FCS, to parallel the absence of factors that support Treg survival in mice and
to promote cell death in vitro. To this end, BBG reduced the loss of hTregs in vitro
supporting the notion that P2X7 activation can mediate Treg death and that P2X7
blockade can prevent Treg death in vivo. It is also possible that P2X7 activation in GVHD
may promote the conversion of Tregs to Th17 cells (Schenk et al., 2011) rather than cell
death. However, the presence of serum hIL-17 in humanised mice is minimal (Geraghty
et al., 2017), despite detection of IL-17-producing cells and hIL17 expression in the
spleens and gastrointestinal tracts of these mice, respectively (Geraghty et al., 2017;
Geraghty et al., 2019b). Use of intracellular hIL-17 staining or the Th17 marker CD161
(Maggi et al., 2010) may help to determine this in future studies using this humanised
mouse model.
4.3.2. BBG treatment and hIFNγ in humanised mice
Similar to previous studies in allogeneic (Wilhelm et al., 2010) and humanised (Geraghty
et al., 2017) mouse models, serum hIFNγ was reduced following P2X7 blockade in this
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chapter. IFNγ has known roles in GVHD progression, with IFNγ-producing CD4 + and
CD8 + T cells present early in GVHD development (Zhao et al., 2016) and IFNγ
promoting the trafficking of T cells to GVHD tissues (Choi et al., 2012). Notably,
transplantation or expansion of Tregs reduces serum IFNγ in allogeneic (Edinger et al.,
2003) and humanised (Hu et al., 2020a) mouse models of GVHD. Therefore, the observed
reduction in serum hIFNγ may be due to the increase in hTregs. Alternatively, since P2X7
activation can stimulate the NLRP3 inflammasome in DCs to prime antigen-specific
IFNγ-producing T cells (Ghiringhelli et al., 2009) the observed reduction in serum hIFNγ
may be due to blockade of this P2X7-mediated pathway. A role for hIFNγ in GVHD
development in the current study is further supported by the presence of h IFNG
expression in the liver, skin or lung of humanised mice. However, h IFNG expression in
these tissues was not significantly different between treatment groups. Noting that hIFNG
expression is relative to hHPRT1 gene expression, this observation suggests that the
reduction in histological GVHD is most likely due to reduced infiltration of human T cells
rather than a reduction in the proportion of hIFNγ producing cells in these tissues.
4.3.3. BBG treatment and hB cells in humanised mice
This chapter also revealed that P2X7 blockade with BBG increased the proportion of
hB cells, as well as hTregs, while supporting the engraftment of other hT cells and
hNK cells. This suggests that in addition to reducing GVHD, more frequent dosing with
P2X7 antagonists early after transplantation may result in improved donor immune cell
engraftment and homeostasis, potentially resulting in a greater protection from
opportunistic infections and cancer relapse. In regard to B cell engraftment, previous
studies have repeatedly shown absent or negligible B cell engraftment in this humanised
mouse model (Geraghty et al., 2017; Geraghty et al., 2019a; Geraghty et al., 2019b;
Geraghty et al., 2019c). The action of BBG in promoting B cell engraftment in humanised
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mice in the current study appeared to be attributed to improved survival of these cells, as
BBG prevented the loss of hB cells when cultured with limited amounts of FCS.
However, unlike Tregs, whether the engraftment of B cells promotes or prevents GVHD
remains controversial. B cells are key mediators of chronic GVHD (Li et al., 2019), but
less is known about their role in acute GVHD. Studies report that B cells may play a
pro-inflammatory role in GVHD progression and that depletion of these cells results in
reduced acute GVHD in mice and humans (Dominietto et al., 2012; Kamble et al., 2006;
Schultz et al., 1995). On the contrary, IL-10-producing B cells have immunoregulatory
effects and can suppress acute GVHD in allogeneic mice (Weber et al., 2014). Also,
supporting an immunoregulatory role in GVHD, the majority of hB cells express the
ecto-nucleotidases, CD39 and CD73, resulting in reduced extracellular ATP and
increased immunosuppressive extracellular adenosine (Saze et al., 2013). Thus, it is
possible that enhanced engraftment of hB cells in humanised mice at early time points
may be suppressing ATP-induced P2X7 activation on DCs and T cells to limit GVHD
development. In this regard, pharmacological blockade of CD39/CD73 during the first
week following hPBMC engraftment increases weight loss and worsens GVHD in
humanised mice (Geraghty et al., 2019c).
4.3.4. BBG treatment and histological and clinical GVHD in humanised mice
The BBG regime used in the current chapter resulted in reduced histological GVHD in
the liver, ear and lung at end point. In contrast, previous studies with less frequent dosing
of BBG in humanised mice mainly reduced liver GVHD (Geraghty et al., 2017; Geraghty
et al., 2019d). This reduction in histological GVHD in multiple tissues also corresponded
to reduced clinical GVHD, an effect not observed in the prior studies with less frequent
dosing of BBG. The current chapter also examined, for the first time, histological GVHD
prior to the development of clinical GVHD (day 21) in this humanised mouse model. This
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analysis revealed that histological GVHD is evident in the liver, but not other tissues, at
day 21 and was decreased by BBG. This emerging role of P2X7 activation in the
development of liver GVHD in humanised mice is supported by observations in which
CD39/CD73 blockade, which potentially increases extracellular ATP (Covarrubias et al.,
2016), worsens liver GVHD in these mice (Geraghty et al., 2019c).
BBG treatment did not extend overall survival despite reductions in clinical score and
histological GVHD. As discussed above, splenic, but not circulating, hTregs were
increased early in disease in BBG-treated mice, however the difference in splenic hTreg
proportions was smaller at endpoint. This lack of an increase in circulating hTregs, or the
loss of hTregs over time may explain why there was no difference in survival between
groups. Extending BBG injections may increase hTreg survival over longer time periods,
potentially increasing the survival of mice. Given that long-term BBG treatment (at least
90 days) does not cause adverse events (Bartlett et al., 2017a), future studies could
explore extended regime lengths with BBG. Notably, treatment with BBG (50 mg/kg,
thrice weekly until endpoint) reduces liver disease but not clinical GVHD in humanised
mice (Geraghty et al., 2019d). Thus, long-term BBG regimes should also consider
increasing the drug dose or frequency to potentially improve the therapeutic benefits of
BBG observed in this chapter.
4.3.5. BBG treatment and P2X7 gene expression in humanised mice
Despite this modified BBG regime reducing both clinical and histological GVHD, the
expression of mP2rx7 and hP2RX7 in GVHD tissues was largely unaltered between
treatment groups. mP2rx7 expression is increased in the duodenum and skin of
humanised mice with GVHD (Chapter 3), and the liver of allogeneic mice with GVHD
(Zhong et al., 2016). Thus, it was predicted that BBG would reduce mP2rx7 in some
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GVHD tissues. Unexpectedly, BBG increased mP2rx7 expression in the gastrointestinal
tract at endpoint. Given that cellular infiltrates in the duodenum were minimal and similar
between groups, this increase in mP2rx7 expression may represent BBG blockade of
ATP-mediated death of P2X7-expressing host cells such as intestinal epithelial cells (de
Campos et al., 2012), M cells (Kim et al., 2015) or myenteric plexus neurons (Palombit
et al., 2019). This notion is indirectly supported by BBG impairing molecular
development of gastrointestinal GVHD as evidenced by reduced mReg3g expression in
the duodenum at endpoint. Finally, as argued for hIFNG expression above, the lack of
difference in hP2RX7 expression in the liver, skin or lung between treatments suggests
that BBG is not altering hP2RX7 expression at the cellular level. This indicates that BBG
is mediating its effect by blocking P2X7 activity rather than expression, and in contrast
to an allogeneic mouse model in which BBG reduced mP2rx7 expression in the livers of
these mice (Zhong et al., 2016).
4.3.6. Conclusion
In conclusion, this chapter demonstrated that P2X7 blockade with BBG impaired clinical
and histological GVHD development in humanised mice, which corresponded to
increased donor hTregs and reduced hIFNγ. In addition, this study demonstrated that
BBG increased hTreg and hB cell survival in vitro, suggesting that this compound may
act via a similar mechanism in vivo to contribute to reduced GVHD.
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Chapter 5: P2X7 antagonism with PPADS in a humanised mouse
model of GVHD
5.1. Introduction
Chapters 3 and 4 of this thesis support a role for P2X7 in the progression of GVHD, a
severe T cell-mediated inflammatory disorder that occurs following allo-HSCT (Ferrara
et al., 1999). Chapter 3 demonstrated that mP2rx7 is upregulated in the duodenum, ileum
and skin and hP2RX7 expressing cells are present in the liver, skin, lung, gut and spleen.
Chapter 4 demonstrated that humanised mice treated with the P2X7 antagonist BBG
(50 mg/kg, daily from day 0 - 10) had reduced clinical and histological GVHD, and
increased hTreg engraftment. Previously, the P2X7 antagonist, PPADS (300 mg/kg, daily
from day 0-10), increased survival and Treg engraftment in an allogeneic mouse model
of GVHD (Wilhelm et al., 2010). Therefore, the current chapter aimed to investigate the
impact of the P2X7 antagonist PPADS on human immune cell engraftment and GVHD
in humanised mice.
The majority of mouse monitoring, euthanasia and flow cytometry collection in the
current chapter was completed by research assistants, Nicholas J. Geraghty and Sam R.
Adhikary. All subsequent tissue and data analysis is original.

5.2.Results
5.2.1. PPADS prevents P2X7 activation in murine macrophages
Prior to investigating PPADS in humanised mice, this P2X7 antagonist was tested in vitro
using murine J774 macrophages, which are well known to express functional P2X7
(Coutinho-Silva et al., 2005), by measuring ATP-induced dye uptake and mIL-1β release
as described in Chapter 4 (Section 4.2.1). Pre-incubation of J774 macrophages with
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10 μM PPADS completely impaired ATP-induced dye uptake into (P < 0.01) (Figure
5.1a and 5.1b) and IL-1β release from (P < 0.01) (Figure 5.1c) these cells compared to
cells pre-incubated with vehicle control.

Figure 5.1: PPADS blocks P2X7-mediated dye uptake into and IL-1β release from J774
mouse macrophages. (a, b) J774 cells in low-divalent medium were pre-incubated with PPADS
(10 μM) or saline for 15 min, followed by addition of YO-PRO-12+ (1 μM) in the absence or
presence of ATP (0.5 mM) for 5 min. (a) Single cells were identified using FSC-H and FSC-A
and J774 cells were selected with SSC-A and FSC-A. J774 cells were examined for YO-PRO-12+
fluorescence and (b) YO-PRO-12+ uptake (expressed as MFI) was determined. (c) J774 cells in
RPMI-1640 medium containing 10 % FCS were primed with LPS (1 μg/mL) for 4 h. Medium
was replaced with physiological medium, and cells were pre-incubated with PPADS (10 μM) or
saline for 30 min, followed by incubation in the absence or presence of ATP (1 mM) for 20 min.
mIL-1β in cell supernatants was measured by ELISA. (a) The histogram for PPADS alone was
not shown for clarity but was similar to saline alone. (b, c) Data presented as mean ± SEM.
Symbols represent independent experiments (n = 3). Significance determined by One-Way
ANOVA with a Tukey’s post-hoc test. P values as shown.

152

5.2.2. PPADS reduces ear swelling and partially reduces clinical GVHD in
humanised mice
To investigate if PPADS could prevent GVHD in humanised mice the injection dose and
regime of Wilhelm et al. (2010) was adopted. NSG mice were injected with hPBMCs
(day 0) and injected daily (days 0-10) with PPADS (300 mg/kg) or saline and monitored
thrice weekly until endpoint (Figure 5.2a). Due to the survival of some humanised mice
treated with BBG (Section 4.2.2) this study was extended to day 100. Initial weight gain
was slightly, but not significantly, lower in PPADS-treated mice compared to
saline-treated mice, with PPADS-treated mice beginning to lose weight from day 70
(Figure 5.2b). In contrast, saline-treated mice started losing weight from day 45.
PPADS-treated mice had partially reduced clinical score (from day 50 onwards)
compared to saline-treated mice although this did not reach significance (P = 0.10)
(Figure 5.2c). Ear thickness, a measure of cutaneous GVHD, was significantly reduced
in PPADS-treated mice compared to saline-treated mice (P < 0.05) (Figure 5.2d). Despite
differences in clinical score and ear thickness there was no difference in overall survival
between the two treatment groups (P = 0.93) (Figure 5.2e). Further, mortality at day 100
was the same in PPADS-treated mice (62.5 %) compared to saline-treated mice (62.5 %)
(P > 0.99).
5.2.3. PPADS does not significantly alter splenic human cells at endpoint
The effect of PPADS and saline treatment on human leukocyte engraftment was assessed
by flow cytometric analysis of spleens at endpoint (Figure 5.3a). Proportions of hCD45+
leukocytes (P = 0.27) (Figure 5.3b) or hCD3 + T cells (P = 0.97) (Figure 5.3c) were
similar in both PPADS- and saline-treated mice. A previous study revealed that an
increased splenic hCD4 +:hCD8 + T cell ratio corresponds to clinical GVHD (Geraghty et
al., 2019b). There was no difference in the proportion of hCD4 + or hCD8 + T cells
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Figure 5.2: PPADS reduces ear swelling and partially reduces clinical GVHD in humanised
mice. (a) Schematic representation of the humanised mouse model of GVHD. (a-e) NSG mice
were injected i.p. with 10 x 106 hPBMCs (n = 2 donors) at day 0, then injected i.p. daily (day 010) with 300 mg/kg PPADS (n = 8 mice) or saline (n = 8 mice). Mice were assessed thrice weekly
for up to 100 days for (b) weight change, (c) clinical score, (d) ear thickness and (e) survival. (bd) Data presented as mean ± SEM. (e) Data presented as percent survival. Significance determined
by a (b-d) repeated measures Two-Way ANOVA or (e) Mantel-Cox log-rank test for survival or
χ2 test for mortality (box). P values as shown.

(P = 0.73 and P = 0.89, respectively) (Figure 5.3d) or the hCD4 +:hCD8 + T cell ratio
(P = 0.50) (Figure 5.3e) between treatments. The proportion of hCD4+hCD25+hCD127lo
Tregs was not significantly (P = 0.23) different in PPADS-treated mice compared to
saline-treated mice, although this was largely due to one outlier (Grubbs’ test) in the saline
group with a much higher proportion of Tregs (Figure 5.3f). Proportions of hCD39+
Tregs, which have the capacity to metabolise extracellular ATP (Borsellino et al., 2007)
and reduce GVHD in humanised mice (Gu et al., 2017), were slightly, but not
significantly, increased in PPADS-treated mice (P = 0.19) (Figure 5.3g). The proportions
of hCD19 + B cells (P = 0.19) (Figure 5.3h) and hCD56 +hCD3 -hCD19- NK cells
(P = 0.49) (Figure 5.3i) were similar between treatment groups. Since hCD19 + B cell
proportions were small they were not examined further for expression of hCD27.
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Figure 5.3: PPADS does not significantly alter splenic human cells at endpoint. (a-i) Spleens
from humanised mice treated with PPADS or saline were examined by flow cytometry to identify
human cell populations at endpoint. Zombie NIR dye, FSC-A, FSC-H and SSC-A were used to
select live single lymphocytes (not shown). (a) Live single lymphocytes were gated as shown to
determine the proportion of (b) hCD45+ leukocytes, (c) hCD3+ T cells, (d) hCD4+ or hCD8+ T
cell subsets, (f) hCD4+hCD25+hCD127lo regulatory T cells (hTreg), (g) hCD39+ Tregs, (h)
hCD19+ B cells or (i) hCD56+hCD3-hCD19- NK cells. (e) The ratio of hCD4+ to hCD8+ T cells
was calculated from (d). (b-i) Data presented as mean ± SEM. Symbols represent individual mice
(n = 8, PPADS; n = 8, saline). Significance determined by (b, g) unpaired Student’s t test (c, e, f,
h, i) Mann Whitney test or (d) One-Way ANOVA. P values as shown.
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Analysis of total splenic cell numbers by flow cytometry provides another method for
investigating if engraftment of human immune cells was altered by PPADS at endpoint.
The number of splenic hCD45 + leukocytes (P = 0.30) (Figure 5.4a), hCD3 + T cells
(P = 0.29) (Figure 5.4b) and hCD4 + or hCD8 + T cell subsets (P > 0.99 and P > 0.99,
respectively) (Figure 5.4c) were similar between treatment groups, although within
treatment groups there was large variation in total cell numbers. The numbers of splenic
hTregs (Figure 5.4d) and hCD39 + Tregs (Figure 5.4e) were similar between treatment
groups (P = 0.49 and P = 0.57 respectively). Similarly, the numbers of hCD19 + B cells
(Figure 5.4f) and hCD56 +hCD3 -hCD19- NK cells (Figure 5.4g) in the spleen were
similar between groups (P = 0.78 and P = 0.85, respectively).

Figure 5.4: PPADS does not significantly alter splenic human cell numbers at endpoint.
Absolute splenic numbers of (a) hCD45+ leukocytes, (b) hCD3+ T cells, (c) hCD4+ or hCD8+ T
cell subsets, (d) hCD4+hCD25+hCD127lo hTregs, (e) hCD39+ Tregs, (f) hCD19+ B cells or (g)
hCD56+hCD3-hCD19- NK cells from Figure 5.3 were quantified using flow cytometric count
beads. (a-g) Data presented as mean ± SEM. Symbols represent individual mice (n = 5-8, PPADS;
n = 6-8 saline). Significance determined by (a, b) unpaired Student’s t test, (d-g) Mann Whitney
test or (c) Kruskal-Wallis test. P values as shown.
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5.2.4. PPADS partially reduces histological GVHD in the liver and ear at
endpoint
Liver, skin (flank and ear) and lung are the major tissues affected by GVHD in this
humanised mouse model (Sections 3.2.6 - 3.2.9) and BBG reduced histological GVHD
in the liver, ear and lung (Section 4.2.4). Therefore, the impact of PPADS treatment on
histological GVHD was assessed in these tissues as well as the duodenum (Figure 5.5).
Saline-treated mice displayed moderate to severe inflammation in the liver, ear and lung
with prolific immune cell infiltration. Epidermal thickening was present in the flank skin
and ear of four of six (66 %) saline-treated mice. In contrast, PPADS-treated mice had
mild to moderate inflammation with reduced immune cell infiltration in the liver and ear
compared to saline-treated mice. Moreover, epidermal thickening was not apparent in
either the skin or ear of any PPADS-treated mice. Histological grades were partially
reduced in livers (P = 0.13) and ears (P = 0.061), of PPADS-treated mice compared to
saline-treated mice. Lung inflammation was not altered by treatment (P = 0.47).
Histological grades in the skin (P > 0.99) and duodenum (P = 0.51) were similar between
treatments, with mild to no histological GVHD in these tissues for all mice except one
saline-treated mouse which had severe skin GVHD.
5.2.5. PPADS partially reduces serum hIFNγ and hTNFα at endpoint
PPADS reduced histological liver, but not skin or lung, GVHD above and BBG altered
the expression of mP2rx7 in the duodenum, but not other tissues, of humanised mice
(Section 4.2.5), so expression of this gene was examined in the liver and duodenum. There
was no difference in mP2rx7 expression in the liver (Figure 5.6a) or duodenum (Figure
5.6b) between treatments (P = 0.85 and P = 0.65, respectively). The expression of
mReg3g, a gene encoding the murine homologue of the GVHD biomarker REG3α
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Figure 5.5: PPADS partially reduces histological GVHD in the liver and ear at endpoint.
Tissues from PPADS- or saline-treated humanised mice at endpoint were stained with
haematoxylin and eosin. Sections of liver, skin, ear, lung and duodenum from humanised mice
were examined for evidence of histological GVHD. Histological GVHD in the liver, skin, ear and
duodenum was assessed using a standardised grading system. Histological lung GVHD was
determined as the percent of clear alveoli area of total lung area. Arrowheads indicate epidermal
thickening in the skin. Images representative of 5-8 mice per treatment group. Data presented as
mean ± SEM. Symbols represent individual mice. Significance determined by Mann Whitney test
or unpaired Student’s t test (lung only). P values as shown. Scale bars represent 100 µm.
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(Ferrara et al., 2011), was not altered by treatment in the duodenum (P = 0.48) (Figure
5.6c). As BBG did not significantly alter expression of hP2RX7 or hIFNG (Section 4.2.5),
and PPADS had a smaller effect on clinical and histological GVHD than BBG, these
genes were not examined in the current chapter.

Figure 5.6: PPADS partially reduces serum hIFNγ and hTNFα at endpoint. RNA isolated
from the (a) liver or (b, c) duodenum of humanised mice treated with PPADS (n = 6) or saline (n
= 6) was converted to cDNA and analysed by qPCR. Relative expression of (a, b) mP2rx7 or (c)
mReg3g was examined. (d) hIFNγ concentrations in sera from humanised mice were determined
by ELISA (n = 8 PPADS; n = 8 saline) (e) hIL-2, (f) hIL-6, (g) hIL-10, (h) hIL-17A and (i) hTNFα
concentrations in sera from humanised mice (n = 4 PPADS; n = 4 saline) were examined by
LEGENDplex. (a-i) Data presented as mean ± SEM. Symbols represent individual mice.
Significance was determined by (a, c, d-f, h) Mann Whitney test or (b, g, i) unpaired Student’s t
test. P values as shown.

BBG significantly reduced the concentration of serum hIFNγ (Section 4.2.9) so serum
from PPADS- or saline-treated mice was also examined for this cytokine. PPADS
reduced serum hIFNγ concentrations by more than 50 %, with this difference approaching
statistical significance (P = 0.11) (Figure 5.6d). Other T cell cytokines, including IL-2,
IL-6, IL-10, IL-17A and TNFα, also have roles in GVHD development (Markey et al.,

159

2014). Therefore, these cytokines were examined in four mice from each treatment group.
Serum

concentrations

of

hIL-2

(Figure

5.6e),

hIL-6

(Figure

5.6f),

hIL-10 (Figure 5.6g) or hIL-17A (Figure 5.6h) were similar between treatment groups
(P = 0.43, P = 0.91, P = 0.49 and P = 0.97, respectively). PPADS reduced the
concentration of serum hTNFα by more than 50 %, a difference which approached
significance (P = 0.15) (Figure 5.6i).
5.2.6. PPADS increases splenic hTreg proportions at day 21
BBG treatment in humanised mice increased hTregs and hB cells early in GVHD
development (Section 4.2.6). Despite PPADS only partially reducing clinical and
histological GVHD, human cell engraftment was also examined at day 21 to determine if
P2X7 blockade with PPADS had similar effects on early human immune cell
engraftment. To do this, NSG mice were injected with hPBMCs from the same donors as
above and treated with PPADS (300 mg/kg) or saline (days 0-10), but euthanised on
day 21 (Figure 5.7a). Splenic human leukocyte engraftment was examined by f low
cytometry as described above (Section 5.2.3). Frequencies of hCD45 + leukocyte
(P = 0.35) (Figure 5.7b), hCD3 + T cell (P = 0.86) (Figure 5.7c) and hCD4 + or hCD8+
T cells (P = 0.16 and P = 0.28, respectively) (Figure 5.7d) were similar between treatment
groups. However, the hCD4 +:hCD8 + T cell ratio was significantly reduced in
PPADS-treated mice compared to saline-treated mice (P < 0.05) (Figure 5.7e). Notably,
proportions of hCD4 +hCD25 +hCD127lo Tregs were increased almost two-fold in
PPADS-treated mice compared to saline-treated mice (P < 0.05) (Figure 5.7f). However,
the proportion of hCD39+ Tregs was slightly reduced in PPADS-treated mice compared
to saline-treated mice (P = 0.05) (Figure 5.7g). The proportion of hCD19 + B cells was
almost two-fold greater in PPADS-treated mice compared to saline-treated mice,
although this was not significant (P = 0.25) (Figure 5.7h). Further analysis revealed that
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most of these hB cells expressed hCD27, a marker of memory B cells (Tangye et al.,
1998), and the proportion of these memory hB cells was similar between treatment groups
(P = 0.54) (Figure 5.7i). Both PPADS- and saline-treated mice had small proportions of
hCD56 +hCD3 -hCD19- NK cells (P = 0.87) (Figure 5.7j).

Figure 5.7: PPADS increases splenic hTreg proportions at day 21. (a) Schematic
representation of the humanised mouse model of GVHD. (b-j) Spleens from humanised mice
treated with PPADS or saline were examined by flow cytometry to identify human cell
populations at day 21. (b) hCD45+ leukocytes, (c) hCD3+ T cells, (d) hCD4+ or hCD8+ T cell
subsets, (f) hCD4+hCD25+hCD127lo Tregs, (g) hCD39+ Tregs, (i) hCD19+ B cells, (j) hCD27+
memory B cells or (k) hCD56+hCD3-hCD19- NK cells proportions were determined as previously
shown (Figure 5.3). (e) The ratio of hCD4+ to hCD8+ T cells was calculated from (d). (b-j) Data
presented as mean ± SEM. Symbols represent individual mice (n = 8 PPADS; n = 7 saline).
Significance was determined by (b) Welch’s t-test, (c, e, f, h) unpaired Student’s t test, (d) OneWay ANOVA or (g, i, j) Mann Whitney test. P values as shown.
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Further analysis of the flow cytometric data from day 21 revealed that the numbers of
splenic hCD45 + leukocytes (P = 0.094) (Figure 5.8a), hCD3+ T cells (P = 0.15) (Figure
5.8b) and hCD4 + T cells (P = 0.18) (Figure 5.8c) were partly, but not significantly,
reduced in PPADS-treated mice compared to saline-treated mice. However, the numbers
of splenic hCD8 + T cells were significantly reduced in PPADS-treated mice compared to
saline-treated mice (P < 0.05) (Figure 5.8c). In contrast to an increase in the proportion
of splenic hTregs above (Figure 5.7f), the numbers of hTregs were reduced in
PPADS-treated mice compared to saline-treated mice (P < 0.05) (Figure 5.8d). Splenic
hCD39 + Tregs counts were also reduced in PPADS-treated mice compared to
saline-treated mice (P < 0.05) (Figure 5.8e). Finally, splenic hCD19 + B cell (P = 0.96)
(Figure

5.8f), hCD27 + memory B

cell (P

= 0.96) (Figure 5.8g) and

hCD56 +hCD3 -hCD19- NK cells (P = 0.23) (Figure 5.8h) counts were similar between
treatment groups.
5.2.7. PPADS increases hCD39 + Tregs and decreases hNK cells in the blood at
day 21
The current chapter also investigated whether PPADS altered human cell proportions in
the blood at day 21. The proportion of hCD45 + cells was decreased in the blood of
PPADS-treated mice compared to saline-treated mice, but this difference did not reach
significance (P = 0.14) (Figure 5.9a). There was no difference in the proportions of
circulating hCD3 + T cells (P = 0.97) (Figure 5.9b), hCD4 + or hCD8+
T cell subsets (P = 0.87 and P = 0.98, respectively) (Figure 5.9c) or the hCD4:hCD8 ratio
(P = 0.27) (Figure 5.9d) between treatments. Furthermore, proportions of circulating
hTregs (P = 0.94) (Figure 5.9e) were similar between treatments. Of note, hCD39 + Treg
proportions were partially increased in PPADS-treated mice compared to saline-treated
mice (P = 0.078) (Figure 5.9f). Proportions of hCD19+ B cells were similar between
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Figure 5.8: PPADS decreases splenic hCD8 +, hTreg and hCD39+ Treg numbers at day 21.
Absolute splenic numbers of (a) hCD45+ leukocytes, (b) hCD3+ T cells, (c) hCD4+ or hCD8+ T
cell subsets, (d) hCD4+hCD25+hCD127lo hTregs, (e) hCD39+ Tregs, (f) hCD19+ B cells, (g)
hCD27+ memory B cells or (h) hCD56+hCD3-hCD19- NK cells from Figure 5.7 were quantified
using flow cytometric count beads. (a-h) Data presented as mean ± SEM. Symbols represent
individual mice (n = 8 PPADS; n = 7, saline). Significance determined by (a, b, d-h) Mann
Whitney test or (c) Kruskal-Wallis test. P values as shown.

treatment groups (P = 0.61) (Figure 5.9g), while proportions of hCD56 +hCD3 -hCD19NK cells were significantly decreased in PPADS-treated mice compared to saline-treated
mice (P < 0.05) (Figure 5.9h). Cell numbers were not calculated due to relatively low
event counts in the blood (data not shown).
5.2.8. Histological GVHD at day 21 is relatively mild and is unaltered by PPADS
BBG reduced histological GVHD in multiple tissues at endpoint (Section 4.2.4) and in
the liver at day 21 in humanised mice (4.2.8) and PPADS reduced histological GVHD in
some organs at endpoint (Section 5.2.4.). Therefore, the effect of PPADS treatment on
histological GVHD at day 21 was also examined. The majority (~85 %) of saline-treated
mice displayed moderate to severe liver GVHD, while PPADS-treated mice had absent
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Figure 5.9: PPADS increases hCD39 + Tregs and decreases hNK cells in the blood at day 21.
Proportions of (a) hCD45+ leukocytes, (b) hCD3+ T cells, (c) hCD4+ or hCD8+ T cell subsets, (e)
hCD4+hCD25+hCD127lo hTregs, (f) hCD39+ Tregs, (g) hCD19+ B cells or (h) hCD56+hCD3hCD19- NK cells in the blood were determined by flow cytometry. (d) The ratio of hCD4+ to
hCD8+ T cells was calculated from (c). (a-h) Data presented as mean ± SEM. Symbols represent
individual mice (n = 7, PPADS; n = 7, saline). Significance determined by (a, b) Welch’s t test,
(c) One-Way ANOVA, (d, e, g, h) Mann Whitney test or (f) unpaired Student’s t-test. P values as
shown.

to severe liver GVHD (Figure 5.10). However, the difference in histological grade was
not significant (P = 0.28). Contrary to the liver, histological GVHD was absent to
relatively mild in the skin, ear, lung and duodenum of all mice regardless of treatment,
with no difference in histological grades (P > 0.40) or clear alveolar space (P = 0.73).
5.2.9. PPADS partially reduces serum hIFNγ
PPADS treatment did not alter mP2rx7 expression in the liver or duodenum, or mReg3g
expression in the duodenum, at endpoint. However, there remains a possibility that these
genes were altered by PPADS treatment early in disease. Therefore, the expression of
these genes in humanised mice treated with PPADS or saline at day 21 was examined by
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Figure 5.10: Histological GVHD at day 21 is relatively mild and is unaltered by PPADS.
Tissues from PPADS- or saline-treated humanised mice at endpoint were stained with
haematoxylin and eosin. Sections of liver, skin, ear, lung and duodenum from humanised mice
were examined for evidence of histological GVHD. Histological GVHD in the liver, skin, ear and
duodenum was assessed using a standardised grading system. Histological lung GVHD was
determined as the percent of clear alveoli area of total lung area. Images representative of 3-8
mice per treatment group. Data presented as mean ± SEM. Symbols represent individual mice.
Significance determined by Mann Whitney test or unpaired Student’s t test (lung only). P values
as shown. Scale bars represent 100 µm.

165

qPCR. Expression of mP2rx7 was reduced by 50 % in the liver (P = 0.10) (Figure 5.11a),
but unaltered in the duodenum (P = 0.94) (Figure 5.11b), of PPADS-treated mice
compared to saline-treated mice. There was large variation (100-fold) in the expression
of mReg3g in the duodenum between PPADS-treated mice which resulted in a mean
expression five-fold higher then saline mice, although this was not significantly different
(P = 0.59) (Figure 5.11c).
BBG reduced serum hIFNγ concentrations at endpoint (Section 4.2.5) and day 21 in
humanised mice (Section 4.2.9) and PPADS displayed a similar trend at endpoint (Section
5.2.5). Therefore, this cytokine was examined at day 21 in saline- and PPADS-treated
mice. Sera concentrations of hIFNγ were reduced by 50 % in PPADS-treated mice
compared to saline-treated mice, however this difference was not significant (P = 0.21)
(Figure 5.11d).

Figure 5.11: PPADS partially reduces serum hIFNγ at day 21. RNA isolated from the (a) liver
or (b, c) duodenum of humanised mice treated with PPADS (n = 6) or saline (n = 6) was converted
to cDNA and analysed by qPCR. Relative expression of (a, b) mP2rx7 or (c) mReg3g was
examined. (d) hIFNγ concentrations in sera from humanised mice were determined by ELISA
(n = 7, saline; n = 8, PPADS). (a-i) Data presented as mean ± SEM. Symbols represent individual
mice. Significance was determined by (a-d) Mann Whitney test. P values as shown.
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5.2.10. PPADS increases the proportion of hCD4 + T cells in vitro
Similar to BBG (Section 4.2.6), PPADS increased hTreg proportions at day 21 (Section
5.2.6). Therefore, the effect of this P2X7 antagonist on hPBMCs was examined in vitro.
As in section 4.2.6, hPBMCs from three healthy donors were cultured in low serum
conditions to promote cell death in the presence of PPADS (10 μM) or saline for 20 h
(Figure 5.12a). The number of live lymphocytes and proportions of lymphocyte subsets
were examined by flow cytometry. Incubation of hPBMCs in RPMI-1640 (2.5 % FCS)
in the presence of saline or PPADS resulted in similar numbers of viable lymphocytes at
20 h (P = 0.18) (Figure 5.12b). Amongst these cells, hCD3 + T cell proportions were
similar following incubation with either saline or PPADS (P = 0.59) (Figure 5.12c).
hCD4 + T cell proportions were significantly increased (P < 0.05) (Figure 5.12d) and
hCD8 + T cell proportions slightly decreased (P = 0.14) (Figure 5.12d) in hPBMC cultures
containing PPADS compared to cultures with saline. Subsequently, there was a slightly
increased hCD4 +:hCD8 + T cell ratio in hPBMCs cultured with PPADS compared to
hPBMCs cultured with saline (P = 0.17) (Figure 5.12e). There was no difference in
hCD4 +hCD25 +hCD127lo Tregs (P > 0.99) (Figure 5.12f) or hCD39 + Tregs (P > 0.99)
(Figure 5.12g) proportions in hPBMCs cultured with PPADS compared to those with
saline. Finally, there were slightly higher proportions of hCD19 + B cells in hPBMCs
cultured with PPADS compared to hPBMCs cultured with saline (P = 0.080)
(Figure 5.12h).
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Figure 5.12: PPADS increases the proportion of hCD4+ T cells in vitro. PBMCs from (a-h)
three healthy donors were cultured overnight in RPMI-1640 medium containing 2.5 % FCS with
10 μM PPADS or saline. (a) Schematic representation of experiment. The (a) number of live
lymphocytes or proportions of (c) hCD3+ T cells, (d) hCD4+ or hCD8+ T cell subsets, (f)
hCD4+hCD25+hCD127lo Tregs, (g) hCD39+ Tregs and (h) hCD19+ B cells were determined by
flow cytometry as previously shown (Figure 5.3). (e) The ratio of hCD4+ to hCD8+ T cells was
calculated from (d). Data presented as mean ± SEM. Symbols represent individual donors.
Significance determined by (b, c, e, h) paired Student’s t test, (d) repeated measures One-Way
ANOVA or (f, g) Wilcoxon matched-pairs test. P values as shown.

5.3.Discussion
This chapter aimed to determine if P2X7 blockade with PPADS, used at a dose and
regime previously shown to have efficacy in an allogeneic mouse model of GVHD
(Wilhelm et al., 2010), could reduce GVHD in humanised mice. This chapter
demonstrated that PPADS reduced clinical score, ear swelling and histological GVHD in
the ear and liver. This reduction in GVHD corresponded with increased hTreg proportions
early in disease. These effects were similar to BBG treatment (Chapter 4), but differences
between PPADS- and saline-treated mice were not as large as those seen between
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BBG- and saline-treated mice. The differences between P2X7 blockade with PPADS or
BBG may be due to the different off-target effects of each compound as discussed below.
5.3.1. PPADS and clinical and histological GVHD in humanised mice
Despite increased hTregs and decreased hIFNγ in PPADS-treated mice, clinical GVHD
was only partially reduced in the current chapter. The ability of PPADS to reduce clinical
GVHD appears to have been confounded by decreased weight gain in mice treated with
this compound. Similar to BBG treatment in humanised mice (Section 4.2.2), but in
contrast to PPADS treatment in allogeneic mice (Wilhelm et al., 2010), and despite
reductions in histological and clinical GVHD, PPADS was unable to extend survival in
the current chapter. This is likely due to the loss of hTregs over time, supporting the idea
that extended pharmacological blockade of P2X7 may provide greater benefits in this
humanised mouse model. Furthermore, PPADS has ten times great potency against
hP2X7 than against mP2X7 (Donnelly-Roberts et al., 2009), suggesting that PPADS may
be blocking hP2X7 on hTregs to increase their survival, but not mP2X7 on mouse cells
in the current chapter. Treatment with antibodies specific for mP2X7, such as 1F11 which
reduced intestinal inflammation in colitis (Kurashima et al., 2012), or hP2X7 (Buell et
al., 1998a) could be used to identify the role of each receptor in humanised mice.
However, the same PPADS regime used in this chapter impaired GVHD and prolonged
survival in allogeneic mice (Wilhelm et al., 2010), which may indicate that GVHD is
more difficult to prevent in the xenogeneic humanised mouse model compared with
allogeneic mouse models of this disease.
PPADS has the ability to antagonise most human P2X receptors and some P2Y receptors.
PPADS, but not BBG, can inhibit P2X1, P2X2, P2X3 and P2Y 1 (Donnelly-Roberts et al.,
2009), although the role of these receptors in GVHD is largely unknown. P2X1 and P2Y1
are expressed by DCs but their roles on this cell type are undefined (Jacob et al., 2013).
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Likewise, T cells express P2X1, P2X2, P2X3 and P2Y 1 (Jacob et al., 2013) but the role
of these receptors remains largely unknown, with some evidence that P2X1 (Woehrle et
al., 2010b) and P2Y1 (Woehrle et al., 2019) are involved in IL2 transcription. Therefore,
it is possible that inhibition of any of these purinergic receptors is worse ning GVHD,
counteracting the benefits provided by P2X7 blockade. Future studies could selectively
inhibit these P2X and P2Y receptors in humanised mice to determine what role they play.
Alternatively, the benefits of BBG may be greater than PPADS as BBG can inhibit the
ATP release channel pannexin-1 (Qiu et al., 2009). Therefore, BBG is likely inhibiting
P2X7 and reducing ATP release in humanised mice, while PPADS can only do the
former. Further, BBG may be longer lasting in tissues as organs are visibly stained blue
until endpoint (Chapter 4: data not shown), but the orange colour of PPADs was not
noticeable at endpoint (data not shown). Quantitative analysis of these compounds in
tissues at endpoint could confirm or deny these observations.
Wilhelm et al. (2010) demonstrated that PPADS could reduce histological GVHD in the
small intestine and skin but did not examine other tissues. The current chapter
demonstrated that PPADS mainly reduced liver GVHD, similar to previous studies
examining P2X7 blockade in humanised (Geraghty et al., 2017; Geraghty et al., 2019d)
and allogeneic (Zhong et al., 2016) mice, with some benefits in the skin. Notably, reduced
histological GVHD in the ear of PPADS-treated mice at endpoint was paralleled by
decreased ear swelling over time. The current chapter also revealed that the liver, but not
skin, ear, lung or duodenum, is affected by GVHD at an early timepoint in this humanised
mouse model.
5.3.2. PPADS and human cell engraftment in humanised mice
Similar to BBG (Section 4.2.6), P2X7 blockade with PPADS increased hTregs. A
previous study provided limited evidence that PPADS could increase Tregs in allogeneic
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mice, but concluded that P2X7 on host, but not donor, cells contributed to GVHD
(Wilhelm et al., 2010). Activation of P2X7 on Tregs induces the death of these cells
(Schenk et al., 2011) and Tregs have been shown to prevent GVHD in allogeneic (Semple
et al., 2011) and humanised (Sato et al., 2020) mice. Therefore, it is likely that blockade
of P2X7 on hTregs is increasing survival of these cells, allowing them to reduce GVHD
for longer. As mentioned above, increasing the duration of P2X7 blockade may further
increase the survival of hTregs and better prevent GVHD. The proportion of hCD39 +
hTregs was slightly reduced in PPADS-treated mice compared to saline-treated mice at
day 21. CD39 + Tregs have greater suppressive effects than CD39 - Tregs and protect
against GVHD (Gu et al., 2017). Therefore, it is possible that despite an increase in total
hTregs, the slight decrease in hCD39 + hTregs meant that the benefits of PPADS were
reduced.
Splenic T cell, including Treg, numbers were decreased at day 21 in PPADS-treated mice
but recovered by endpoint. P2X7 activation on T cells leads to activation and proliferation
of these cells and inhibition of P2X7 on T cells can reduce this proliferation (Yip et al.,
2009; Yu et al., 2010). Therefore, it is possible that PPADS reduced the proliferation of
T cells early in disease, but once treatment ceased T cell numbers began to return to
normal. PPADS also allowed the splenic engraftment of other human cells including
B cells and NK cells. Similar to BBG (Section 4.3.3), this suggests that early treatment
with P2X7 antagonists may allow for the engraftment of multiple cell types, potentially
resulting in greater protection from infection or cancer relapse.
Mice from both treatment groups had detectable proportions of circulating NK cells at
day 21 in the current chapter, with PPADS-treated mice having smaller proportions than
saline-treated mice. Circulating NK cells were not detectable in either saline- or
BBG-treated mice (Section 4.2.7). This increase in NK cells in all mice is likely due to
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human donor variation between studies. Differences in circulating NK cells between
saline- and PPADS-treated may be due to differential activation of DCs in these mice.
P2X7 activation on DCs leads to the release of cytokines including IL-1β and IL-18
(Englezou et al., 2015; Ferrari et al., 2000b; Sakaki et al., 2013) and IL-18 has the ability
to inhibit NK cell death (Hodge et al., 2006). Therefore, it is possible that P2X7 blockade
with PPADS is reducing the availability of IL-18, leading to greater NK cell death.
Analysis of serum IL-18 in humanised mice may shed light on this result. If P2X7
blockade does consistently reduce NK cell engraftment, it may not present a viable
therapeutic following allo-HSCT as NK cells are important for anti-cancer immunity
(Shimasaki et al., 2020).
Unlike BBG (Section 4.2.6), PPADS only slightly increased proportions of hB cells in
humanised mice, despite increasing these cells in vitro. As discussed previously (Section
4.3.3), B cells may play pro-inflammatory (Dominietto et al., 2012; Kamble et al., 2006;
Schultz et al., 1995) or anti-inflammatory (Saze et al., 2013; Weber et al., 2014) roles in
GVHD. If hB cells are playing an anti-inflammatory role in this humanised mouse model,
an increase in these hB cells may be tied to reduced GVHD. As such, the smaller
difference in clinical and histological GVHD between PPADS- and saline-treated mice
compared to BBG- and saline-treated mice (Chapter 4) is paralleled by a smaller
difference in hB cell proportions.
5.3.3. PPADS and human cytokines in humanised mice
Similar to BBG (Section 4.2.9), PPADS also reduced serum hIFNγ concentrations
although this effect was not as pronounced in the current chapter. As discussed in the
previous chapter (Section 4.3.2), IFNγ has multiple known roles in GVHD (Choi et al.,
2012; Zhao et al., 2016) and Tregs have the ability to reduce this cytokine in mouse
models of GVHD (Edinger et al., 2003; Hu et al., 2020a). As such, the reduction in hIFNγ
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in the current chapter may be due to increases in hTregs. Alternatively, the reduction in
circulating hNK cells, which produce multiple cytokines including hIFNγ and hTNFα
(Fauriat et al., 2010), may have led to a reduction in serum hIFNγ, as well as hTNFα in
the current chapter. Future studies could better examine the role of NK cells in this
humanised mouse model, although inconsistent engraftment of these cells may impede
this.
As mentioned above, PPADS may be blocking P2X1 and P2Y 2 in the current chapter.
Despite the involvement of these receptors in IL2 gene expression (Woehrle et al., 2010b;
Woehrle et al., 2019) there was no difference in endpoint serum IL-2 concentrations
between treatments. This may be due to the small number of samples examined, although
the concentration of hIL-2 in most mice was below the detection limit. Future studies
could examine whether PPADS has the ability to reduce IL2 gene expression in this
model, which may provide evidence for a role for P2X1 and/or P2Y 2 in GVHD
5.3.4. Conclusion
In conclusion, this chapter demonstrated that P2X7 blockade with PPADS displayed
similar, but smaller, benefits to P2X7 blockade with BBG. PPADS increased hTregs and
reduced clinical (partially) and histological GVHD. This outcome is likely due to
differences in the inhibition profiles of each compound. Nevertheless, the current chapter
has confirmed that P2X7 blockade can increase hTregs and reduce GVHD in this mouse
model.
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Chapter 6: P2X7 antagonism and post-transplant cyclophosphamide
combinational therapy in a humanised NSG mouse model of
GVHD
6.1. Introduction
GVHD is a severe inflammatory response against recipient tissues following allogeneic
HSCT mediated by reactive donor T cells (Ferrara et al., 2009). This T cell-mediated
inflammatory response involves the release of multiple pro -inflammatory cytokines
including IFNγ, TNFα and various ILs and leads to damage in the liver, skin, lungs and
gut (Blazar et al., 2012). As such, depletion of these reactive donor T cells prior to, or
following, HSCT is currently used to reduce GVHD (Kanakry et al., 2016b;
Vadakekolathu et al., 2017). One such T cell depletion strategy is PTCy which prevents
the expansion of rapidly proliferating cells, such as reactive donor T cells in GVHD
(Williams et al., 2020). PTCy has shown efficacy in allogeneic (Ganguly et al., 2014;
Wachsmuth et al., 2019) and humanised (Adhikary, 2020; Kanakry et al., 2013) mouse
models, as well as in allogeneic HSCT recipients in the clinic (Luznik et al., 2008;
McCurdy et al., 2015). PTCy-mediated protection against GVHD appears to be reliant on
the recovery of donor Tregs, as depletion of reactive donor T cells alone is insufficient to
prevent disease in allogeneic (Ganguly et al., 2014) and humanised mice (Kanakry et al.,
2013). Similarly, in a humanised mouse model PTCy (33 mg/kg, i.p., days 3, 4) delays
GVHD onset, reduces weight loss and clinical score and increases survival, but donor
Tregs are reduced at endpoint and PTCy-treated humanised mice eventually succumb to
GVHD (Adhikary, 2020). Moreover, PTCy does not always prevent GVHD related
mortality in HSCT recipients, and cancer relapse and infection can still occur with this
treatment (Ruggeri et al., 2017). As such, improved therapeutic strategies are required.
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As discussed in detail previously (Chapters 3-5), P2X7 activation contributes to GVHD
development and P2X7 antagonism with BBG (50 mg/kg, i.p., daily from day 0-10)
reduces clinical and histological GVHD but does not increase survival in humanised mice
(Section 4.2.2). Further, BBG preserves hTregs in humanised mice early in disease
(Section 4.2.6). As such, combinational therapy with PTCy and P2X7 antagonism may
be able to overcome the shortcomings of PTCy alone, further reducing GVHD and
increasing Treg engraftment. Therefore, this chapter aimed to determine if combinational
therapy with PTCy and BBG (PTCy+BBG) could further reduce disease and increase
hTregs compared to PTCy alone in a humanised mouse model of GVHD.

6.2. Results
6.2.1. Combinational therapy with PTCy+BBG does not alter clinical GVHD
To investigate if combinational therapy with PTCy+BBG could further reduce GVHD
compared to PTCy alone, NSG mice were injected with hPBMCs (day 0), injected twice
(day 3, 4) with cyclophosphamide (33 mg/kg) and injected daily (day 0 -10) with BBG
(50 mg/kg) or saline and monitored thrice weekly until endpoint (Figure 6.1a). In this
model, mice are injected with twice as many hPBMCs as previous Chapters, to account
for the PTCy-mediated depletion of T cells (Adhikary, 2020). All mice steadily gained
weight until day 30 at which time weights plateaued with no significant difference
between treatment groups (P = 0.37) (Figure 6.1b). Clinical scores increased in both
treatment groups from day 20, while from day 50 scores for PTCy+BBG-treated mice
plateaued and scores for PTCy+Saline-treated mice continued to increase, although this
difference was not significant over time (P = 0.48) (Figure 6.1c). Ear thickness, a
measure of cutaneous GVHD, was not significantly different between treatment groups
(P = 0.70) (Figure 6.1d). Likewise, overall survival was similar between groups (MST:
PTCy+BBG > day 70; PTCy+Saline > day 70) (P = 0.30) but mortality was partially
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reduced in PTCy+BBG-treated mice (20 %) compared to PTCy+Saline-treated mice
(46 %) a difference which approached statistical significance (P = 0.10) (Figure 6.1e).

Figure 6.1: Combinational therapy with PTCy+BBG does not alter clinical GVHD. (a)
Schematic representation of the humanised mouse model of GVHD. (a-e) NSG mice were
injected i.p. with 20 x 106 hPBMCs (n = 3 donors) at day 0, injected twice (day 3, 4) with
cyclophosphamide (33 mg/kg), and injected i.p. daily (day 0-10) with 50 mg/kg BBG (n = 10
mice) or saline (n = 11 mice). Mice were assessed thrice weekly for up to 70 days for (b) weight
change, (c) clinical score, (d) ear thickness and (e) survival. (b-d) Data presented as mean ± SEM.
(e) Data presented as percent survival. Significance determined by a (b-d) repeated measures
Two-Way ANOVA or (e) Mantel-Cox log-rank test for survival or χ2 test for mortality (box). P
values as shown.

6.2.2. Combinational therapy with PTCy+BBG partially increased splenic
hTreg numbers, but not proportions, at endpoint
To determine if combinational treatment could alter human cell engraftment, spleens from
endpoint mice were examined by flow cytometry (Figure 6.2a). The proportions of
hCD45 + leukocytes (P = 0.51) (Figure 6.2b), hCD3+ T cells (P = 0.50) (Figure 6.2c) and
hCD4 + or hCD8 + T cell subsets (P > 0.99) (Figure 6.3d) were similar between treatment
groups. Likewise, the hCD4 +:hCD8 + T cell ratio was similar in both groups (P = 0.35)
(Figure 6.2e). PTCy reduces hTregs (Adhikary, 2020) and P2X7 blockade with BBG
preserves hTregs (Section 4.2.6) in the humanised mouse model of GVHD. Therefore,
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Figure 6.2: Combinational therapy with PTCy+BBG does not alter splenic human cell
proportions at endpoint. (a-h) Spleens from humanised mice treated with PTCy+Saline or
PTCy+BBG were examined by flow cytometry to identify human cell populations at endpoint.
Zombie NIR dye and FSC-A and FSC-H were used to select live single lymphocytes (not shown).
(a) Live single lymphocytes were gated as shown to determine the proportion of (b) hCD45+
leukocytes, (c) hCD3+ T cells, (e) hCD4+ or hCD8+ T cell subsets, (f) hCD4+hCD25+hCD127lo
regulatory T cell (hTreg), (g) hCD39+ Tregs or (h) hCD19+ B cells. (e) The ratio of hCD4+ to
hCD8+ T cells was calculated from (d). (b-h) Data presented as mean ± SEM. Symbols represent
individual mice (n = 10, PTCy+BBG; n = 11, PTCy+Saline). Significance determined by (b, c, eh) Mann Whitney test or (d) Kruskal-Wallis test. P values as shown.
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the current chapter investigated if combinational treatment with PTCy+BBG could
protect hTregs in this model. Proportions of hCD4 +hCD25+hCD127 lo Tregs were
unaltered at endpoint with similar proportions in both treatment groups (P = 0.51) (Figure
6.2f). Further, proportions of hCD39+ hTregs, which have increased stability and reduce
GVHD in humanised mice (Gu et al., 2017), were similar between treatment groups
(P = 0.92) (Figure 6.2g). Proportions of hCD19 + B cells were small (< 0.5 %) in both
treatment groups, although these cells were slightly increased in PTCy+BBG-treated
mice compared to PTCy+Saline-treated mice (P = 0.11) (Figure 6.2h). Due to the low
proportions of hB cells, these cells were not examined for the presence of hCD27.
hCD56 +hCD3 -hCD19- NK cells were not detectable in any mice at endpoint (data not
shown).
Next, total splenic cell numbers was analysed by flow cytometry. The number of
hCD45 + leukocytes (P = 0.15) (Figure 6.3a) and hCD3+ T cells (P = 0.15) (Figure 6.3b)
were increased approximately two-fold in PTCy+BBG-treated mice compared to
PTCy+Saline-treated mice, although these differences were not significant. The number
of splenic hCD4 + or hCD8 + T cells was similar between treatment groups (P > 0.99)
(Figure 6.3c). Notably, the number of hCD4+hCD25+hCD127 lo Tregs (Figure 6.3d) and
hCD39 + hTregs (Figure 6.3e) were two- and three-fold, respectively, higher in
PTCy+BBG-treated mice compared to PTCy+Saline-treated mice, differences which
approached statistical significance (P = 0.11 and P = 0.099, respectively). Event counts
of hCD19 + B cells were too low to accurately calculate total splenic numbers (data not
shown).
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Figure 6.3: Combinational therapy with PTCy+BBG partially increases splenic hTreg
numbers at endpoint. Absolute splenic numbers of (a) hCD45+ leukocytes, (b) hCD3+ T cells,
(c) hCD4+ or hCD8+ T cell subsets, (d) hCD4+hCD25+hCD127lo hTregs or (e) hCD39+ hTregs
from Figure 6.2 were quantified using flow cytometric count beads. (a-e) Data presented as mean
± SEM. Symbols represent individual mice (n =10 PTCy+BBG; n = 11, PTCy+Saline).
Significance determined by (a, b, d, e) Mann Whitney test or (c) Kruskal-Wallis test. P values as
shown.

6.2.3. Combinational therapy with PTCy+BBG reduces histological liver GVHD
at endpoint
PTCy reduces histological liver GVHD in humanised mice (Adhikary, 2020) and BBG
reduces histological liver and skin GVHD (Section 4.2.4). Therefore, the current chapter
examined whether combinational treatment with PTCy+BBG could reduce histological
GVHD in the liver, skin and other GVHD target organs to a greater extent than PTCy
alone (Figure 6.4). PTCy+Saline-treated mice displayed mild to severe histological
GVHD with prolific immune cell infiltrates in the liver, skin, ear and lung, with some
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Figure 6.4: Combinational therapy with PTCy+BBG reduces histological liver GVHD at
endpoint. Tissues from PTCy+Saline- or PTCy+BBG-treated humanised mice at endpoint were
stained with haematoxylin and eosin. Sections of liver, skin, ear, lung and duodenum from
humanised mice were examined for evidence of histological GVHD. Histological GVHD in the
liver, skin, ear and duodenum was assessed using a standardised grading system. Histological
lung GVHD was determined as the percent of clear alveoli area of total lung area. Arrowheads
indicate epidermal thickening in the skin. Images representative of 5-8 mice per treatment group.
Scale bars represent 100 µm. Data presented as mean ± SEM. Symbols represent individual mice.
Significance determined by (liver, ear, duodenum) Mann Whitney test or (lung, skin) unpaired t
test. P values as shown.
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mice also having increased epidermal thickening and apoptotic bodies in the skin and ear.
PTCy+BBG-treated mice displayed mild to moderate histological GVHD with immune
cell infiltrates in the skin, ear and lung and some evidence of epidermal thickening.
GVHD was negligible in the duodenum of all mice. Histological grades were significantly
reduced in the livers of PTCy+BBG-treated mice compared to PTCy+Saline-treated mice
(P < 0.05). However, these grades were similar in the skin (P = 0.40) and ear (P = 0.28),
and clear alveoli space was similar in the lung (P = 0.95), between treatment groups.
6.2.4. Combinational therapy with PTCy+BBG reduces serum hIFNγ
concentrations at endpoint
T cell cytokines play important roles in GVHD (Blazar et al., 2012) and treatment with
PTCy reduced multiple serum cytokine concentrations in allogeneic mice (Wachsmuth et
al., 2019) and partially reduced serum hIL-2 in humanised mice (Adhikary, 2020).
Additionally, P2X7 blockade with BBG has been shown to reduce hIFNγ in humanised
mice on multiple occasions (Section 4.2.9) (Geraghty et al., 2017). Therefore, a multiplex
cytokine analysis kit was utilised to determine if treatment was altering the serum
concentration of multiple T cell cytokines. Serum concentrations of hIL-2 (P = 0.96),
hIL-4 (P = 0.80), hIL-5 (P = 0.20), hIL-6 (P = 0.40), hIL-9 (P = 0.46), hIL-10 (P = 0.21),
hIL-13 (P = 0.19), hIL-17A (P = 0.44), hIL-17F (P = 0.74), hIL-21 (P = 0.98),
hIL-22 (P = 0.13) and hTNFα (P = 0.72) were similar between treatment groups
(Figure 6.5a-l). Serum hIFNγ concentrations were reduced by 40 % in
PTCy+BBG-treated mice compared to PTCy+Saline-treated mice, a difference which did
not reach statistical significance due to the presence of two outliers (Grubb’s test) in the
PTCy+BBG group (P = 0.20) (Figure 6.5m). The removal of these two statistical outliers
makes this difference in hIFNγ concentrations significant (P < 0.01) (Figure 6.5n).
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Figure 6.5: Combinational therapy with PTCy+BBG reduces serum hIFNγ concentrations
at endpoint. (a) hIL-2, (b) hIL-4, (c) hIL-5, (d) hIL-6, (e) hIL-9, (f) hIL-10, (g) hIL-13, (h) hIL17A, (i) hIL-17F, (j) hIL-21, (k) hIL-22, (l) TNFα and (m, n) hIFNγ concentrations in sera from
PTCy+Saline- and PTCy+BBG-treated humanised mice were examined by LEGENDplex. (n)
Depicts the same data as (m) but with two outliers (Grubb’s test) in the PTCy+BBG group
removed. (a-n) Data presented as mean ± SEM. Symbols represent individual mice (n = 10
PTCy+BBG; n = 11 PTCy+Saline). Significance was determined by (a-m) Mann Whitney test or
(n) Welch’s t test. P values as shown.

6.2.5. Combinational therapy with PTCy+BBG increases hTregs in some mice
and increases the proportion of hCD39 + hTregs at day 21
Treatment with BBG alone increases hTreg engraftment early (day 21) in GVHD
development (Section 4.2.6) but the effect of PTCy on splenic human cell engraftment at
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this time point is unknown. As such, NSG mice were injected with hPBMCs from the
same donors as above (day 0) (Section 6.2.1), injected twice (day 3,4) with
cyclophosphamide (33 mg/kg) and injected daily (day 0-10) with BBG (50 mg/kg) or
saline and euthanised on day 21 to examine human leukocyte engraftment, early
histological GVHD and serum cytokines (Figure 6.6a). Clinical disease over the 21 days
was minimal (results not shown). Flow cytometry revealed that the proportions of
hCD45 + leukocytes (P = 0.89) (Figure 6.6b), hCD3+ T cells (P = 0.39) (Figure 6.6c) and
hCD4 + or hCD8 + T cell subsets (P > 0.99) (Figure 6.6d) were similar between treatment
groups. Moreover, the hCD4 +:hCD8 + T cell ratio was unaltered by the combinational
treatment (P = 0.93) (Figure 6.6e). hCD4 +hCD25 +hCD127 lo Tregs proportions were
increased nearly two-fold in PTCy+BBG-treated mice (P = 0.065), with four (of ten) of
these mice having relatively high proportions of these cells compared to
PTCy+Saline-treated mice (Figure 6.6f). Notably, the proportion of hCD39 + hTregs was
increased more

than

two-fold in

PTCy+BBG-treated

mice

compared to

PTCy+Saline-treated mice (P < 0.001) (Figure 6.6g). Proportions of hCD19 + B cells
were

similar

between

treatment

groups

(P

=

0.48)

(Figure

6.6h).

hCD56 +hCD3 -hCD19- NK cells were detectable at day 21 (Figure 6.6i) with proportions
similar between treatment groups. (P = 0.48) (Figure 6.6j). Total splenic counts were not
examined in this experiment due to quality control issues with precision count beads.
6.2.6. Combinational therapy with PTCy+BBG does not alter proportions of
circulating human cells at day 21
Neither PTCy (Adhikary, 2020) or BBG (Section 4.2.7) significantly altered circulating
human cells early in disease in this humanised mouse model of GVHD. Nevertheless, the
current chapter examined if combinational therapy would impact human cell proportions
in the blood by flow cytometry. Proportions of hCD45+ leukocytes were similar between
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Figure 6.6: Combinational therapy with PTCy+BBG increases hTregs in some mice and
increases the proportion of hCD39+ hTregs at day 21. (a) Schematic representation of the
humanised mouse model of GVHD. (b-j) Spleens from humanised mice treated with
PTCy+Saline or PTCy+BBG were examined by flow cytometry to identify human cell
populations at day 21. The proportions of (b) hCD45+ leukocytes, (c) hCD3+ T cells, (d) hCD4+
or hCD8+ T cell subsets, (f) hCD4+hCD25+hCD127lo Tregs, (g) hCD39+ Tregs or (h) hCD19+ B
cell were determined as previously shown (Figure 6.2). (e) The ratio of hCD4+ to hCD8+ T cells
was calculated from (d). (i) hCD45+hCD3-hCD19- cells were gated as shown to determine the
proportion of (j) hCD56+hCD3-hCD19- NK cells. (b-h, j) Data presented as mean ± SEM.
Symbols represent individual mice (n = 7-11 PTCy+BBG; n = 7-11 PTCy+Saline). Significance
was determined by (b, c, e, h, j) Mann Whitney test, (d) One-Way ANOVA, (f) Welchs’ t-test or
(g) unpaired t-test. P values as shown.
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treatment groups (P = 0.51) (Figure 6.7a) while hCD3+ T cells were slightly increased in
PTCy+BBG-treated mice compared to PTCy+Saline-treated mice (P = 0.085) (Figure
6.7b). Proportions of hCD4 + or hCD8 + T cell subsets (P = 0.36 and P = 0.78, respectively)
(Figure 6.7c) and the ratio of hCD4 +:hCD8 + T cells (P = 0.20) (Figure 6.7d) were similar
between treatments. Likewise, proportions of hCD4 +hCD25 +hCD127lo Tregs in the blood
were similar between treatment groups (P = 0.88) (Figure 6.7e), although circulating
hTregs were not detected in most mice (four of eight PTCy+Saline and five of eight
PTCy+BBG). As such, hTregs were not assessed for the expression of hCD39. hCD19 +
B cells were not detected in the blood of the majority of mice (seven of nine PTCy+Saline
and eight of twelve PTCy+BBG) with no difference between treatment groups (P = 0.53)
(Figure 6.7f). Similarly, hCD56 +hCD3 -hCD19 - NK cells were not detected in the
majority of mice (five of seven PTCy+Saline and zero of eight PTCy+BBG) with no
difference between treatment groups (P = 0.20) (Figure 6.7g).
6.2.7. All mice treated with PTCy did not have histological GVHD at day 21
Combinational treatment with PTCy+BBG reduced histological liver GVHD at endpoint
(Section 6.2.3). Therefore, the current chapter examined whether combinational therapy
could also reduce histological GVHD early in disease. Histological GVHD was absent in
the liver, skin, ear, lung and duodenum of all mice examined at day 21 (Figure 6.8). There
was no evidence of immune cell infiltrates in any tissue, nor bile duct destruction in the
liver, nor epidermal thickening or apoptotic bodies in the skin or ear. Further, lungs from
all mice looked healthy with no inflammation. As there was no visible evidence of GVHD
tissues were not graded.
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Figure 6.7: Combinational therapy with PTCy+BBG does not alter proportions of
circulating human cells at day 21. Blood from humanised mice treated with PTCy+Saline or
PTCy+BBG was examined by flow cytometry to identify human cell populations at day 21. The
proportions of (a) hCD45+ leukocytes, (b) hCD3+ T cells, (c) hCD4+ or hCD8+ T cell subsets, (e)
hCD4+hCD25+hCD127lo Tregs, (f) hCD19+ B cell or (g) hCD56+hCD3-hCD19- NK cells were
determined as previously shown (Figure 6.2 and Figure 6.6). (d) The ratio of hCD4+ to hCD8+
T cells was calculated from (c). (a-g) Data presented as mean ± SEM. Symbols represent
individual mice (n = 8-12 PTCy+BBG; n = 7-11 PTCy+Saline). Significance was determined by
(a, b, d-g) Mann Whitney test or (c) One-Way ANOVA. P values as shown.

6.2.8. Serum cytokines are not detectable in the majority of mice treated with
PTCy at day 21
As mentioned previously, BBG reduced serum hIFNγ in humanised mice and this effect
was more prominent at day 21 compared to endpoint (Section 4.2.9), while the effect of
PTCy on serum cytokine levels at early time points in this model is unknown. Therefore,
a multiplex cytokine analysis kit was utilised to determine the serum concentration of
various T cell cytokines at day 21 in PTCy+BBG- and PTCy+Saline-treated mice. The
majority of mice in both treatment groups had serum cytokine concentrations below the
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Figure 6.8: All mice treated with PTCy do not have histological GVHD at day 21. Tissues
from PTCy+BBG- or PTCy+Saline-treated humanised mice at endpoint were stained with
haematoxylin and eosin. Sections of liver, skin, ear, lung and duodenum from humanised mice
were examined for evidence of histological GVHD. Images representative of 3-7 mice per
treatment group. Scale bars represent 100 µm.
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detection limit of the assay. As such, serum concentration of hIL-2 (P = 0.48), hIL-4
(P = 0.14), hIL-5 (P > 0.99), hIL-6 (P = 0.96), hIL-9 (P = 0.85), hIL-10
(P unable to be determined), hIL-13 (P = 0.47), hIL-17A (P = 0.74), hIL-17F (P unable
to be determined), hIL-21 (P > 0.99) or hIL-22 (P = 0.59) were similar between treatment
groups (Figure 6.9a-k). Serum concentrations of hTNFα were slightly increased
(P = 0.090) in PTCy+BBG-treated mice compared to PTCy+Saline-treated mice but this
small difference was largely due to an outlier (Grubb’s test) in the PTCy+BBG group
(Figure 6.9l). hIFNγ was detected in more mice than any other cytokine (four of eleven
PTCy+Saline and five of ten PTCy+BBG), however there was no difference between
treatment groups (P = 0.63) (Figure 6.9m).

6.3.Discussion
The current chapter aimed to determine if combinational therapy with PTCy and BBG
could prevent disease better and increase hTregs further than PTCy alone in a humanised
mouse model of GVHD. This chapter demonstrated that combinational therapy with
PTCy+BBG reduced histological liver GVHD at endpoint, corresponding with increased
splenic hTregs at day 21 and reduced serum hIFNγ at endpoint. Further, while not
statistically significant, improved trends in weight loss and clinical score were developing
at day 70 in PTCy+BBG-treated mice compared to PTCy+Saline-treated mice. Together,
this chapter indicates that P2X7 antagonism can provide some additional benefits to, and
does not impede, PTCy-mediated reductions in GVHD.
6.3.1. Combinational PTCy+BBG therapy and clinical and histological GVHD
Combinational therapy with PTCy+BBG showed improved trends in clinical score and
weight loss. This improvement in clinical score and weight change in mice treated with
PTCy+BBG began developing from day 55 in the current chapter but was not significant
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Figure 6.9: Serum cytokines are not detectable in the majority of mice treated with PTCy
at day 21. (a) hIL-2, (b) hIL-4, (c) hIL-5, (d) hIL-6, (e) hIL-9, (f) hIL-10, (g) hIL-13, (h) hIL17A, (i) hIL-17F, (j) hIL-21, (k) hIL-22, (l) TNFα and (m) hIFNγ concentrations in sera from
PTCy+Saline- and PTCy+BBG-treated humanised mice were examined by LEGENDplex. (a-m)
Data presented as mean ± SEM. Symbols represent individual mice (n = 11 PTCy+BBG; n = 11
PTCy+Saline). Significance was determined by (a-e, g, h, j-m) Mann Whitney test. (f, i)
Significance unable to be determined as all values in both groups are equal. P values as shown.

by day 70, the ethically approved endpoint at the time of this study. In the absence of
PTCy, differences in clinical score between saline- and BBG-treated mice began from
day 30 but were statistically significant from day 50 onwards (Section 4.2.2). As such,
there remains the possibility that significant treatment-dependent differences in clinical
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score, weight loss or survival may have developed after day 70. Future studies could
determine if these differences develop by increasing the endpoint to 100 days or longer.
Similar to previous work from our group, which used the same dose of PTCy in the same
humanised mouse model (Adhikary, 2020), the current chapter indirectly demonstrated
PTCy treatment delays GVHD onset in humanised mice when compared to GVHD
development in untreated humanised mice (Section 3.2.2), despite the injection of 50 %
less hPBMCs in this prior chapter. Adhikary (2020) demonstrated that humanised mice
treated with PTCy developed clinical signs of GVHD, including weight loss, from day
30. Further, survival of PTCy-treated mice was increased compared to non-PTCy-treated
mice with a MST of 52 and 30.5 days respectively (Adhikary, 2020). The current chapter
showed similar trends, with clinical GVHD also developing from day 30 in all
PTCy-treated mice, however both treatment groups had minimal weight loss and
prolonged survival, with MSTs beyond day 70 for both treatment groups. This increase
in survival time from Adhikary (2020) is unlikely due to the additional 11 injections of
either saline (or BBG) early in disease counteracting early weight loss. This notion is
based on comparisons between non-treated humanised mice (Section 3.2.2) and
saline-treated humanised mice (Section 4.2.2), which indicate that the additional 11
injections does not impact weight change, disease onset or survival. As such, it is likely
that the increased survival of all mice observed in the current chapter is due to human
donor variation. This impacts comparisons to previous studies as discussed below.
PTCy (Adhikary, 2020; Ganguly et al., 2014) and BBG (Section 4.2.4) (Geraghty et al.,
2017; Geraghty et al., 2019d; Zhong et al., 2016) significantly reduce histological liver
GVHD in allogeneic and humanised mice. The current chapter demonstrates that the
effects of these two compounds are complementary in the liver. Furthermore, PTCy
reduced histological skin GVHD in allogeneic (Ganguly et al., 2014), but not humanised
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mice (Adhikary, 2020) and BBG reduced histological GVHD in ear skin of humanised
mice (Section 4.2.4). Similar trends were observed in the current chapter, with
combinational therapy partially reducing histological GVHD in the skin and ear. Similar
to previous work (Chapters 3-5) (Adhikary, 2020), evidence of histological GVHD was
absent in the duodenum, indicating that combinational therapy is not inducing damage in
this tissue.
For the first time following PTCy treatment in mice with GVHD, lungs were assessed for
histological damage. Chapter 4 indicated that lungs from saline-treated mice had
20-40 % clear alveoli space while BBG-treated mice had 30-70 % clear alveoli space
(Section 4.2.4). In the current chapter, clear alveoli space ranged from 10-40 % in both
treatment groups suggesting that PTCy alone or in combination with BBG may have
worsened histological lung GVHD in this study. Whether this simply reflects differences
between studies, or that PTCy can partly abrogate the benefits of BBG remains unknown.
In support of the latter, cyclophosphamide has long been used as a chemotherapeutic
agent and has been linked to various lung complications including interstitial pneumonia
and pulmonary fibrosis (Langford, 1997; Segura et al., 2001). While higher doses of
cyclophosphamide (>120 mg/kg) are more commonly associated with toxic effects, lower
doses (<40 mg/kg) can also cause toxicity in cancer patients (Emadi et al., 2009).
Moreover, recent evidence suggests that PTCy in allogeneic HSCT patients is associated
with increased viral respiratory infections (Mulroney et al., 2021), as well as CMV
infections (Goldsmith et al., 2021), which can cause pneumonia in allogeneic HSCT
recipients (Iglesias et al., 2017). As such, the effects of cyclophosphamide on lung GVHD
should be further examined in mouse models and/or allogeneic HSCT recipients treated
with PTCy.
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6.3.2. Combinational PTCy+BBG therapy and hTregs
Combinational PTCy+BBG therapy increased the proportion of hTregs at day 21 and
significantly increased the proportion of these cells that express hCD39 +. The total
number of splenic hTregs and hCD39 + hTregs were partially increased by this
combinational therapy at endpoint. Together this indicates that BBG is a potential therapy
for increasing suppressive hTregs during PTCy. CD39 + Tregs have greater suppressive
effects than CD39 - Tregs (Borsellino et al., 2007) and can reduce GVHD in humanised
mice (Gu et al., 2017). Despite a smaller increase in hTregs in PTCy+BBG vs
PTCy+Saline (Section 6.2.5) compared to BBG vs saline (Section 4.2.6), observed
increases in hCD39 + hTregs may explain why GVHD was partially reduced in the current
chapter. CD39 + Tregs have reduced expression of P2X7 compared to CD39 - Tregs
(Cortés-Garcia et al., 2016) so should be less susceptible to P2X7-mediated cell death.
Though it remains a possibility, it is unlikely BBG is selectively protecting hCD39 +
hTregs in the current chapter as BBG alone did not alter hCD39 + hTregs in humanised
mice (Chapter 4) and decreased these cells in vitro (Section 4.2.10). Further, PTCy alone
did not alter these cells in humanised mice (Adhikary, 2020). However, the possibility
remains that P2X7 blockade may be altering the differentiation of hTregs in vivo (Schenk
et al., 2011), or that the combination of PTCy+BBG may be having an unknown effect
on these cells. This could be studied in vitro using a cyclophosphamide analogue such as
mafosfamide, or in vivo by examining the effects of combinational treatment on sorted
CD39 + or CD39 - Tregs in mice.
Increases in hTregs at day 21 in PTCy+BBG-treated mice compared to
PTCy+Saline-treated mice were diminished by endpoint, similar to Chapter 4. Despite
this, clinical GVHD was still worsening at day 70 in PTCy+Saline-treated mice but
remaining stable in PTCy+BBG-treated mice. This indicates that early increases in
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hTregs can reduce GVHD but not abolish disease. Likewise, the increase in hTregs was
associated with reduced histological GVHD in the liver at endpoint, similar to BBG
previously (Chapter 4). As such, future studies should use immunohistochemistry and/or
flow cytometry to examine hTregs directly in the liver to determine if these suppressor
cells are directly diminishing inflammation in this tissue.
The current chapter indicated that PTCy+Saline- and PTCy+BBG-treated mice had
similar proportions of hTregs at endpoint compared to saline- and BBG-treated mice
(Section 4.2.3), although mice in the current chapter received twice as many hPBMCs
compared to similar studies in earlier chapters making direct comparisons hard to draw.
The current chapter also examined hTregs at day 21, but again, hTreg proportions in all
PTCy treated mice were similar to non-PTCy treated mice in Chapter 4, indicating that
PTCy did not selectively deplete these cells. Ganguly et al. (2014) demonstrated that
PTCy (200 mg/kg, day 3) increased donor Tregs in an allogeneic mouse model. The
inability of PTCy to increase Tregs in humanised mice in the current chapter is unlikely
due to differences in cyclophosphamide dosage as Tregs also expand in allogeneic mice
treated with a lower dose of PTCy (25 mg/kg, day 3, 4) (Wachsmuth et al., 2019). As
such, these differences are likely due to differences in the allogeneic and humanised
mouse models, such as the absence of adequate human growth factors in humanised mice
(Theocharides et al., 2016), which may prevent the expansion of these cells.
Alternatively, donor variation may indicate hTregs are responding differently to
treatments, compared to a previous study using PTCy (Adhikary, 2020), in this
humanised mouse model.
A previous study indicated that PTCy (200 mg/kg, day 3) treatment increased
thymically-derived (natural) Tregs, but not peripherally-derived (induced) Tregs in the
blood and spleen of allogeneic mice, and this increase was associated with reduced
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GVHD (Ganguly et al., 2014). Additionally, artificially induced Tregs have also been
shown to prevent GVHD in allogeneic (Semple et al., 2011) and humanised (Sato et al.,
2020) mouse models. As such, it appears that both natural and induced Tregs play a role
in GVHD. Further, blockade of P2X7 on naive CD4 + T cells, following TCR activation,
can induce their conversion to Tregs (Schenk et al., 2011). Thus, it is possible BBG
treatment in the current chapter is inducing hTreg development instead of, or as well as,
preventing P2X7-mediated cell death, leading to increases in these cells early in disease.
Future studies could use cell sorting and in vitro expansion to examine natural and
induced Tregs separately in the humanised mouse model of GVHD, particularly under
the effects of PTCy and/or BBG treatment.
6.3.3. Combinational PTCy+BBG therapy and engraftment
The current chapter demonstrated that combinational therapy did not impede the
engraftment of human immune cells. Mice in both treatment groups engrafted both hCD4+
and hCD8 + T cell subsets with some mice engrafting low amounts of B cells and NK cells
in the spleen consistent with previous chapters. Notably, despite similar proportions of
splenic hCD4 + and hCD8 + T cells in both groups at Day 21, by endpoint the ratio of
splenic hCD4 + to hCD8 + T cells was 1:2, paralleling the ratio of these T cell subsets in
the spleens of healthy individuals (Langeveld et al., 2006). This suggests that either
treatment leads to normal hT cell engraftment in mice. Furthermore, despite BBG
increasing hB cell engraftment previously (Section 4.2.6), combinational therapy with
PTCy+BBG did not increase hB cell engraftment compared to PTCy alone. PTCy
treatment in HSCT recipients depletes B cells but allows the recovery of these cells to
pre-treatment levels within as little as 2-3 months (Kanakry et al., 2016a). However,
humanised mice consistently reveal absent or negligible hB cell engraftment (Geraghty
et al., 2017; Geraghty et al., 2019a; Geraghty et al., 2019c, 2019d) and mice treated with

194

PTCy alone or saline displayed negligible engraftment of hB cells (Adhikary, 2020). As
such, it is likely P2X7 blockade on hB cells was insufficient to prevent their depletion by
PTCy in the current chapter, and without sufficient growth factors these cells did not
recover. As discussed in depth previously (Section 4.3.3), it is unknown whether hB cells
play a pro- or anti-inflammatory role in this humanised mouse model. Therefore, it is
unknown if depletion of these cells by PTCy is beneficial or detrimental.
6.3.4. Combinational PTCy+BBG therapy and serum cytokines
Combinational therapy reduced serum hIFNγ, but not other T cell cytokines, in the current
chapter. Previous studies indicated that PTCy alone does not reduce IFNγ in either
allogeneic (Wachsmuth et al., 2019) or humanised (Adhikary, 2020) mouse models of
GVHD. In contrast, P2X7 blockade reduces IFNγ in both allogeneic (Fowler et al., 2014;
Wilhelm et al., 2010) and humanised (Section 4.2.9) (Geraghty et al., 2017) mouse
models. Thus, the reduction of hIFNγ is most likely due to P2X7 blockade, again
suggesting this treatment can provide additional benefits to PTCy alone. As discussed
previously (Chapter 4), this decrease in hIFNγ may be due to increases in hTregs which
can reduce serum IFNγ (Edinger et al., 2003; Hu et al., 2020a) or due to direct blockade
of P2X7 on DCs, which would reduce stimulation of effector T cells (Ghiringhelli et al.,
2009). P2X7 blockade has been shown to reduce serum TNFα and IL-6 in allogeneic mice
(Fowler et al., 2014). However, combinational therapy did not reduce serum TNFα or
IL-6 in the current chapter compared to PTCy alone indicating that BBG is unlikely to
alter these cytokines in humanised mice. Consistent with this, blockade of CD39 and
CD73, which may increase extracellular ATP (Covarrubias et al., 2016), does not alter
serum IL-6 or TNFα in this humanised mouse model of GVHD (Geraghty et al., 2019c).
The current chapter examined, for the first time, human cytokine levels at day 21 in
humanised mice treated with PTCy. The majority of cytokines examined were
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undetectable at day 21 despite being detected at endpoint. These findings parallel previous
chapters (Chapters 4, 5) which revealed lower amounts of serum hIFNγ at day 21
compared to endpoint in humanised mice. Reduced cytokine concentrations at early
timepoints are likely due to reduced effector T cell numbers in the early stages of this
humanised mouse model (King et al., 2008). Additionally, PTCy is known to reduce
serum cytokines, including IL-2, IL-4, IL-5, IL-6 and IL-13, in allogeneic mice
(Wachsmuth et al., 2019). As such, the depletion and/or suppression of reactive donor
T cells by PTCy is likely impairing the ability of these cells to produce and release
cytokines, especially early in disease. This could be confirmed by examining a wider
range of cytokines in humanised mice not treated with PTCy at day 21.
6.3.5. Conclusion
In conclusion, this chapter demonstrated that P2X7 blockade with BBG in combination
with PTCy enhanced protection against GVHD in humanised mice compared to PTCy
alone. Histological liver GVHD was reduced with differences in clinical disease
becoming larger as time went on. These reductions in GVHD were accompanied by
increased donor hTregs, particularly splenic hCD39+ hTregs, and reduced serum hIFNγ.
Notably, BBG did not diminish the beneficial effects provided by cyclophosphamide,
suggesting that P2X7 blockade may be able to be used with PTCy, if ever used clinically.
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Chapter 7: P2X7 antagonism in the SOD1G93A mouse model of ALS
7.1. Introduction
ALS is the most common form of motor neuron disease (Talbott et al., 2016) and is
characterised by the death of both upper and lower motor neurons resulting in muscle
weakness and paralysis that worsens over time, eventually leading to death (Brown et al.,
2017). ALS is currently incurable and approved therapies, riluzole and edavarone, have
limited clinical benefits (Jaiswal, 2019). As such, there is a need for new ALS treatments.
P2X7 plays multiple roles during ALS development. P2X7 is upregulated in the spinal
cords of patients (Yiangou et al., 2006) and SOD1 G93A rats (Casanovas et al., 2008) with
ALS. P2X7 activation on astrocytes and microglia from SOD1 G93A mice and rats leads to
motor neuron death (D'Ambrosi et al., 2009; Gandelman et al., 2010), and P2X7
activation on motor neurons can also directly induce cell death (Gandelman et al., 2013).
As motor neurons die they could release ATP, initiating a positive feedback loop that
activates P2X7 on nearby cells, promoting further motor neuron death and worsened
ALS.
Previous studies have shown that blockade of P2X7 in SOD1 G93A mice with BBG, a
compound which does not readily cross the BBB (Bhattacharya et al., 2016), from disease
onset (first signs of clinical disease) improved motor coordination (Apolloni et al., 2014;
Cervetto et al., 2013) and reduced weight loss (Bartlett et al., 2017a; Cervetto et al.,
2013). These studies suggest that blockade of P2X7 outside the CNS can reduce, but not
prevent, ALS in SOD1 G93A mice, and indicate that the effects of CNS P2X7 blockade
have not been fully explored.
The CNS penetrant P2X7 antagonist JNJ-47965567 was originally described as a
competitive inhibitor of human and rat P2X7 (Bhattacharya et al., 2013), but activity and
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structural studies revealed that it acts as a non-competitive antagonist against pdP2X7
(Karasawa et al., 2016). The mechanism of action of JNJ-47965567 against P2X7 from
other species, including mice, remains to be elucidated. However, JNJ-47965567 has
shown efficacy in neurological disorders such as neuropathic pain (Bhattacharya et al.,
2013) and epilepsy (Fischer et al., 2016; Jimenez-Pacheco et al., 2016). Recent work
from our group indicated that JNJ-47965567 (30 mg/kg, thrice per week, from disease
onset: day 97 - 104 until endpoint) did not alter clinical score, weight loss, motor
coordination or survival in SOD1 G93A mice (Dongol, 2018), but other molecular and
cellular effects of P2X7 blockade in these mice were not examined.
P2X7 has attracted interest as a therapeutic target for ALS due to its expression on
microglia and astrocytes (Jimenez-Mateos et al., 2019). However, as repeatedly
illustrated throughout this thesis, P2X7 is also expressed on T cells, and P2X7 activation
on other leukocytes typically results in pro-inflammatory effects (Di Virgilio et al., 2017).
Moreover, there is increasing evidence that various T cell subsets are altered in ALS
patients and that increased Treg proportions are associated with reduced ALS (Gustafson
et al., 2017; Henkel et al., 2013; Murdock et al., 2017; Sheean et al., 2018). Finally, there
is evidence to suggest pro-inflammatory cytokines are increased in ALS patients (Hu et
al., 2017) and SOD1 G93A mice (Jeyachandran et al., 2015), and that systematic cytokines
are involved in ALS progression (McCombe et al., 2020).
The current chapter aimed to elucidate the mechanism of action of JNJ-47965567 against
mouse P2X7 and then to analyse data and tissues from a recently completed preclinical
trial using JNJ-47965567 in SOD1 G93A ALS mice (Dongol, 2018).
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7.2.Results
7.2.1. JNJ-47965567 inhibits murine P2X7 in a non-competitive manner
JNJ-47965567 is a CNS-penetrant P2X7 antagonist (Bhattacharya et al., 2013) but
conflicting studies report it as a competitive (Bhattacharya et al., 2013) or
non-competitive (Karasawa et al., 2016) antagonist against rat and panda P2X7,
respectively. Therefore, JNJ-47965567 was characterised against murine P2X7 using
ATP-induced dye uptake in murine J774 macrophage cells, which express functional
P2X7 (Coutinho-Silva et al., 2005). To determine the EC50 value of ATP against P2X7,
these J774 cells were incubated with ethidium + and varying concentrations of ATP before
uptake was measured by flow cytometry (Figure 7.1a). ATP-induced ethidium + uptake
in J774 cells was concentration-dependent with a maximal response at 3 mM and an EC50
of 510 ± 96 μM (Figure 7.1b). J774 cells were pre-incubated with vehicle (DMSO) or
varying concentrations of JNJ-47965567, then with ethidium + and 500 μM ATP
(approximate EC50). JNJ-47965567 impaired ethidium + uptake in a concentrationdependant manner with 100 % inhibition at 30 μM and an IC 50 of 54 ± 24 nM (Figure
7.1c). Finally, J774 cells were pre-incubated with vehicle or 0.03 μM, 0.3 μM or 3 μM
JNJ-47965567 followed by ethidium+ and varying concentrations of ATP. In the presence
of vehicle alone, ATP induced ethidium + uptake with an EC50 of 360 ± 27 μM (Figure
7.1d). J774 cells incubated with 0.03 μM, 0.3 μM or 3 μM JNJ-47965567 had ATP EC50
values of 520 ± 13 μM, 1020 ± 61 μM and 1850 ± 40 μM, respectively (Figure 7.1d).
Maximal P2X7-mediated ethidium + uptake responses were reduced as the concentration
of JNJ-47965567 increased, with maximal responses of 89 ± 2 %, 61 ± 4 % or
37 ± 0.5 % for 0.03 μM, 0.3 μM or 3 μM JNJ-47965567, respectively (Figure 7.1d). This
inhibition of maximal responses by JNJ-47965567 is consistent with a non-competitive
mode of inhibition (Hall et al., 2010).
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Figure 7.1: JNJ-47965567 inhibits murine P2X7 in a non-competitive manner. (a, b) J774
cells were incubated with ethidium+ in the absence (basal) or presence of ATP for 5 min. (c-d)
J774 cells were preincubated with JNJ-47965567 (JNJ) (as indicated) or vehicle (DMSO) for 15
min, then with 25 μM ethidium + in the absence or presence of (c) 500 μM ATP or (d) ATP (as
indicated) for 5 min. (a-d) ATP incubations were halted by the addition of ice-cold Mg2+ and
centrifugation. Ethidium+ uptake was assessed (a) in single J774 cells with a consistent flow
cytometry gating strategy. (b-d) Basal fluorescence was subtracted to determine the ATP-induced
fluorescence in each sample and data were normalised to the maximal ATP-induced response in
each experiment. Data is presented as mean ± SEM (n = 3 independent experiments).
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7.2.2. JNJ-47965567 increases Nqo1 spinal cord gene expression in SOD1 G93A
mice at endpoint
Our group has previously examined the CNS-penetrant P2X7 antagonist JNJ-47965567
in SOD1 G93A mice (Dongol, 2018). In this prior study, SOD1 G93A mice were injected i.p.
with 30 mg/kg JNJ-47965567 or vehicle, β-CD (control mice) thrice weekly from disease
onset until endpoint. This regime did not impact disease progression (Appendix Figure
A7.1), but various tissue samples were collected and stored, or analysed, at endpoint. To
determine if JNJ-47965567 affected molecular CNS parameters in SOD1 G93A mice, RNA
was isolated from stored spinal cords of JNJ-47965567-treated and control mice, and the
expression of 760 genes was analysed by NanoString. Three mice of each sex treated with
JNJ-47965567 were randomly selected and matched, for sex and age, with control mice.
Analysis of spinal cord RNA revealed a large number (504) of genes were upregulated,
and a smaller number (140) downregulated, in JNJ-47965567-treated mice compared to
control mice (Figure 7.2a). However, after correcting for the false discovery rate, using
the Bonferroni test, there were no statistically significant differences in expression for
any gene. Fold-change of expression for the twenty most different genes, when ordered
by corrected P value, in JNJ-47965567-treated mice compared to control mice are shown
in Table 7.1.
To determine if qPCR of a larger number of samples could reveal significant differences,
expression of Nqo1, the top ranked gene from NanoString analysis (log2 fold-change of
-2.2, P = 0.090), and P2rx7, which ranked twelfth (log2 fold-change of 1.8, P = 1), were
further examined. Expression of these genes in spinal cord RNA from the twelve mice
used for NanoString analysis, as well as spinal cord RNA from a further six
JNJ-47965567-treated mice and two control mice was determined after converting this
RNA to cDNA. Contrary to the NanoString analysis, qPCR analysis revealed increased
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Nqo1 expression in JNJ-47965567-treated mice compared to control (P < 0.05) (Figure
7.2b), while P2rx7 expression was similar between groups (P = 0.38) (Figure 7.2c).

Figure 7.2: JNJ-47965567 increases Nqo1 spinal cord gene expression in SOD1 G93A mice at
endpoint. (a-c) RNA was isolated from spinal cords of JNJ-treated or control SOD1G93A mice at
endpoint and analysed by (a) NanoString or (b, c) converted to cDNA and the relative expression
of (b) Nqo1 or (c) P2rx7 determined by qPCR. Data presented as (a) a volcano plot showing
relative mean change in gene expression (n = 6 per group) or (b, c) mean ± SEM (n = 9 control;
n = 12 JNJ). Symbols represent individual (a) genes or (b, c) mice. Significance determined by
(a) nSolver Advanced Analysis software or (b, c) Mann Whitney test. P values as shown.

Table 7.1 Top 20 genes altered by JNJ-47965567 in the spinal cord at endpoint. RNA from
spinal cords of SOD1G93A mice at endpoint was analysed by NanoString to determine if JNJ
altered expression. Fold change is JNJ compared to control (n = 6 per treatment).
Gene
Nqo1
Gga1
Cntn4
Pllp
Mal
Plcb1
Ugt8a
Cdkn1a
Bcl2l1
Jam3
Gnai1
P2rx7
Pla2g16
Arhgef10
Fa2h
Plcb4
Cers2
Gria3
Pmp22
Nf1

Log2 (fold change)
± SEM
-2.2 ± 0.4
-2.0 ± 0.4
-1.7 ± 0.4
1.6 ± 0.6
1.8 ± 0.6
1.0 ± 0.3
1.7 ± 0.6
1.7 ± 0.6
1.6 ± 0.5
1.5 ± 0.6
1.1 ± 0.4
1.8 ± 0.7
1.5 ± 0.6
1.5 ± 0.6
1.5 ± 0.6
0.9 ± 0.4
1.4 ± 0.6
1.1 ± 0.5
2.2 ± 0.9
1.0 ± 0.4

P value
0.00014
0.00030
0.0024
0.018
0.018
0.019
0.019
0.019
0.022
0.024
0.026
0.025
0.027
0.027
0.027
0.030
0.030
0.033
0.034
0.035

Corrected P value
(Bonferroni)
0.0897
0.193
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
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7.2.3. JNJ-47965567 does not alter proportions of T cell subsets in SOD1 G93A
mice at endpoint
As mentioned earlier, immune cells, including T cells, express P2X7 (Di Virgilio et al.,
2017) and are involved in ALS (Gustafson et al., 2017; Murdock et al., 2017). Previous
studies examining P2X7 blockade in SOD1 G93A mice did not examine systemic T cells
(Apolloni et al., 2014; Cervetto et al., 2013; Fabbrizio et al., 2017) or only examined
them in the spleen (Bartlett et al., 2017a). Therefore, the current chapter determined if the
CNS-penetrant P2X7 antagonist JNJ-47965567 altered the proportion of various T cell
subsets in the CNS draining and non-draining lymph nodes and spleens of SOD1 G93A
mice. T cells in these three lymphoid tissues were examined by flow cytometry (Figure
7.3) with proportions of T cell subsets presented in Table 7.2. There was no significant
difference in the proportions of total CD4 + or CD8 + T cells, conventional CD4 + T cells
(CD4 +Foxp3 -) or Tregs (CD4 +Foxp3 +) between treatment groups within any of the three
tissues analysed. Furthermore, there was no difference in the proportion of activated
(CD44 +) CD4 +, CD8 +, conventional CD4 + T cells or Tregs within any of the tissues
between treatment groups. CD39 is an ectonucleotidase expressed on immune cells,
including T cells (Borsellino et al., 2007; Purvis et al., 2014), and can hydrolyse
extracellular ATP, potentially limiting the activation of P2X7 on these, and nearby, cells.
The expression of CD39 on activated CD4 +, CD8 +, conventional CD4 + T cells or Tregs,
however, was similar between treatment groups in all tissues.
7.2.4. JNJ-47965567 does not alter proportions of DC subsets in SOD1 G93A mice
at endpoint
DCs in spinal cord tissues have been implicated in the pathogenesis of ALS (Henkel et
al., 2004) and may contribute to inflammation by recruiting other immune cells in ALS
(Rusconi et al., 2017). Despite this, DCs have not been well studied in either ALS patients
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Figure 7.3: Flow cytometry gating strategy for the identification of T cell subsets in
SOD1G93A mice. Live single cells from the draining and non-draining lymph nodes and spleen
from SOD1G93A mice at endpoint were gated as shown and proportions of CD4 +, CD8+,
CD4+FoxP3+ regulatory T (Treg) or conventional CD4 + T (Tconv) cells were determined. These
T cell subtypes were further divided into CD44+ or CD44- subtypes and CD39 MFI on each of
these cell subsets was determined (Table 7.2). Images displayed are from a representative spleen
sample.

or mouse models of disease. Therefore, DCs in CNS draining lymph nodes of control and
JNJ-47965567-treated SOD1 G93A mice were compared to non-draining lymph nodes
examined by flow cytometry (Figure 7.4) with proportions presented in Table 7.3. There
was no difference in the proportions of conventional DCs (CD11c hiMHC class IIint) or
migratory DCs (CD11cintMHC class IIhi) in the CNS draining or non-draining lymph
nodes between treatment groups. The two major DC subtypes, CD11b+ DCs and CD11bDCs (CD8 + DCs) (Merad et al., 2013), in both DC categories, were also examined. Again,
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Table 7.2: JNJ-47965567 does not alter proportions of T cell subsets in SOD1 G93A mice at
endpoint. Spleens and CNS draining and non-draining lymph nodes from control and JNJ-treated
SOD1G93A mice at endpoint were examined by flow cytometry and proportions of T cell subsets
and CD39 MFI was determined. Data presented as mean ± SEM (n = 14 control; n = 19-21 JNJ).
Differences between control and JNJ were not statistically significant using a unpaired Student’s
t test.
Spleen
Cell Type
Control
JNJ
+
% CD4
55 ± 0.7
54 ± 2.1
+
% CD44
19 ± 1.1
17 ± 0.8
CD39 MFI
18 ± 3.8
15 ± 2.0
a
+
% Treg (Foxp3 ) 13 ± 0.7
13 ± 0.5
% CD44+
26 ± 1.7
23 ± 1.1
CD39 MFI
27 ± 6.6
21 ± 2.1
b
% Tconv (Foxp3 ) 87 ± 0.7
87 ± 0.5
% CD44+
18 ± 1.2
17 ± 0.9
CD39 MFI
16 ± 3.4
14 ± 1.9
+
% CD8
33 ± 1.7
35 ± 0.7
% CD44+
15 ± 1.3
13 ± 0.8
CD39 MFI
6.4 ± 1.8 5.3 ± 1.3
aRegulatory T cell, b conventional CD4+ T cell

Draining lymph node Non-draining lymph node
Control
JNJ
Control
JNJ
48 ± 1.0
50 ± 0.6
49 ± 1.4
50 ± 0.8
16± 0.8
16 ± 0.8
14 ± 1.0
14 ± 0.8
8.9 ± 1.1 9.0 ± 0.9 10 ± 2.2
8.0 ± 0.8
17 ± 0.7
18 ± 0.9
14 ± 0.6
15 ± 0.7
40 ± 1.7
38 ± 1.6
43 ± 2.2
43 ± 1.9
15 ± 2.1
14 ± 1.4
20 ± 4.4
16 ± 1.3
83 ± 0.7
82 ± 1.0
86 ± 0.6
85 ± 0.7
11 ± 0.8
12 ± 0.7 9.2 ± 0.7
9.5 ± 0.6
5.9 ± 0.7 6.2 ± 0.7 5.9 ± 1.3
4.4 ± 0.5
41 ± 2.7 42. ± 0.8 41 ± 2.1
41 ± 1.2
16 ± 1.3
13 ± 0.6
15 ± 1.6
15 ± 0.5
3.4 ± 0.6 2.6 ± 0.2 5.4 ± 1.7
2.9 ± 0.3

Figure 7.4: Flow cytometry gating strategy for the identification of DC subsets in SOD1G93A
mice. Live single cells (gated as per Figure 7.3) from the CNS draining and non-draining lymph
nodes from SOD1G93A mice were gated as shown and proportions of conventional DCs (cDC)
(CD11chi MHC class II int ) and migratory DCs (mDCs) (CD11cint MHC class II hi ) were determined.
These DCs were further divided into CD11b + or CD11b- subtypes and CD80 MFI on all DC
subsets was determined (Table 7.2). Images displayed are from a representative CNS draining
lymph node.
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Table 7.3: JNJ-47965567 does not alter proportions of DC subsets in SOD1 G93A mice at
endpoint. CNS draining and non-draining lymph nodes from control and JNJ-treated SOD1G93A
mice at endpoint were examined by flow cytometry and proportions of DC subsets and CD80
MFI was determined. Data presented as mean ± SEM (n = 10-13 control; n = 17-18 JNJ).
Differences between control and JNJ, or draining and non-draining lymph nodes were not
statistically significant using a unpaired Student’s t test.
Draining lymph node
Cell Type
Control
JNJ
a
hi
int
% cDC (CD11c MHC class II ) 0.24 ± 0.25 0.27 ± 0.04
CD80 MFI
31 ± 6.7
45 ± 9.7
+
% CD11b
39 ± 3.7
39 ± 3.7
CD80 MFI
57 ± 8.5
83 ± 14.8
% CD11b57 ± 3.8
57 ± 3.7
CD80 MFI
17 ± 2.6
24 ± 3.3
b
int
hi
% mDC (CD11c MHC class II ) 0.94 ± 0.15 0.74 ± 0.11
CD80 MFI
4.2 ± 1.7
11 ± 4.6
+
% CD11b
38 ± 1.6
40 ± 1.7
CD80 MFI
6.4 ± 3.6
15 ± 6.2
% CD11b
58 ± 1.8
57 ± 1.8
CD80 MFI
3.1 ± 0.94
8.6 ± 4.1
aConventional dendritic cell, b migratory dendritic cell

Non-draining lymph node
Control
JNJ
0.76 ± 0.15 0.87 ± 0.14
20 ± 3.8
42 ± 8.4
24 ± 3.1
30 ± 2.1
75 ± 18.1
107 ± 27.6
76 ± 3.1
70 ± 2.1
14 ± 2.8
28 ± 5.6
1.0 ± 0.35
0.84 ± 0.13
3.2 ± 0.68
13 ± 6.2
29 ± 3.9
29 ± 2.5
6.5 ± 2.3
19 ± 7.6
71 ± 3.9
71 ± 2.5
2.7 ± 1.7
12 ± 5.9

there was no difference in CD11b+ or CD11b - conventional or migratory DC proportions
between treatment groups in either lymph node. Further, there was no significant
difference between treatment groups in expression of CD80, a DC activation marker, on
any of the aforementioned DC subsets. Moreover, there was no significant difference in
any DC subset between the CNS draining or non-draining lymph nodes within each
treatment group. Conventional and migratory DCs were absent or near absent in the
majority of spleens, so DC subsets were not examined (data not shown).
7.2.5. JNJ-47965567 does not alter serum cytokine concentration in SOD1 G93A
mice at endpoint
Systemic cytokines are increased in ALS patients (Hu et al., 2017; Tortelli et al., 2020)
and SOD1 G93A mice (Jeyachandran et al., 2015), and are involved in ALS progression
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(McCombe et al., 2020). Further, P2X7 is involved in cytokine release during
neurodegeneration (Oliveira-Giacomelli et al., 2021). Therefore, serum from endpoint
control and JNJ-47965567-treated mice was examined by a flow cytometric
LEGENDplex assay to determine if treatment could alter cytokine concentrations. There
was no significant difference in the concentration of any of the thirteen cytokines
measured between treatment groups, although differences in MCP-1 concentrations did
approach significance (P = 0.077) (Figure 7.5). Notably, mean concentrations of IL-27,
IFNβ ad IL-10 were approximately one log greater than the other ten cytokines examined
with a rank order of IL-27 > IFNβ > IL-10 > IL-1β = IL-6 = IL-17A = GM-CSF > IL-23
= MCP-1 = TNFα > IL-1α = IFNγ > IL-12p70.

Figure 7.5: JNJ-47965567 does not alter serum cytokine concentration in SOD1 G93A mice at
endpoint. Serum from control and JNJ-treated SOD1G93A mice at endpoint was analysed by a
flow cytometric LEGENDplex assay to determine the concentration of thirteen cytokines.
Cytokines are listed (left to right) in rank order of concentration (high to low). Data presented as
mean ± SEM and presented as two seperate panels to better illustrate individual values. Symbols
represent individual mice (n = 20 for each treatment). Differences between control and JNJ were
not statistically significant using a Mann Whitney test.

7.3.Discussion
The current chapter demonstrated that JNJ-47965567 acts as a non-competitive inhibitor
against murine P2X7 and when used in vivo it altered Nqo1 expression in the spinal cord
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of SOD1 G93A ALS mice but had limited effects on immune cells and serum cytokines.
During the course of this thesis, and following our publication which includes data from
this chapter (Ly et al., 2020), Ruiz-Ruiz et al. (2020) demonstrated that JNJ-47965567
administered four times per week prior to disease onset could significantly delay and
reduce ALS progression in female SOD1 G93A mice. Thus, the absence of differences
between treatment groups in the current chapter may reflect under dosing, but
comparisons at endpoint only cannot be excluded as an explanation for the limited
differences observed between groups. Furthermore, another study published during the
course of this thesis used the propriety P2X7 antagonist AXX71 in SOD1 G93A mice and
demonstrated that P2X7 blockade reduced markers of inflammation, including IL-1β in
the spinal cord, but did not prolong mouse survival (Apolloni et al., 2021). Neither of
these two studies examined immune cell populations or serum cytokines, and only
Apolloni et al, (2021) examined gene expression. As such, comparisons between these
studies and the current chapter are limited.
7.3.1. JNJ-47965567 as a non-competitive antagonist
The current chapter aimed firstly to elucidate the mechanism of action of JNJ-47965567
against mouse P2X7. Pharmacological studies using a P2X7-mediated dye uptake assay
demonstrated that JNJ-47965567 acts in a concentration-dependent, non-competitive
manner against mouse P2X7. This is consistent with a previous study, using molecular
modelling and a similar dye uptake assay, that reported JNJ-47965567 interacts with the
non-competitive drug binding site on panda P2X7 (Karasawa et al., 2016). Further,
inhibition curves for JNJ-47965567 in the current chapter closely resemble those shown
for other non-competitive antagonists (Karasawa et al., 2016). Contrary to the current
chapter, the original characterisation of JNJ-47965567 revealed this compound as a
competitive inhibitor against rat and human P2X7 (Bhattacharya et al., 2013). This
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former study demonstrated that JNJ-47965567 blockade was prevented when cells were
preincubated with the competitive P2X7 antagonist A-438079. The authors concluded
that JN-47965567J was binding to a similar site as A-438079, however it is possible the
binding of A-438079 to P2X7 induced a conformational change which reduced the ability
of JNJ-47965567 to bind P2X7. This is partially supported by Karasawa et al. (2016) who
proposed binding to the ATP pocket induces a conformational change that narrows the
allosteric drug binding pocket. However, it is unknown whether A-438079 produces this
conformational change. As such, the mode of inhibition of JNJ-47965567 against P2X7
from other species remains ambiguous.
7.3.2. JNJ-47965567 and gene expression in SOD1 G93A ALS mice
Despite no differences in clinical disease, weight loss, motor coordination or survival in
the preclinical trial using JNJ-47965567 in SOD1 G93A ALS mice (Dongol, 2018), the
current chapter aimed to determine if JNJ-47965567 treatment was altering molecular or
cellular effects in these mice. JNJ-47965567 altered gene expression in the spinal cords
of endpoint mice, although these differences were not significant once corrected for the
false discovery rate. Of these changes, downregulation of Nqo1 was the closest to
significance, however when examined by qPCR this difference reversed. This may be due
to differences in methodology between assays, or perhaps due to a smaller sample size in
the NanoString analysis compared to qPCR. Nqo1 encodes NAD(P)H dehydrogenase
(quinone 1) (NQO1), an enzyme which reduces oxidative stress (Beaver et al., 2019).
Increases in Nqo1 expression protect neuronal cells in a mouse model of Parkinson’s
disease (Son et al., 2015). Moreover, increased expression of, or polymorphisms in,
Nqo1, or the human equivalent NQO1, has been linked to other neuronal diseases,
including Alzheimer’s disease (Wang et al., 2006), multiple sclerosis (van Horssen et al.,
2006), tardive dyskinesia (Pae et al., 2004), mood disorders (Mendez-David et al., 2015)
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and atherosclerotic stroke (Shyu et al., 2010), where NQO1 is also thought to combat
oxidative stress (Beaver et al., 2019). As such, it is likely NQO1 plays a similar role in
ALS. Thus, P2X7 blockade may be having a beneficial effect and increasing expression
of this gene to prevent oxidative stress. Consistent with this, P2X7 blockade with BBG
downregulates NADPH oxidase in SOD1 G93A mice (Apolloni et al., 2014). NanoString
indicated that P2rx7 expression was increased in JNJ-47965567-treated mice. However,
qPCR demonstrated no difference in P2rx7 between treatments, aligning with other
studies which indicated P2X7 protein and gene expression were unaltered by P2X7
blockade (Apolloni et al., 2014; Bartlett et al., 2017a; Ruiz-Ruiz et al., 2020).
7.3.3. JNJ-47965567 and immune cells in SOD1 G93A mice
The current chapter examined the largest range of immune cell subsets in SOD1 G93A
treated with a P2X7 antagonist to date. Bartlett et al. (2017a) previously demonstrated
that treatment with BBG in SOD1 G93A mice did not alter CD4 + or CD8 + T cells, Tregs or
DCs in the spleen. The current chapter expanded these findings and showed that P2X7
antagonism did not alter T cell or DC subsets in the CNS draining or non -draining lymph
nodes. P2X7 activation on DCs leads to NLRP3 inflammasome activation (Ferrari et al.,
2000b) and the release of pro-inflammatory cytokines which prime pro-inflammatory
T cells (Ghiringhelli et al., 2009). Further, activation of P2X7 on T cells can directly
induce activation of these cells (Yip et al., 2009). As such, it is somewhat surprising that
JNJ-47965567 did not alter the proportions of activated T cells. Further, JNJ-47965567
did not alter the proportion of Tregs despite P2X7 blockade increasing Tregs in vitro
(Schenk et al., 2011) and in mouse models of renal ischemia-reperfusion injury (Koo et
al., 2017), muscular dystrophy (Gazzerro et al., 2015) and GVHD (Chapters 4-6). These
studies injected mice daily with P2X7 antagonists, while SOD1 G93A mice in the current
chapter, and in a previous study (Bartlett et al., 2017a), received injections thrice weekly.
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Therefore, it is possible that more frequent injections are required for P2X7 blockade to
have a noticeable effect on Tregs in ALS.
Additional to its role in the activation of the NLRP3 inflammasome, P2X7 on DCs can
contribute to the migration of these cells (Sáez et al., 2017). Further, extracellular ATP
increases CD80 on DCs in GVHD (Wilhelm et al., 2010) and P2rx7 knockout mice have
reduced CD80 expression, albeit on liver resident macrophages (Chatterjee et al., 2012).
Despite the involvement of ATP and P2X7 on DCs, JNJ-47965567 did not alter
proportions, or the activation, of these cells in either the CNS draining or non -draining
lymph node. Nor, was there a difference between the two tissues indicating that DC
migration was unaffected. Analysis of both T cells and DCs in the current chapter is
limited as these cells were only examined at endpoint. Examining the effect of P2X7
blockade in SOD1 G93A mice early after disease onset, or treating prior to disease onset,
may indicate if treatment with a P2X7 antagonist can alter immune cells early in these
mice.
7.3.4. JNJ-47965567 and serum cytokines in SOD1 G93A mice
This chapter examined a number of serum cytokines in SOD1 G93A mice that have not been
examined in this model previously. JNJ-47965567 treatment in SOD1 G93A mice did not
significantly alter serum cytokine concentrations. Despite this, concentrations of IL-27,
IFNβ and IL-10 were one log greater than other cytokines detected in these ALS mice.
Thus, these cytokines may play a role in ALS progression and be biomarkers for disease.
Previous meta-analyses of several cytokines revealed that serum IL-10 was similar
between controls and ALS patients (Hu et al., 2017). Moreover, fifteen serum cytokines,
including IL-10, were increased in asymptomatic (40 days old) SOD1 G93A compared to
wild type mice, although most of these cytokines, including IL-10, were not predictive of
survival (Moreno-Martínez et al., 2019). As such, it is unlikely IL-10 would be a useful
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marker for disease, however the use of IL-27 and IFNβ as biomarkers cannot be excluded
at this stage. Future studies could examine whether either of these cytokines are increased
earlier in disease and can predict ALS development or progression.
Of the cytokines found in lower concentrations, there was an increased trend in MCP-1
in serum from JNJ-47965567-treated mice compared to control mice. This aligns with
previous work, which demonstrated that SOD1 G93A mice treated with BBG had partially
increased MCP-1 (Bartlett et al., 2017a). However, in vitro P2X7 blockade reduces
intracellular MCP-1 in rat (Fang et al., 2011) and MCP-1 release from murine (Shieh et
al., 2014) microglia. Moreover, MCP-1 levels are increased in both the cerebral spinal
fluid and serum of ALS patients (Guo et al., 2017) and increases in MCP-1 are associated
with worsened disease (Kuhle et al., 2009). As such, increases in MCP-1 caused by P2X7
blockade may be worsening ALS in the SOD1 G93A mouse model.
Despite the strong link between P2X7 activation and NLRP3 inflammasome-mediated
IL-1β release (Di Virgilio, 2007), JNJ-47965567 did not alter serum IL-1β concentrations
in the current chapter. Furthermore, P2X7 is involved in the release of IL-6 (Shieh et al.,
2014; Solini et al., 1999), IL-10 (Chessell et al., 2005) and TNF-α (Ferrari et al., 2000b;
Shieh et al., 2014), however JNJ-47965567 treatment did not alter these cytokines. Thus,
this data along with the T cell and DC findings, supports the notion that the JNJ-47965567
treatment regime used in this chapter was insufficient to effectively inhibit P2X7 in
SOD1 G93A mice, which also explains the lack of clinical differences.
Despite the importance of cytokines in ALS and the abundance of studies reporting
expression of genes that encode these cytokines (Jeyachandran et al., 2015; McCombe et
al., 2020), studies reporting the serum concentrations of many of these cytokines in
SOD1 G93A mice are scarce. Of the cytokines examined in the current chapter serum
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concentrations of TNF-α (Rabinovich-Nikitin et al., 2016), MCP-1 (Bartlett et al., 2017a)
and IL-6 (Moreno-Martínez et al., 2019) in SOD1 G93A mice are similar to previous
studies. Contrarily, serum IL-10 concentrations are a hundred-fold greater in the current
chapter then in a previous study (Moreno-Martínez et al., 2019). This difference in IL-10
may be indicative of the different assays used to examine this cytokine. Alternatively, it
may indicate that SOD1 G93A mice in the current chapter are better protected from ALS
than those in the previous study (Moreno-Martínez et al., 2019), as overexpression of
IL-10 in microglia (Gravel et al., 2016) or spinal cords (Ayers et al., 2015; Strickland et
al., 2020) significantly reduces ALS in SOD1 G93A mice.
7.3.5. Conclusion
In conclusion, the current chapter demonstrated that JNJ-47965567 acts in a
non-competitive manner to inhibit murine P2X7 and that use of this compound th rice
weekly from disease onset altered spinal cord gene expression, but not peripheral immune
cells or serum cytokines in SOD1 G93A mice. The lack of efficacy of P2X7 blockade in the
current chapter is likely due to the treatment regime used. As such, future studies looking
at P2X7 blockade in ALS should treat mice from earlier timepoints, and more frequently,
then reassess whether P2X7 blockade has the ability to alter inflammatory parameters in
this mouse model.

213

Chapter 8: Identification and characterisation of a novel P2X7
antagonist
8.1.Introduction
Purinergic signalling has multiple physiological roles (Burnstock, 2018) and comprises a
range of nucleotide activated receptors including P2X and P2Y receptors which are
typically activated by extracellular ATP (Giuliani et al., 2019). P2X7 is found on many
cell types, including most immune cells, and once activated by ATP induces the flux of
Ca2+, Na+ and K+ cations and allows a pore to form which facilitates the transfer of large
organic cations and fluorescent dyes across the cell membrane (Sluyter, 2017). Activation
of P2X7 leads to multiple downstream events including NLRP3 inflammasome activation
and the subsequent release of the pro-inflammatory cytokines IL-1β and IL-18 (Dubyak,
2012). As such, P2X7 is a potential therapeutic target for multiple inflammatory diseases
(De Marchi et al., 2016), including GVHD and ALS as discussed in depth previously.
Novel compounds that block P2X7 could be used as therapeutics for these diseases or as
tools to better understand P2X7 on the molecular and cellular level.
P2X7 function can be examined using a variety of assays including Ca 2+ flux and dye
uptake assays. The fixed time dye uptake assay involves incubating cells with an organic
cationic dye such as ethidium+ or YO-PRO-1 +, inducing P2X7 pore-formation with ATP
for 5 min, and measuring the uptake by flow cytometry (Georgiou et al., 2005). This assay
has been routinely used to study P2X7 receptor function in our laboratory (Adhikary,
2020; Bartlett et al., 2013; Bartlett et al., 2017b; Farrell et al., 2010; Geraghty et al.,
2017), however, due to technical constraints, only 20 samples can be tested at a time.
Current P2X7 screening assays typically use spectrophotometry to measure either dye
uptake or Ca 2+ responses over time (Namovic et al., 2012; Piyasirananda et al., 2021;
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Soares-Bezerra et al., 2015), however both of these methods require relatively extensive
preparation, compared to a fixed time assay, as adherent cells are typically seeded in
plates overnight. As such, there is scope to adapt the fixed time flow cytometric assay
into a plated-based format and screen P2X7 antagonists using an automated flow
cytometer.
Evidence suggests that amiloride, a commonly used diuretic (Sun et al., 2020), inhibits
P2X7 at relatively high concentrations (50 % blockade at 1 mM) (Wiley et al., 1990).
Moreover, two 5-susbtituted amiloride analogues, HMA and EIPA, inhibit P2X7 more
potently than amiloride (>70 % blockade at 40 μM) (Wiley et al., 1990) with HMA the
most studied of these compounds in the context of P2X7 inhibition (Chessell et al., 1998a;
Nuttle et al., 1994; Wiley et al., 1993; Wiley et al., 1998). However, the use of amiloride
or its analogues as P2X7 antagonists has not been pursued since these early studies. Kelso,
Buckley and colleagues have recently designed and synthesised a series of amiloride and
HMA analogues to potentially inhibit human urokinase-type plasminogen activator
(Buckley et al., 2018; Buckley et al., 2021). Thus, it was hypothesised this library may
contain potential P2X7 antagonists. Therefore, this chapter aimed to identify and
characterise a novel P2X7 antagonist from this library of amiloride and HMA analogues.

8.2.Results
8.2.1. A plate-based dye uptake assay was established for compound screening
To screen the library of novel amiloride and HMA analogues a plate-based dye uptake
assay was developed using human RPMI8226 multiple myeloma cells, which express
P2X7 (Farrell et al., 2010). To determine the optimal time for ATP incubation in this
screening assay cells were plated into 96-well plates and incubated with YO-PRO-1 2+ in
the absence (basal) or presence of ATP for various lengths of time (4, 6, 8, 10, 12, or 16
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min) before the reaction was halted by the addition of ice-cold Mg2+ and centrifugation
(Figure 8.1a). YO-PRO-1 2+ uptake into cells was assessed by automated flow cytometry
using an Attune NxT flow cytometer and Autosampler (Figure 8.1b) and the
hP2X7-mediated uptake at each time point was determined (Figure 8.1c). There was a
linear increase in hP2X7-mediated dye uptake from 4 to 8 min but from 8 min onwards
the curve began to flatten. As such, 8 min was chosen as the optimal period of time for
ATP addition as it had the largest difference between ATP and basal fluorescence within
the linear portion of the curve. To determine the EC 50 value for ATP in this assay,
RPMI8226 cells were plated, incubated with YO-PRO-1 2+ with varying concentrations
of ATP for 8 min and dye uptake was assessed by flow cytometry. ATP induced dye
uptake in a concentration-dependent manner with a maximum response at 1 mM and an
EC50 of 250 ± 11 μM (Figure 8.1d). To assess the ability of this assay to detect inhibition
of hP2X7 activity, RPMI8226 cells were plated, incubated with 10 μM BBG, PPADS or
JNJ-47965567 or vehicle (saline for BBG and PPADS; DMSO for JNJ-47965567) for
15 min followed by YO-PRO-1 2+ in the presence or absence of 1 mM ATP for 8 min and
dye uptake was assessed by flow cytometry. BBG reduced ATP-induced dye uptake by
38 % while PPADS and JNJ-47965567 reduced dye uptake near completely (98 % and
100 % respectively) compared to the vehicle (P < 0.001 for all three inhibitors compared
to vehicle) (Figure 8.1e). These experiments developed an assay which allows the
screening of up to 40 compounds at once and requires a total time of 2 h (1 h hands on
experimental work and 1 h automatic plate sampling).
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Figure 8.1: A plate-based dye uptake assay was established for compound screening. (a)
Schematic representation of plate-based flow cytometric dye uptake assay. Wells that did not
receive ATP received an equivalent volume of low-divalent medium (LDM: basal). (b, c)
RPMI8226 cells were plated and incubated with 1 μM YO-PRO-12+ in the absence (basal) or
presence of (c) 1 mM ATP or (d) ATP (as indicated) for (c) 4-16 min or (d) 8 min. (e) RPMI8226
cells were plated and preincubated with 10 μM BBG, PPADS or JNJ or vehicle (saline for BBG
and PPADS; DMSO for JNJ) for 15 min, then with YO-PRO-12+ in the absence or presence of 1
mM ATP. (a-e) ATP incubations were stopped by the addition of ice-cold Mg2+ then
centrifugation. YO-PRO-12+ uptake was assessed by (b) a consistent flow cytometry gating
strategy. (c-e) Basal fluorescence was subtracted to determine the ATP-induced fluorescence in
each sample and (d, e) data were normalised to the maximal ATP-induced response in each
experiment. Data is presented as mean ± SEM. (c) n = 3, (d) n = 6 and (e) n = 2 independent
experiments. (e) Symbols represent individual experiments. P values shown where relevant.
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8.2.2. Compound screening revealed 6-furopyridine substituted HMA as a novel
candidate for further characterisation
Eighty compounds from the amiloride and HMA library, including the parent compounds,
were screened using the above assay. RPMI8226 cells were plated, incubated with vehicle
(DMSO) or compound (5 μM) for 15 min followed by YO-PRO-1 2+ in the absence or
presence of 250 μM ATP (approximate EC 50) for 8 min and dye uptake was assessed by
flow cytometry. Compounds were ranked from most to least inhibition of hP2X7 activity
(Figure 8.2). HMA better inhibited ATP-induced dye uptake than amiloride (25 % and
15 % mean inhibition respectively). The top 7 compounds all blocked ATP-induced
uptake by at least 75 % in at least one of three independent screens. Unfortunately, there
was large variation between the three independent screens, with each of these top 7
compounds showing reduced or no inhibition in at least one experiment. Moreover, there
was large variation for almost all compounds tested. Large responses (>100 %) are likely
due to the intrinsic fluorescence of the compounds despite the fluorescence of the
corresponding basal sample being taken into account.
6-furopyridine-substituted HMA (6-FPHMA) (Figure 8.3) was selected for further
characterisation as this compound showed relatively high blockade (ranked seventh
overall with 75 % blockade at 5 μM in one experiment) and was less studied (more novel)
with lower cytotoxicity than the compounds ranked above it (Buckley, unpublished). The
equivalent amiloride analogue, 6-furopyridine-substituted amiloride (6-FPA) (Figure
8.3) (ranked 78 th, no blockade), was examined alongside 6-FPHMA as a potential inactive
analogue control.
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Figure 8.2: Compound screening revealed 6-furopyridine substituted HMA as a novel
candidate for further characterisation. RPMI8226 cells were plated and preincubated with 5
μM of each compound or vehicle (DMSO) for 15 min, then with 1 μM YO-PRO-12+ in the absence
or presence of 250 μM ATP. ATP incubations were halted by the addition of ice-cold Mg+ then
centrifugation and YO-PRO-12+ uptake was assessed by a consistent flow cytometry gating
strategy shown previously (Figure 8.1b). Basal fluorescence was subtracted to determine the
ATP-induced fluorescence for each compound and data were normalised to the vehicle
ATP-induced response in each experiment. Data is presented as mean ± SEM. n = 3 independent
experiments. Symbols represent individual experiments. Compounds of interest have been
coloured for easier identification.
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Figure 8.3: Chemical structures of amiloride, hexamethylene amiloride (HMA),
6-furopyridine substituted HMA (6-FPHMA) and 6-furopyridine substituted amiloride
(6-FPA). Structures were drawn with ChemDraw software (PerkinElmer Informatics, Waltham,
USA).

8.2.3. 6-FPHMA, but not 6-FPA, inhibits endogenous hP2X7-mediated dye
uptake into RPMI8226 cells in a concentration-dependent manner
As the screening assay displayed large variation between repeat experiments (Figure
8.2), 6-FPHMA and 6-FPA were characterised using ATP-induced dye uptake as
previously described (Section 4.2.1) in RPMI8226 cells. Additionally, the dye was
changed from YO-PRO-1 2+ to ethidium + because 6-FPA appeared to increase
fluorescence in the YO-PRO-1 2+ measurement channel in the screening assay. Thus,
before proceeding with this assay to investigate 6-FPHMA and 6-FPA the EC50 value for
ATP against endogenous hP2X7 in this assay was assessed. RPMI8226 cells were
incubated with ethidium + and varying concentrations of ATP for 5 min and dye uptake
was assessed by flow cytometry (Figure 8.4a). ATP induced hP2X7-mediated uptake in
a concentration-dependent manner with a maximum response at 1 mM and an EC50
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Figure 8.4: 6-FPHMA, but not 6-FPA, inhibits endogenous hP2X7-mediated dye uptake into
RPMI8226 cells in a concentration-dependent manner. (a, b) RPMI8226 cells were incubated
with 25 μM ethidium+ in the absence (basal) or presence of ATP (as indicated) for 5 min. (c)
RPMI8226 cells were preincubated with 6-FPHMA or 6-FPA (as indicated) or vehicle for 15 min,
then with ethidium+ in the absence or presence of 300 μM ATP. (a-c) ATP incubations were halted
by the addition of ice-cold Mg2+ then centrifugation. Ethidium+ uptake was assessed in (a) single
RPMI8226 cells using a consistent flow cytometry gating strategy. (b, c) Basal fluorescence was
subtracted to determine the ATP-induced fluorescence in each sample and data were normalised
to the maximal ATP-induced response in each experiment. Data is presented as mean ± SEM. (b,
c) n = 5 independent experiments.

of 311 ± 21 μM (Figure 8.4b). To determine the IC50 of each compound, RPMI8226 cells
were incubated with varying concentrations of 6-FPHMA or 6-FPA for 15 min, followed
by ethidium + in the absence or presence of 300 μM ATP (approximate EC 50) for 5 min
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and dye uptake was assessed by flow cytometry. 6-FPHMA inhibited hP2X7-mediated
dye uptake in a concentration-dependent manner with 100 % blockade at 30 μM and an
IC50 of 0.58 ± 0.05 μM (Figure 8.4c). In contrast, 6-FPA did not inhibit hP2X7-mediated
dye uptake at any concentration up to 30 μM (Figure 8.4c).
8.2.4. 6-FPHMA inhibits hP2X7-mediated dye uptake into HEK-hP2X7 cells in
a non-competitive manner
To provide additional evidence for the above results (Figure 8.4), hP2X7 -mediated dye
uptake was also studied in stably transfected HEK-hP2X7 cells (Bhaskaracharya et al.,
2014). To determine the EC50 value of ATP against transfected hP2X7 in this ethidium+
uptake assay, HEK-hP2X7 cells were incubated with ethidium + with varying
concentrations of ATP for 5 min and dye uptake was assessed by flow cytometry (Figure
8.5a). ATP induced hP2X7-mediated dye uptake in a concentration-dependent manner
with a max response at 2 mM and an EC 50 of 466 ± 17 μM (Figure 8.5b). To determine
the IC50 of each compound, HEK-hP2X7 cells were incubated with varying
concentrations of 6-FPHMA or 6-FPA for 15 min, followed by ethidium + in the absence
or presence of 450 μM ATP (approximate EC 50) for 5 min and dye uptake was assessed
by flow cytometry. 6-FPHMA inhibited hP2X7-mediated dye uptake in a
concentration-dependent manner with 95 % inhibition at 100 μM and an IC 50 of 1.63 ±
0.42 μM (Figure 8.5c). Similar to RPMI8226 cells (Figure 8.4c), 6-FPA did not inhibit
hP2X7-mediated dye uptake at any concentration up to 30 μM (Figure 8.5c). Finally, to
determine if 6-FPHMA was acting in a competitive or non-competitive manner,
HEK-hP2X7 cells were incubated with 0.3, 3 or 30 μM of 6-FPHMA or vehicle (DMSO)
for 15 min, followed by ethidium + with varying concentrations of ATP for 5 min and dye
uptake was assessed by flow cytometry. Typical of a non -competitive inhibitor the
maximum response decreased as the concentration of 6-FPHMA increased, with
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Figure 8.5: 6-FPHMA inhibits hP2X7-mediated dye uptake into HEK-hP2X7 cells in a
non-competitive manner. (a, b) HEK-hP2X7 cells were incubated with 25 μM ethidium + in the
absence (basal) or presence of ATP (as indicated) for 5 min. (c, d) HEK-hP2X7 cells were
preincubated with 6-FPHMA or 6-FPA (as indicated) or vehicle (DMSO) for 15 min, then with
25 μM ethidium+ in the absence or presence of (c) 450 μM ATP or (d) ATP (as indicated). (a-d)
ATP incubations were halted by the addition of ice-cold Mg2+ then centrifugation. Ethidium+
uptake was assessed in (a) single HEK-hP2X7 cells using a consistent flow cytometry gating
strategy. (b-d) (b, c) Basal fluorescence was subtracted to determine the ATP-induced
fluorescence in each sample and data were normalised to the maximal ATP-induced response in
each experiment. Data is presented as mean ± SEM. (b-d) n = 5 independent experiments.
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maximum responses of 100 ± 0 % (vehicle), 90 ± 4 % (0.3 μM 6-FPHMA), 52 ± 3 %
(3 μM 6-FPHMA) and 13 ± 1 % (30 μM 6-FPHMA) (Figure 8.5d). Further, consistent
with a non-competitive mode of inhibition the EC 50 of ATP was not significantly different
(P = 0.18) between groups with EC 50 values of 419 ± 24 μM (vehicle), 464 ± 52 μM
(0.3 μM 6-FPHMA), 517 ± 49 μM (3 μM 6-FPHMA) and 557 ± 47 μM (30 μM
6-FPHMA) (Figure 8.5d).
8.2.5. 6-FPHMA inhibits hP2X7-mediated Ca 2+ influx in HEK-hP2X7 cells in a
non-competitive manner
hP2X7 activation by ATP results in Ca2+ influx, and this influx can be measured using
the intracellular calcium indicator Fura-2AM (Ma et al., 2009; Sophocleous et al., 2020).
Non-transfected HEK293 cells natively express hP2Y receptors, including hP2Y 1 and
hP2Y2 (Fischer et al., 2005), and activation of these receptors by ATP induces a Ca2+
response (Sophocleous et al., 2020). As such, HEK293 cells were examined alongside
HEK-hP2X7 cells to differentiate between hP2Y- and hP2X7-mediated Ca 2+ responses.
When stimulated with ATP, HEK293 cells had an immediate Ca 2+ response that peaked
within seconds of ATP addition and decreased to baseline by 100 sec (Figure 8.6a).
Robust, transient Ca 2+ responses were observed at all concentrations of ATP tested (0.01
to 5 mM). On the contrary, HEK-hP2X7 cells had a sustained Ca 2+ response lasting longer
than 180 sec (Figure 8.6b). As such, hP2X7-mediated Ca2+ responses were determined
by measuring the area under the curve from 100-180 sec for each concentration of ATP.
Using these criteria, ATP-induced Ca 2+ responses in non-transfected HEK293 cells were
minimal and ATP-induced Ca 2+ responses in HEK-hP2X7 were concentration-dependent
with a maximal response at 2 mM and an EC50 of 722 ± 76 μM (Figure 8.6c).
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Figure 8.6: ATP induces Ca2+ in HEK-hP2X7 cells in a concentration-dependent manner.
(a) HEK293 or (b) HEK-hP2X7 cells, pre-loaded with Fura-2AM, were incubated in the absence
(basal) or presence of ATP (as indicated) from 15-180 sec. (a, b) Ca2+ traces (F340/380nm) were
normalised to baseline (0-15 sec) readings and the area under the curve from 100-180 sec (bar
marker) was used as a measure of hP2X7-mediated Ca2+ flux. (c) The basal response was
subtracted to determine the ATP-induced response in each sample and data were normalised to
the maximal ATP-induced response in each experiment. Data presented as (a, b) mean or (c) mean
± SEM. (a-c) n = 6 independent experiments.

To determine if 6-FPHMA could inhibit hP2X7-mediated Ca2+ influx, HEK-hP2X7 cells
were preincubated with varying concentrations of 6-FPHMA for 30 min and the effect of
720 μM ATP (approximate EC50) on Ca 2+ responses was measured by calculating area
under the curve from 100-180 sec (Figure 8.7a). 6-FPHMA inhibited hP2X7-mediated
Ca2+ influx in a concentration-dependent manner with100 % inhibition at 30 μM and an
IC50 of 0.46 ± 0.14 μM (Figure 8.7b). To determine if 6-FPHMA was acting in a
competitive or non-competitive manner, HEK-hP2X7 cells were preincubated with
0.3, 3 or 30 μM of 6-FPHMA or vehicle (DMSO) and the effect of ATP on Ca 2+ responses

225

was measured. Similar to ethidium + uptake (Figure 8.5d), the maximum response
decreased as the concentration of 6-FPHMA increased, with average maximum responses
of 88 ± 9 % (vehicle), 54 ± 7 % (0.3 μM 6-FPHMA), 43 ± 6 % (3 μM 6-FPHMA) and
5 ± 1 % (30 μM 6-FPHMA) (Figure 8.7c). Further, consistent with a non-competitive
mode of inhibition the EC50 of ATP was not significantly different (P = 0.63) between
groups with EC50s of 526 ± 127 μM (vehicle), 526 ± 131 μM (0.3 μM 6-FPHMA),
857 ± 317 μM (3 μM 6-FPHMA) and 691 ± 151 μM (30 μM 6-FPHMA) (Figure 8.7c).

Figure 8.7: 6-FPHMA inhibits hP2X7-mediated Ca2+ influx in HEK-hP2X7 cells in a
non-competitive manner. (a-c) HEK-hP2X7 cells pre-loaded with Fura-2AM, were incubated
with 6-FPHMA (as indicated) or vehicle (DMSO) for 30 min then incubated in the absence (basal)
or presence of (a, b) 720 μM ATP or (c) ATP (as indicated) from 15-180 sec. (a) Ca2+ traces
(F340/380nm) were normalised to baseline (0-15 sec) readings and the area under the curve from 100180 sec was used as a measure of hP2X7-mediated Ca2+ flux. (b, c) The basal response was
subtracted to determine the ATP-induced response in each sample and data were normalised to
the maximal ATP-induced response in each experiment. Data presented as (a) mean or (b, c) mean
± SEM. (a, b) n = 8 or (c) n = 5 independent experiments.

226

8.2.6. 6-FPHMA reduces dye uptake in hCD3 +, hCD4 + and hCD8 + T cells
Prior chapters in this thesis have primarily focused on P2X7 on T cells (Chapters 4 -7), so
the ability of 6-FPHMA to inhibit hP2X7 on primary human T cells was examined. Flow
cytometric analysis of fluorescence on hPBMCs incubated with 6-FPHMA indicated that
this compound fluoresced brightly in multiple channels (450/50, 525/50, 610/20 and
710/50) when excited by a violet [405] laser (data not shown). As such, the fluorochrome
panel available for use was restricted, so only hCD3 +, hCD4 + and hCD8 + T cells were
examined. Further, ethidium + fluoresced brightly in multiple channels (586/15 and
780/60) when excited by a yellow [561] laser (data not shown). As such YO-PRO-12+
was used for dye uptake in hPBMCs to increase the flexibility of antibody panel design.
To determine if 6-FPHMA could inhibit hP2X7-mediated dye uptake in hT cells, and to
examine how this compound compares to other P2X7 antagonists, hPBMCs were
incubated with vehicle (DMSO) or 30 μM 6-FPHMA, JNJ-47965567, BBG or PPADS
for 15 min. YO-PRO-1 2+ and ATP, at a concentration (1 mM) previously shown to induce
dye uptake in hPBMCs (Adhikary et al., 2019), were added for 5 min and dye uptake into
hCD3 +, hCD4 + and hCD8 + T cells was assessed by flow cytometry (Figure 8.8a).
6-FPHMA reduced hP2X7-mediated uptake into hCD3 + by 62 ± 3 %, while
JNJ-47965567, BBG and PPADS reduced hP2X7-mediated uptake into these cells by
79 ± 14 %, 90 ± 8 % and 85 ± 9 % respectively (Figure 8.8b). Similar responses were
seen in hCD4 + T cells, with 6-FPHMA, JNJ-47965567, BBG and PPADS reducing uptake
by 62 ± 3 %, 78 ± 15 %, 83 ± 17 % and 85 ± 11 % respectively (Figure 8.8c), and in
hCD8 + T cells, with 6-FPHMA, JNJ-47965567, BBG and PPADS reducing uptake by
62 ± 4 %, 80 ± 11 %, 72 ± 22 % and 86 ± 7 % respectively (Figure 8.8d). All antagonists
except 6-FPHMA showed reduced inhibition of dye uptake in T cells from one human
donor, compared to the other three donors.
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Figure 8.8: 6-FPHMA reduces dye uptake in hCD3 +, hCD4+ and hCD8+ T cells. (a-d)
hPBMCs were preincubated with vehicle or 30 μM 6-FPHMA, JNJ, BBG or PPADS then
incubated with YO-PRO-12+ in the absence (basal) or presence of 1 mM ATP for 5 min. (a-d)
ATP incubations were halted by the addition of ice-cold Mg2+ and centrifugation. (a) A consistent
flow cytometry gating strategy was used to assess YO-PRO-12+ uptake in (b) hCD3+, (c) hCD4+
or (d) hCD8+ T cells. (b-d) Basal fluorescence was subtracted to determine the ATP-induced
fluorescence in each sample and data were normalised to the vehicle ATP-induced response in
each experiment. (b-d) Data presented as mean ± SEM. (b-d) n = 4 independent donors. P values
as shown. Differences between 6-FPHMA and other antagonists were not significant (P > 0.2 for
all comparisons).
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8.2.7. 6-FPHMA reduces hIL-1β release from whole blood
6-FPHMA inhibited hP2X7-mediated dye uptake and Ca 2+ flux in cell lines, and reduced
dye uptake in primary human T cells. P2X7 activation leads to activation of the NLRP3
inflammasome and release of IL-1β (Dubyak, 2012). As such, the current chapter
examined whether 6-FPHMA, and other P2X7 antagonists, could block hP2X7-mediated
hIL-1β release using a whole blood assay following priming with LPS (Spildrejorde et
al., 2014b). In the absence of ATP (basal), hIL-1β release in whole blood was negligible
(< 100 pg/mL) regardless of treatment (Figure 8.9). In the presence of ATP, 6-FPHMA
and JNJ-47965567 reduced hP2X7-mediated hIL-1β by 56 ± 15 % and 98 ± 1 %,
respectively, compared to the vehicle, while BBG and PPADS did not alter hIL-1β release
(Figure 8.9).

Figure 8.9: 6-FPHMA reduces hIL-1β release from whole blood. Whole blood was mixed 1:1
with serum free RPMI-1640 media containing LPS for 105 min. This mixture was incubated with
vehicle (DMSO) or 30 μM 6-FPHMA, JNJ, BBG or PPADS for 15 min, then for a further 30 min
in the absence (basal) or presence of 6 mM ATP. hIL-1β in cell-free supernatants was measured
by ELISA. Data presented as mean ± SEM. n = 3 independent donors. P values as shown for
significant differences between ATP groups.
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8.2.8. 6-FPHMA inhibits mP2X7-mediated dye uptake into HEK-mP2X7 cells
Common P2X7 antagonists have species specific potencies, with many compounds
having reduced inhibitory effects against mP2X7 (Donnelly-Roberts et al., 2009). As this
thesis has focused on both hP2X7 and mP2X7 in mouse models of disease, the ability of
6-FPHMA to inhibit mP2X7 was examined. To determine the EC 50 of ATP against
mP2X7, HEK293 cells were transfected with mP2X7-GFP (HEK-mP2X7) or mock
transfected and ethidium + uptake conducted as described above (Section 8.2.4). Mock
transfected HEK293 cells showed no ATP-induced ethidium + uptake (Figure 8.10a).
Transfected HEK-mP2X7 cells were selected by identifying GPF+ cells, and ethidium+
uptake in these cells was assessed by flow cytometry (Figure 8.10a). ATP induced
ethidium+ uptake into GFP+ HEK-mP2X7 cells in a concentration-dependent manner with
a maximum response at 2 mM and an EC50 of 364 ± 48 μM (Figure 8.10b). To determine
the IC50 of 6-FPHMA against mP2X7, transfected cells were pre-incubated with
6-FPHMA then incubated with ethidium + in the presence of 360 μM ATP (approximate
EC50) as described previously (Section 8.2.4). 6-FPHMA inhibited mP2X7-mediated dye
uptake in a concentration-dependent manner with 96 % blockade at 100 μM and an IC50
of 23 ± 2.4 μM (Figure 8.10c).
8.2.9. 6-FPHMA inhibits cP2X7-mediated dye uptake into HEK-cP2X7 cells
Canine P2X7 (cP2X7) and hP2X7 have relatively high homology (85 %) (Sluyter et al.,
2007) and respond similarly to ATP (Roman et al., 2009; Stevenson et al., 2009).
Additionally, cP2X7 and hP2X7 display similar responses to the P2X7 antagonists KN62,
BBG (Roman et al., 2009; Spildrejorde et al., 2014a; Stevenson et al., 2009), and
probenecid (Bartlett et al., 2017b; Bhaskaracharya et al., 2014). Therefore, the effect of
6-FPHMA against cP2X7 was examined. To determine the EC 50 of ATP against cP2X7,
HEK293 cells were transfected with cP2X7-GFP (HEK-cP2X7) or mock transfected and

230

Figure 8.10: 6-FPHMA inhibits mP2X7-mediated dye uptake into HEK-mP2X7 cells. (a, b)
HEK293 cells were transfected with mP2X7-GFP (HEK-mP2X7) or mock transfected and
incubated with ethidium+ in the absence (basal) or presence of ATP (as indicated) for 5 min. (c)
HEK293 or HEK-mP2X7 cells were preincubated with 6-FPHMA (as indicated) or vehicle
(DMSO) for 15 min, then with ethidium + in the absence or presence of 360 μM ATP. (a-c) ATP
incubations were halted by the addition of ice-cold Mg2+ and centrifugation. Single HEK cells
were gated as previously shown (Figure 8.5a) then (a) GFP + HEK-mP2X7 cells were selected
using the marker as shown, and ethidium + uptake was assessed in mock transfected HEK293 or
GFP+ HEK-mP2X7 cells by flow cytometry. (b, c) Basal fluorescence was subtracted to determine
the ATP-induced fluorescence in each sample and data were normalised to the maximal ATPinduced response in each experiment. (b, c) Data is presented as mean ± SEM. (b, c) n = 3
independent experiments.

ethidium+ uptake was conducted as described above (Section 8.4.8). Transfected
HEK-cP2X7 cells were selected by identifying GPF+ cells, and ethidium + uptake in these
cells was assessed by flow cytometry (Figure 8.11a). ATP induced ethidium + uptake into
GFP+ HEK-cP2X7 cells in a concentration-dependent manner with a maximum response
at 2 mM and an EC50 of 424 ± 67 μM (Figure 8.11b). To determine the IC50 of 6-FPHMA
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against cP2X7, transfected cells were pre-incubated with 6-FPHMA for 15 min, then
incubated with ethidium + uptake in the presence of 420 μM ATP (approximate EC 50) as
described previously (Section 8.2.8). 6-FPHMA inhibited cP2X7-mediated dye uptake in
a concentration-dependent manner with 100 % blockade at 30 μM and an IC 50 of
1.28 ± 0.47 μM (Figure 8.11c).

Figure 8.11: 6-FPHMA inhibits cP2X7-mediated dye uptake into HEK-cP2X7 cells. (a, b)
HEK293 cells were transfected with cP2X7-GFP (HEK-cP2X7) or mock transfected and
incubated with ethidium+ in the absence (basal) or presence of ATP (as indicated) for 5 min. (c)
HEK293 or HEK-cP2X7 cells were preincubated with 6-FPHMA (as indicated) or vehicle
(DMSO) for 15 min, then with ethidium + in the absence or presence of 420 μM ATP. (a-c) ATP
incubations were halted by the addition of ice-cold Mg2+ and centrifugation. Single HEK cells
were gated as previously shown (Figure 8.5a) then (a) GFP + HEK-cP2X7 cells were selected
using the marker as shown, and ethidium + uptake was assessed in mock transfected HEK293 or
GFP+ HEK-cP2X7 cells by flow cytometry. (b, c) Basal fluorescence was subtracted to determine
the ATP-induced fluorescence in each sample and data were normalised to the maximal ATPinduced response in each experiment. (b, c) Data is presented as mean ± SEM. (b, c) n = 3
independent experiments.
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8.2.10. 6-FPHMA inhibits hP2X4-mediated Ca 2+ flux in HEK-hP2X4 cells
Next, to determine whether 6-FPHMA could inhibit other P2X receptors HEK293 cells
were transfected with hP2X4-EmGFP (HEK-hP2X4) or mock transfected. Transfection
efficiency was determined by flow cytometry (Figure 8.12a) before proceeding with Ca2+
response assays. Preliminary testing was unable to generate an ATP dose-response curve
as ATP concentrations outside the range of 1 to 10 μM did not produce a consistent Ca 2+
response in HEK-hP2X4 cells (data not shown). As such, 1 μM ATP (approximate EC90
(Sophocleous et al., 2020)) was used to induce Ca 2+ responses in these cells. Similar to
comparisons between HEK293 and HEK-hP2X7 cells (Section 8.2.5), HEK293 cells in
these experiments had an initial peak response following the addition of ATP that was
reduced near baseline by 100 sec (Figure 8.12b) while HEK-hP2X4 cells had a sustained
response lasting longer than 180 sec (Figure 8.12c). To determine if 6-FPHMA could
inhibit hP2X4-mediated Ca 2+ influx, HEK-hP2X4 cells were preincubated with varying
concentrations of 6-FPHMA and the effect of 1 μM ATP (approximate EC 90) on Ca 2+
responses was measured by calculating area under the curve from 100 -180 sec (Figure
8.12d). 6-FPHMA inhibited hP2X4 in a concentration-dependent manner with 100 %
inhibition at 100 μM and an IC50 of 3.95 ± 0.19 μM (Figure 8.12e).
8.2.11. 6-FPHMA inhibits endogenous hP2Y-mediated Ca 2+ responses in
HEK293 cells
As mentioned above, HEK293 cells express endogenous hP2Y 1 and hP2Y2 (Fischer et
al., 2005) and activation of these receptors can induce Ca 2+ responses in these cells
(Sophocleous et al., 2020). To determine if 6-FPHMA could block P2Y receptors, control
data from HEK293 cells from hP2X7 studies earlier in this chapter (Section 8.2.5) was
analysed. HEK293 cells were preincubated with varying concentrations of 6-FPHMA and
the effect of 720 μM ATP (EC 50 for ATP against hP2X7) on Ca 2+ in these cells was
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assessed (Figure 8.13a). Under these conditions, 6-FPHMA inhibited endogenous
hP2Y-mediated Ca 2+ responses in a concentration-dependent manner with 100 %
inhibition at 100 μM and an IC50 of 2.56 ± 2.00 μM (Figure 8.13b).

Figure 8.12: 6-FPHMA inhibits hP2X4-mediated Ca2+ flux in HEK-hP2X4 cells. (a) HEK293
cells were transfected with hP2X4-EmGFP (HEK-hP2X4) or mock transfected and transfection
efficiency was determine by flow cytometry prior to Ca2+ assays. (b) HEK293 or (c) HEK-hP2X4
cells pre-loaded with Fura-2AM were incubated with 1 μM ATP from 15-180 sec. (d, e) HEKhP2X4 cells pre-loaded with Fura-2AM were incubated with 6-FPHMA (as indicated) or vehicle
for 30 min then incubated in the absence (basal) or presence of 1 μM ATP from 15-180 sec. (bd) Ca2+ traces (F340/380nm) were normalised to baseline (0-15 sec) readings and the area under the
curve from 100-180 sec was used as a measure of hP2X4-mediated Ca2+ flux. (e) The basal
response was subtracted to determine the ATP-induced response in each sample and data were
normalised to the maximal ATP-induced response in each experiment. Data presented as (b-d)
mean or (e) mean ± SEM. (b, c) n = 2 or (d, e) n = 4-7 independent experiments.
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Figure 8.13: 6-FPHMA inhibits endogenous hP2Y-mediated Ca2+ flux in HEK293 cells. (a,
b) HEK293 cells preloaded with Fura-2AM, were incubated with 6-FPHMA (as indicated) or
vehicle for 30 min and incubated in the absence (basal) or presence of 720 μM ATP from 15-180
sec. (a) Ca2+ traces (F340/380nm) were normalised to baseline (0-15 sec) readings and the peak
response was used as a measure of the hP2Y-mediated Ca2+ response. (b, c) The basal response
was subtracted to determine the ATP-induced response in each sample and data were normalised
to the maximal ATP-induced response in each experiment. Data presented as (a) mean or (b) mean
± SEM. (a, b) n = 3 independent experiments.

8.3. Discussion
The current chapter aimed to identify and characterise a novel P2X7 antagonist from a
library of amiloride and HMA analogues. 6-FPHMA was identified as a potential P2X7
antagonist following screening of a library of 80 amiloride and HMA analogues.
6-FPHMA inhibited hP2X7 in a concentration-dependent non-competitive manner. This
antagonist also inhibited hP2X7 on primary human T cells and reduced hP2X7-mediated
IL-1β release in whole blood. Further, 6-FPHMA showed similar potency against cP2X7
but was approximately ten-fold less potent against mP2X7. However, 6-FPHMA also
inhibited hP2X4 and hP2Y 1/hP2Y2 in a concentration-dependent manner with similar
potency to hP2X7. Collectively, this chapter identified 6-FPHMA as a P2X7 antagonist,
but this compound lacked selectivity, limiting its use as a lead compound for future drug
development.
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8.3.1. 6-FPHMA as a P2X7 antagonist
6-FPHMA inhibited P2X7 in a non-competitive manner in the current chapter. Mapping
of pdP2X7 identified a hydrophobic pocket, involving the key residues F95, F103, M105,
F293 and V312, that structurally distinct non-competitive antagonists, A740003,
A804598, AZ10606120, GW791343 and JNJ-47965567, all bind to (Karasawa et al.,
2016). Other studies indicated that the P2X7 antagonists A438079 (Allsopp et al., 2018),
AZ116453731, BBG, KN-62, calmidazolium and ZINC58368839 (Bin Dayel et al.,
2019) bind to an overlapping but distinct intersubunit allosteric site of P2X7 involving
additional residues including F88, D92, T94 and F108. Given these findings it is likely,
but not confirmed, that 6-FPHMA, and potentially other non-competitive amiloride
analogues, are binding to one of these sites. If 6-FPHMA was to be pursued further, future
studies using site directed mutagenesis and/or x-ray crystallography could examine which
residues are involved in 6-FPHMA binding to P2X7.
6-FPHMA inhibited hP2X7 more potently than any other amiloride or HMA analogue
described to date with an IC50 ranging from 0.46 μM to 1.63 μM depending on the assay
and cell type used. Previous studies (Chessell et al., 1998a; Nuttle et al., 1994; Wiley et
al., 1990; Wiley et al., 1993; Wiley et al., 1998), and the screening assay in the current
chapter, indicated that amiloride blocks P2X7 relatively poorly but analogues with
5-carbon chains, like HMA and EIPA, have increased potency. Th is hydrophobic
5-substitution may allow these compounds to better interact with the key residues in the
previously identified allosteric P2X7 drug-binding pockets (Allsopp et al., 2018;
Karasawa et al., 2016), although this has not been directly shown. Moreover, as
6-FPHMA inhibited P2X7 better than HMA it is likely the addition of a second
hydrophobic group, such as furopyridine, at the 6-position increases the ability of these
compounds to interact with the drug binding pocket. This may indicate HMA is
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interacting with a limited number of these key residues and the additional group allows
6-FPHMA to bind more strongly with, or with more, of these residues. Alternatively, it
may indicate the additional furopyridine functional group is interacting with other nearby
residues, not previously identified as important for drug binding. It should be noted that
the 5-hexameththylene substitution is likely more important than the 6-furopyridine group
for interactions in the drug binding pocket, as 6-FPA did not inhibit P2X7 in the current
chapter. Studying other amiloride analogues with similar functional groups to 6 -FPHMA
may help elucidate the binding mechanisms of these compounds.
The current chapter demonstrated that the amiloride analogue 6-FPHMA inhibits P2X7
on both CD4 + and CD8 + human T cells. This parallels the early works that identified
amiloride and its analogues as P2X7 antagonists using human lymphocytes (Wiley et al.,
1990; Wiley et al., 1993). Furthermore, the current chapter demonstrated for the first time
that an amiloride analogue can inhibit hP2X7-mediated IL-1β release. Moreover, despite
reduced inhibition against P2X7 on T cells compared to BBG and PPADS, 6 -FPHMA
inhibited IL-1β release from whole blood more potently than either compound. This may
indicate that 6-FPHMA would be a more potent in vivo antagonist than either of these
compounds, although it should be noted JNJ-47965567 inhibited P2X7 better than
6-FPHMA in both assays.
The current chapter also demonstrated that an amiloride analogue can inhibit P2X7 from
multiple species for the first time. 6-FPHMA had similar potency against hP2X7 and
cP2X7 but reduced potency against mP2X7. This may be due to the greater sequence
homology between hP2X7 and cP2X7 (~85 %) compared with hP2X7 and mP2X7
(~80 %) (Sluyter, 2017). Further, decreased potency against mP2X7 compared to hP2X7
in the current chapter reflects what is observed for multiple other P2X7 antagonists,
including PPADS, PPNDS, MRS2159 and A740003 (Donnelly-Roberts et al., 2009).
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8.3.2. 6-FPHMA as a non-selective P2X7 antagonist
The current chapter provides the first evidence that amiloride or HMA analogues have
the potential to inhibit multiple P2 receptors. 6-FPHMA inhibited hP2X7, hP2X4 and
hP2Y receptors at similar potency. Five selective P2X7 antagonists, A740003, A804598,
AZ10606120, GW791343 and JNJ-47965567, bind non-competitively to the same
allosteric hydrophobic drug-binding pocket on P2X7 but are unable to bind a similar
pocket on P2X4 due to their size (Karasawa et al., 2016). 6-FPHMA is larger than the
smallest of these compounds, so it is unlikely that 6-FPHMA is binding to this
hydrophobic pocket on P2X4. This may suggest 6-FPHMA is binding to a structurally
similar allosteric drug-binding site on P2X4 and P2X7, such as the homologous residues
I312 and I310 which are involved in the binding of the P2X4 antagonist BX430 (Ase et
al., 2019), and not the allosteric binding pocket discussed above. Alternatively, it may
indicate
6-FPHMA is binding to non-related sites on each receptor. Future studies should examine
where and how 6-FPHMA binds to P2X4 using truncated versions of the protein and
x-ray crystallography (Karasawa et al., 2016) to aid the development of a more specific
P2X4 antagonist. Further, it is still unknown whether 6-FPHMA is binding P2X4
competitively or non-competitively. This could be determined using Ca 2+ assays as
conducted in this chapter. 6-FPHMA may also be suitable as a lead compound to develop
a dual P2X7/P2X4 antagonist. Dual blockade of P2X7 and P2X4 may be beneficial as a
therapy for inflammatory diseases as activation of P2X4 can induce (de Rivero Vaccari
et al., 2012) or inhibition of P2X4 can reduce (Sakaki et al., 2013), inflammasome
activation and IL-1β release.
Other non-selective P2X7 antagonists, including BBG, PPADS, PPNDS, MRS2159,
NF449 and NF279 (Sluyter, 2017), all have multiple phosphate or sulphate functional
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groups and can bind to multiple P2X receptors. On the contrary, the P2X7 antagonists
that are considered selective, A438079, A740003, A804598, AZ10606120, AZ11645373,
GW791343 and JNJ-47965567 (Sluyter, 2017), do not have these highly polar functional
groups. Although 6-FPHMA lacks sulphate or phosphate functional groups, the multiple
polar amine functional groups within its structure may be enough to reduce selectivity .
6-FPHMA also inhibited endogenous P2Y receptor-mediated Ca 2+ responses in the
current chapter. Many of the non-selective P2X antagonists, including PPADS, PPNDS,
MRS2159, and NF279, can also bind to P2Y 1 and/or P2Y2 (Sluyter, 2017). Further, the
P2Y1 and P2Y2 receptor antagonists MRS-2500 and AR-C118925, which also have
multiple polar functional groups, bind to, or near, the ATP binding site while
1-(2-(2-(tert-butyl)phenoxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea (BPTU),
which is largely non-polar, binds to an allosteric binding site on P2Y 1 (Müller et al.,
2020). As such, it remains undetermined whether 6-FPHMA, which is largely non-polar
but does have polar regions, is binding to the allosteric binding site of P2Y receptors.
Alternatively, 6-FPHMA may be inserting directly into the cell membrane, like PPADS
and MRS2159 (Schwiering et al., 2017) to inhibit receptor activation. Although not
studied, together this suggests that 6-FPHMA may have the ability to inhibit other P2
receptors as well.
8.3.3. Compound screening assay
Although initial testing of the plate-based assay indicated it was relatively robust, the
results of compound screening were highly variable between experiments. This was likely
due to technical constraints of the assay which led to the plate being at room temperature
for longer during compound screening than during initial testing. P2X7 activity is
temperature dependent, with lower temperatures reducing P2X7 activity (Coutinho-Silva
et al., 1997), so it is possible that a difference in plate temperatures between experiments

239

occurred, altering P2X7-mediated dye uptake. To overcome this shortcoming, the
compound and/or ATP incubation time(s) could be increased to better allow cells to return
to 37 oC after being at room temperature. Nevertheless, the assay was initially useful for
identifying a novel P2X7 antagonist in the current chapter.
8.3.4. Conclusion
In conclusion, this chapter identified and characterised the novel non -competitive P2X7
antagonist 6-FPHMA. This compound had greater potency then either amiloride or HMA
and reduced downstream P2X7-mediated events. Further, 6-FPHMA also inhibited
cP2X7 and mP2X7 but was not selective for P2X7, limiting its use as a lead compound
for future P2X7 drug development. Nevertheless, 6-FPHMA may have its use as a tool
for better understanding P2X7 on a molecular and cellular level.
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Chapter 9: General discussion and conclusions
9.1. Introduction
Purinergic signalling plays roles in multiple physiological systems (Burnstock, 2018) and
comprises a range of nucleotide activated receptors including P2X7 (Giuliani et al.,
2019). P2X7 is present on many cell types, including leukocytes, and the activation of
P2X7 by extracellular ATP on these cells promotes inflammation and immune responses
(Di Virgilio et al., 2017; Savio et al., 2018). Activation of P2X7 on DCs activates the
NLRP3 inflammasome driving the release of pro-inflammatory cytokines including
IL-1β (Ferrari et al., 2000b; Ghiringhelli et al., 2009). P2X7 activation also directly
promotes the activation and proliferation of CD4 + (Yip et al., 2009) and CD8 + (Borges
da Silva et al., 2018) T cells, but diminishes the stability and suppressive function of
Tregs (Schenk et al., 2011). As such, P2X7 has been implicated in the development of
multiple inflammatory diseases and represents a potential therapeutic target for these
diseases (De Marchi et al., 2016). However, clinical trials examining P2X7 have not been
particularly fruitful to date (Eser et al., 2015; Keystone et al., 2012; Stock et al., 2012).
Nevertheless, targeting P2X7 in inflammatory diseases such as GVHD and ALS can
increase our understanding of how this receptor is involved in disease.
GVHD is a severe and often lethal complication of allogeneic HSCT that occurs in the
majority of recipients (Gooley et al., 2010). PTCy is a clinically used T cell depletion
strategy used to treat GVHD (Luznik et al., 2008; McCurdy et al., 2015). Despite
relatively widespread clinical use, PTCy does not always prevent GVHD related mortality
following HSCT, and cancer relapse and infection still occur (Ruggeri et al., 2017), with
evidence suggesting PTCy actually increases viral respiratory infections (Goldsmith et
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al., 2021). As such, improved therapeutic strategies to prevent, or treat, GVHD are still
required.
P2X7 represents a potential therapeutic target for GVHD due to the role of this receptor
on DCs and T cells as mentioned above. Evidence indicates that activation of P2X7 on
host DCs increases the release of cytokines and promotes T cell-mediated inflammation
in an allogeneic mouse model of GVHD (Wilhelm et al., 2010). Moreover, this previous
study indicated that host, but not donor, P2X7 was important for GVHD development,
and demonstrated that blockade of P2X7 with PPADS or KN-62 could reduce disease and
prolong survival in the same model (Wilhelm et al., 2010). Despite this study, and another
study which demonstrated that P2X7 blockade with A-438079 in allogeneic mice reduced
GVHD (Koehn et al., 2019), other studies in allogeneic (Zhong et al., 2016) and
humanised (Geraghty et al., 2017; Geraghty et al., 2019d) mice using the P2X7 antagonist
BBG have seen little alteration of disease, perhaps due to differences in antagonists or
treatment regimens or the models used. As such, the role of P2X7 in the humanised mouse
model of GVHD remained largely undetermined.
P2X7 also represents a therapeutic target for ALS due mainly to its expression on
microglia and astrocytes (Jimenez-Mateos et al., 2019), however, as mentioned above
and as illustrated throughout this thesis, P2X7 is also expressed on T cells, and activation
of P2X7 on these cells, or other leukocytes, typically leads to pro-inflammatory effects
(Di Virgilio et al., 2017). Moreover, increasing evidence suggests that some T cell subsets
are altered in ALS patients and increased Tregs are associated with decreased ALS
(Gustafson et al., 2017; Henkel et al., 2013; Murdock et al., 2017; Sheean et al., 2018).
Furthermore, studies in SOD1 G93A mice indicated that the CNS-impermeant P2X7
antagonist BBG can partially reduce ALS in these mice (Apolloni et al., 2014; Bartlett et
al., 2017a; Cervetto et al., 2013) but did not alter leukocyte proportions (Bartlett et al.,
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2017a). As such, the role of P2X7 in the SOD1 G93A mouse model of ALS remains to be
fully explored.
The aim of this thesis was to examine P2X7 as a therapeutic target in two models of
inflammation, a humanised mouse model of GVHD and a SOD1 G93A mouse model of
ALS. To accomplish this, P2X7 gene expression and inflammation in the widest range of
GVHD target organs to date was examined to better characterise GVHD in humanised
mice. A modified P2X7 antagonist regime was trialled in humanised mice to determine
if blockade with BBG or PPADS could reduce GVHD in this model. BBG treatment was
combined with PTCy to determine if combinational therapy could improve GVHD
outcomes compared to PTCy alone in humanised mice. In relation to the ALS mouse
model, this thesis performed a retrospective analysis of data acquired from a pre-clinical
trial using the P2X7 antagonist JNJ-47965567 in SOD1 G93A mice (Dongol, 2018) to
determine the effect of this treatment on systemic immune responses durin g ALS. Finally,
a library of amiloride analogues was tested to identify and characterise a novel P2X7
antagonist for potential future use in mouse models of disease.

9.2. P2X7 as a therapeutic target for inflammatory diseases
Chapter 3 provided the most comprehensive analysis of hP2RX7 and mP2rx7 gene
expression in the humanised mouse model of GVHD to date, and indicated expression
was increased in the small intestine and skin (Figure 9.1). Further, this Chapter identified
the liver, skin and lung as the tissues most affected by GVHD in this model. Chapters 4
and 5 demonstrated that P2X7 blockade with BBG or PPADS increased hTreg
engraftment, particularly early in disease, and decreased serum hIFNγ, and that these
changes were associated with decreased clinical and histological, GVHD, particularly in
the liver, at endpoint. Chapter 6 showed that combinational therapy with BBG and PTCy
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increased suppressive hTreg engraftment early in disease and reduced histological liver
GVHD at endpoint compared to PTCy alone. Despite such effects in GVHD, Chapter 7
demonstrated that P2X7 blockade in a SOD1 G93A mouse model of ALS did not alter
immune parameters at endpoint. Finally, Chapter 8 identified a novel P2X7 antagonist,
6-FPHMA, which inhibited P2X7 on immune cells and reduced IL-1β release, however
this antagonist was non-specific and inhibited other P2 receptors.

Figure 9.1: Activation of P2X7 on Tregs and antigen presenting cells (APC) contributes to
GVHD. Tissue damage from pre-transplant conditioning, or GVHD, results in adenosine
5’-triphosphate (ATP) release. This ATP activates P2X7 on host antigen presenting cells (APCs)
leading to enhanced activation, proliferation and survival of donor T cells (Wilhelm et al., 2010).
ATP can also activate P2X7 on regulatory T cells, reducing their survival and function (Chapters
4 and 5). Additionally, mP2rx7 expression is increased in the skin and small intestine of mice
with GVHD (Chapter 3). Combined these pathways lead to worsened GVHD.

P2X7 has known roles on CD4 + and CD8 + T cells and Tregs (Borges da Silva et al., 2018;
Schenk et al., 2011; Yip et al., 2009), but studies in allogeneic (Wilhelm et al., 2010) and
humanised (Adhikary, 2020) mouse models, and allogenic HSCT recipients (Koldej et
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al., 2020), suggested that donor P2X7 does not play a role in GVHD. However, recent
evidence indicates that P2X7 activation on donor myeloid -derived suppressor cells
impairs the function of these cells in GVHD (Koehn et al., 2019), providing indirect
evidence that P2X7 may play a role on donor cells. This thesis provided the first direct
evidence that blockade of P2X7 can alter donor immune cells in GVHD, as blockade
increased donor Tregs in humanised mice. As such, this suggests that activation of P2X7
on Tregs induces the death of these cells during GVHD to promote disease (Figure 9.1).
This reduction in Tregs likely reduces the suppression of T cells, resulting in enhancement
of the P2X7-mediated activation of host antigen presenting cells and donor T cells in
GVHD as described previously (Wilhelm et al., 2010). It should be noted that the relative
contributions of donor or host P2X7 to GVHD are still unknown, although it re mains
likely host P2X7 contributes more to disease. As discussed previously (Chapters 4 and
5), utilisation of species-specific inhibitors such as antibodies (Buell et al., 1998a;
Kurashima et al., 2012) or nanobodies (Danquah et al., 2016) to P2X7 will allow us to
distinguish these roles in humanised mice.
Despite the blockade of P2X7 increasing Tregs in GVHD (Chapters 4 -6), muscular
dystrophy (Gazzerro et al., 2015) and renal injury (Koo et al., 2017), blockade of P2X7
in a mouse model of ALS did not alter Tregs (Chapter 7). As discussed in depth previously
(Section 7.3.3), this is likely due to differences in injection regime or the time at which
Tregs were examined, endpoint vs early in disease. Further evidence for the importance
of an optimised injection regime arises from previous studies using BBG in a humanised
mouse model of GVHD (Geraghty et al., 2017; Geraghty et al., 2019d). These studies
indicated that less frequent dosing early in disease or long-term treatment with BBG did
not alter immune cell subsets including Tregs. Moreover, while immune cell subsets were
not examined, P2X7 blockade with JNJ-47965567 prior to disease onset, and injected
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more frequently than our study (Dongol, 2018), can reduce ALS in SOD1 G93A mice (RuizRuiz et al., 2020). Together these studies indicate that P2X7 blockade likely has greater
effects as a prophylactic therapy, opposed to treating after disease onset. Moreover, these
studies highlight the need to carefully consider the P2X7 antagonist regime, which could
be based on pharmacokinetic data, prior to treatment. However, this data is largely absent
for most P2X7 antagonists, and this would need to be determined prior to any preclinical
drug studies.
Although the role of P2X7 in inflammation (Di Virgilio et al., 2017) and disease (De
Marchi et al., 2016) has been studied for many years, P2X7 blockade as a therapeutic is
yet to advance into the clinic despite several clinical trials (Vultaggio-Poma et al., 2022).
This may be due to opposing roles for P2X7 on different cell types, and/or may functional
redundancy of P2X7 when blocked. As such, combinational therapy with P2X7 blockade
and another treatment, like that studied in Chapter 6, may be required to better prevent
diseases which involve P2X7. Despite these challenges, novel P2X7 antagonists are still
being developed and trialled by industry for the treatment of various diseases (Table 9.1).
Table 9.1 Recent industry P2X7 antagonist development.
Compound
JNJ-54175446
JNJ-55308942
AK1780
AXX71
AFC-5128

Disease
Stage
Depressive disorder Phase 2 Clinical Trial
underway
Bipolar disorder
Phase 2 Clinical Trial
underway
Chronic pain
Phase 1 Clinical Trial
complete
ALS
Pre-clinical mouse model
Multiple sclerosis
Pre-clinical mouse model
Refractory status
epilepticus

Pre-clinical mouse model

Company/Ref
Janssen Pharmaceuticals
Janssen Pharmaceuticals
Asahi Kasei
(Apolloni et al., 2021)
Affectis
Pharmaceuticals
(Beamer et al., 2022)
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9.3. P2X7 expression in humanised mice
Chapter 3 demonstrated that mP2rx7 expression was increased in the duodenum, ileum
and skin of humanised mice with GVHD compared to control mice, and these increases
corresponded with increased mP2rx4 expression. As such, these increases were likely due
to the infiltration of murine macrophages which co-express P2X7 and P2X4
(Boumechache et al., 2009). Macrophage recruitment and infiltration contributes to
GVHD through the release of cytokines and interaction with T cells (Hong et al., 2020),
and P2X7 activation on mouse macrophages cells leads to inflammasome activation and
IL-1β release (Qu et al., 2007). Moreover, P2X7 blockade or knockout reduces
inflammatory macrophage migration in models of haemorrhagic cystitis (Martins et al.,
2012) or urethral obstruction (Gonçalves et al., 2006) respectively. As such, it is
somewhat surprising that P2X7 blockade with BBG in Chapter 4, or PPADS in Chapter
5, did not decrease mP2rx7 expression, and that BBG instead increased mP2rx7
expression in the duodenum of humanised mice compared to saline treatment. However,
it should be noted that the role of murine macrophages in this humanised mouse model
of GVHD is unknown, as the NOD/ShiLtJ background results in defective macrophage
function (Shultz et al., 1995). As such, increases in mP2rx7 due to the infiltration of
macrophages may not indicate worsened disease. Aligning with this notion, immune cell
infiltrates were near absent in the duodenum of humanised mice and histological GVHD
in this tissue was minimal throughout this thesis. As such, mP2rx7 in the duodenum
potentially coincides with other early molecular changes, rather than histological GVHD.
A limitation of the expression studies in this thesis is that P2X7 mRNA, but not protein,
expression was assessed based on the initial findings in Chapter 3. Thus, it remains to be
determined if the observed changes in P2X7 mRNA correspond to changes in P2X7
protein.
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9.4. GVHD in humanised mice
This thesis provides the most comprehensive analysis of histological GVHD in
humanised mice to date. Prior to this thesis liver involvement was the only consistently
reported evidence of histological GVHD in humanised mice, with some studies showing
gut and skin involvement (Geraghty et al., 2017; King et al., 2009). Humanised mice in
this thesis consistently (Chapters 3-6) developed histological liver, skin and lung GVHD
even when treated with PTCy. This highlights the importance of examining these three
tissues in future studies, as any treatment effects will likely be most noticeable in these
tissues. Moreover, increasing evidence from rodent models indicates that GVHD is
involved in other organs including the ovaries (Shimoji et al., 2017) and kidneys (Higo
et al., 2014). Future studies could also examine these tissues in humanised mice to
determine if they are involved in this model.
Splenic engraftment of human immune cells, particularly T cells, in humanised mice at
endpoint was similar between chapters (Table 9.2). Moreover, the proportions of T cells
in non-treated or saline-treated humanised mice in this thesis were consistent with
previous studies from our group (Geraghty et al., 2017; Geraghty et al., 2019a; Geraghty
et al., 2019b; Geraghty et al., 2019d) and others (Ali et al., 2012; King et al., 2009).
Although it should be noted some of these studies examined engraftment at dif ferent time
points. Despite this, this thesis further highlights that without treatment, the majority of
splenic human cells in this model are T cells, with a relatively consistent ratio of 2:1
CD4 +:CD8 + T cells, opposite to human spleens (Langeveld et al., 2006), and smaller
proportions of Tregs. Comparisons between these results and Chapter 6 are limited due
to the injection of twice as many human cells, as discussed in depth previously (Section
6.3).
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Due to xenogeneic reactions, GVHD in the humanised mouse model is likely harder to
prevent than GVHD in allogeneic mouse models. PPADS treatment in allogeneic
(Wilhelm et al., 2010) but not humanised (Chapter 5) mice increased survival and
significantly reduced disease. Moreover, PTCy, which is typically used for
HLA-haploidentical HSCT transplantation (Kanakry et al., 2016b), near completely
prevented disease in allogeneic mice (Wachsmuth et al., 2019) but only delayed GVHD
in humanised mice (Adhikary, 2020). The latter of which is indirectly supported by
comparisons of clinical GVHD and survival between Chapters 4 and 6. This difficulty in
reducing or preventing GVHD is likely due to the complete HLA/MHC mismatch
between human donors and mice, as even partial HLA mismatches increase the incidence
of GVHD in human allo-HSCT recipients (Kanda, 2013). This mismatch likely results in
a stronger inflammatory response than those seen in allogeneic mouse models. However,
if a treatment can overcome this HLA/MHC-mismatch it is likely to have greater clinical
benefits as it may allow the wider use of mismatched donors and make allo-HSCT viable
for more patients.
Table 9.2 Human immune cell engraftment in NSG mice summary. Proportions of human
immune cells from Chapters 3-5 are summarised to examine engraftment trends in humanised
mice. Data presented as mean (minimum – maximum).
Chapter 3
Chapter 4
Chapter 5
Humanised mice,
Humanised mice,
Humanised mice,
Cell type
no treatment
saline
saline
% hCD45+ of total CD45
66 (17 – 91)
77 (40 – 98)
71 (34 – 99)
+
+
% hCD3 of hCD45
94 (79 – 100)
96 (87 – 100)
95 (86 – 100)
+
+
% hCD4 of hCD3
61 (28 – 86)
58 (10 – 86)
52 (15 – 92)
% hCD8+ of hCD3+
31 (11 – 68)
36 (12 – 88)
42 (4 – 82)
+
+
a
hCD4 :hCD8 ratio
2.1 (0.4 – 7.8)
1.8 (0.1 – 6.8)
1.5 (0.2 – 18.9)
+
% Treg of hCD4
Not examined
2 (1 – 4)
3 (1 – 11)
aMean values presented are geometric mean to better reflect non-parametric ratio data.
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9.5.P2X7 antagonists
This thesis examined three P2X7 antagonists in vivo, BBG and PPADS, and
JNJ-47965567, in humanised NSG and SOD1 G93A mice respectively, and characterised
the same three antagonists plus a novel P2X7 antagonist, 6-FPHMA, in vitro. Throughout
this thesis the inhibitory effects of these four compounds against hP2X7 and mP2X7 were
tested using dye uptake and IL-1β release assays in human and murine cells (Table 9.3).
BBG is arguably the most published in vivo P2X7 antagonist (Bartlett et al., 2014),
however testing in Chapter 8 indicated that both BBG and PPADS did not effectively
block P2X7 in a whole blood assay. This may indicate that when used for in vivo testing,
including GVHD and ALS, the full efficacy of these compounds is not being displayed,
as they may fail to effectively inhibit P2X7 in circulation and possibly in solid tissues.
Notably, 6-FPHMA inhibited P2X7 better than BBG and PPADS in the whole blood
assay but was similar or less effective in dye uptake assays. Overall, JNJ-47965567 was
the most potent inhibitor in vitro, blocking near completely in almost every in vitro test.
Furthermore, JNJ-47965567 improved outcomes in multiple neuronal disease models
(Bhattacharya et al., 2013; Huang et al., 2021; Romano et al., 2020; Ruiz-Ruiz et al.,
2020), and evidence from this thesis suggests it can near completely reduce IL-1β release
and inhibit P2X7 on T cells. As such, JNJ-47965567 may be better at preventing GVHD
than BBG or PPADS in humanised mice. However, as noted above (Section 9.2) the
optimal drug regime should be established prior to use. Together, these results can help
us pick the most appropriate in vivo inhibitor for future studies.
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Table 9.3: Summary of in vitro antagonist data from Chapters 4, 5, 7 and 8. Data from
in vitro antagonist testing in this thesis is summarised. Data is presented as percent inhibition at
the indicated compound concentration, with IC50 values included where determined. Some
antagonists were not assessed (NA) in some assays. Assays with data for only one antagonist were
excluded from this table.
Percent inhibition
Antagonist

J774 cellsa

BBG

100 %

38 %

90 %

IL-1β release from
J774
Human
a
cells
whole
bloodb
100 %
0%

PPADS

100 %

98 %

85 %

95 %

0%

10 0%

79 %

NA

98 %

95 %
62 %
(IC50 580 nM)
aCompounds at 10 μM, b compounds at 30 μM, cJNJ at 3 μM.

NA

56 %

JNJ-47965567
6-FPHMA

%c

100
(IC50 54 nM)
NA

Dye uptake in
RPMI8226 cellsa

hCD3+
T cellsb

9.6. Conclusions
In summary, this thesis has identified a role for P2X7 on donor immune cells in GVHD,
but not systemic immune cells in ALS, and has identified a novel non -specific P2X7
antagonist. This thesis demonstrated that P2X7 gene expression was upregulated in
multiple tissues during GVHD in a humanised mouse model. For the first time, P2X7
blockade significantly reduced clinical and histological GVHD in a humanised mouse
model. These reductions in disease were consistently associated with increased donor
Tregs, due to the selective preservation of these cells by P2X7 blockade, and decreased
pro-inflammatory hIFNγ. Additionally, this thesis demonstrated that P2X7 blockade
could provide additional benefits to PTCy treatment, increasing suppressive donor CD39 +
Tregs and reducing hIFNγ in humanised mice. In contrast, P2X7 blockade did not alter
immune cell proportions or serum cytokines in endpoint SOD1 G93A ALS mice, however
the effects of P2X7 blockade early in this model remain unknown. This thesis also
identified a novel P2X7 antagonist from a library of amiloride analogues, however this
antagonist was relatively non-specific and inhibited P2X4 and P2Y receptors. Finally,
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this Chapter and the previous Chapters outline future experiments to explore P2X7 in
inflammation and disease. Collectively, this thesis continues to support evidence that
P2X7 blockade is a potential therapeutic for inflammatory diseases, including the
preservation of Tregs to suppress inflammation.
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Appendix

Appendix Figure A7.1: JNJ-47965567 does not alter clinical disease progression in
SOD1G93A mice. (a-d) SOD1G93A mice were injected i.p. with JNJ-47965567 (30 mg/kg) (n = 24)
or β-CD (control) (n = 23) thrice weekly from disease onset until endpoint. Mice were assessed
(a, b, d) thrice or (c) once weekly for (a) ALS score, (b) weight change, (c) motor coordination
(rotarod) and (d) survival. Data presented as mean ± SEM. Significance was determined by (a-c)
Two-Way ANOVA or (d) log-rank (Mantel-Cox) test. P values as shown. Figure adapted from
Dongol (2018) and Ly et al. (2020).
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